{
  "items": "696",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/25/04/44868231/these-analysts-boost-their-forecasts-on-abbott-laboratories-after-better-than-expected-earnings",
      "time_published": "20250417T151112",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday. Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.216666,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.892763",
          "ticker_sentiment_score": "0.165587",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "-0.168928",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Is a Surprise Coming for Abbott  ( ABT )  This Earnings Season?",
      "url": "https://www.zacks.com/stock/news/2350467/is-a-surprise-coming-for-abbott-abt-this-earnings-season",
      "time_published": "20241015T124600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99237"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.4558,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.76191",
          "ticker_sentiment_score": "0.553804",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Looking At Abbott Laboratories's Recent Unusual Options Activity - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/05/38824758/looking-at-abbott-laboratoriess-recent-unusual-options-activity",
      "time_published": "20240514T174557",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 11 trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.189679,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.6809",
          "ticker_sentiment_score": "0.130784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "-0.10946",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/05/38770599/what-the-options-market-tells-us-about-abbott-laboratories",
      "time_published": "20240510T201821",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.195945,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.679118",
          "ticker_sentiment_score": "0.297704",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "-0.109385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Behind the Scenes of Abbott Laboratories's Latest Options Trends - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/07/39967810/behind-the-scenes-of-abbott-laboratoriess-latest-options-trends",
      "time_published": "20240725T184702",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1721933219_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.222887,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.09402",
          "ticker_sentiment_score": "0.210194",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.655281",
          "ticker_sentiment_score": "0.28532",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/05/38566419/what-the-options-market-tells-us-about-abbott-laboratories",
      "time_published": "20240501T204605",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories ABT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.207571,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.116146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.653008",
          "ticker_sentiment_score": "0.324403",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "-0.117159",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Behind the Scenes of Abbott Laboratories's Latest Options Trends - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44482160/behind-the-scenes-of-abbott-laboratoriess-latest-options-trends",
      "time_published": "20250325T203031",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742934628_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.150498,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.067919",
          "ticker_sentiment_score": "0.043309",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.651499",
          "ticker_sentiment_score": "0.124165",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.067919",
          "ticker_sentiment_score": "0.043309",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Market Whales and Their Recent Bets on ABT Options - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/06/39534916/market-whales-and-their-recent-bets-on-abt-options",
      "time_published": "20240627T193306",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bullish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories ABT revealed 8 unusual trades. Delving into the details, we found 50% of traders were bullish, while 37% showed bearish tendencies.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.145936,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.093289",
          "ticker_sentiment_score": "-0.116002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.651499",
          "ticker_sentiment_score": "0.217529",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Market Whales and Their Recent Bets on ABT Options - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/25/01/43199749/market-whales-and-their-recent-bets-on-abt-options",
      "time_published": "20250124T183105",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1737743462_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.185115,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WFC",
          "relevance_score": "0.06623",
          "ticker_sentiment_score": "0.048193",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.63935",
          "ticker_sentiment_score": "0.18674",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Behind the Scenes of Abbott Laboratories's Latest Options Trends - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/04/38321000/behind-the-scenes-of-abbott-laboratoriess-latest-options-trends",
      "time_published": "20240418T173158",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with significant funds have taken a bearish position in Abbott Laboratories ABT, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.194383,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.080458",
          "ticker_sentiment_score": "0.127304",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.636698",
          "ticker_sentiment_score": "0.243372",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.080458",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories's Options: A Look at What the Big Money is Thinking - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/06/39254044/abbott-laboratoriess-options-a-look-at-what-the-big-money-is-thinking",
      "time_published": "20240610T154600",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories ABT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.212351,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.07887",
          "ticker_sentiment_score": "-0.112709",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.627119",
          "ticker_sentiment_score": "0.354346",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.07887",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth",
      "url": "https://www.fool.com/investing/2024/08/02/forget-johnson-johnson-this-could-be-a-much-better/",
      "time_published": "20240802T091700",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher.",
      "banner_image": "https://g.foolcdn.com/editorial/images/784778/a-group-of-scientists-looking-at-a-report.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.272999,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.626755",
          "ticker_sentiment_score": "0.428021",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.462395",
          "ticker_sentiment_score": "0.301853",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/03/37823679/what-the-options-market-tells-us-about-abbott-laboratories",
      "time_published": "20240319T141622",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bearish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories ABT revealed 19 unusual trades. Delving into the details, we found 5% of traders were bullish, while 94% showed bearish tendencies.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.158439,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.620415",
          "ticker_sentiment_score": "-0.017946",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44173783/abbott-laboratories-options-trading-a-deep-dive-into-market-sentiment",
      "time_published": "20250306T180115",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "High-rolling investors have positioned themselves bullish on Abbott Laboratories ABT, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1741284072_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.223823,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "0.061669",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.614697",
          "ticker_sentiment_score": "0.366475",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "0.061669",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41233611/abbott-laboratories-analyst-is-bullish-about-medtech-non-medtech-growth",
      "time_published": "20241008T155952",
      "authors": [
        "Priya Nigam"
      ],
      "summary": "Abbott Laboratories's ABT MedTech portfolio is growing at a CAGR ( compounded annual growing rate ) of 11%-13%. The company's non-MedTech operations are expanding by low-to-mid single-digit percentages, according to Oppenheimer.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/08/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.349263,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.601928",
          "ticker_sentiment_score": "0.356448",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44380444/decoding-abbott-laboratoriess-options-activity-whats-the-big-picture",
      "time_published": "20250318T160038",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742313635_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.154847,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.041147",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.597963",
          "ticker_sentiment_score": "0.163447",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.041147",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This Is What Whales Are Betting On Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/25/01/43243524/this-is-what-whales-are-betting-on-abbott-laboratories",
      "time_published": "20250127T174532",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bearish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories ABT revealed 20 unusual trades. Delving into the details, we found 40% of traders were bullish, while 45% showed bearish tendencies.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1737999929_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.144654,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.588165",
          "ticker_sentiment_score": "0.056156",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.072655",
          "ticker_sentiment_score": "0.033536",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories's Options Frenzy: What You Need to Know - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/07/39993991/abbott-laboratoriess-options-frenzy-what-you-need-to-know",
      "time_published": "20240726T201547",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1722024944_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.200748,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.12742",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.584103",
          "ticker_sentiment_score": "0.254749",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Company News for Oct 17, 2024",
      "url": "https://www.zacks.com/stock/news/2352496/company-news-for-oct-17-2024",
      "time_published": "20241017T151100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Companies In The News Are: ABT, CFG, FHN, IBKR.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.094083,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IBKR",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "-0.075374",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "0.446592",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CFG",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "-0.306309",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "FHN",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "0.43542",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Unusual Options Activity - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/24/04/38209309/abbott-laboratories-unusual-options-activity",
      "time_published": "20240411T183113",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.209188,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.092213",
          "ticker_sentiment_score": "0.119894",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "0.25019",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.092213",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Company News for Apr 17, 2025",
      "url": "https://www.zacks.com/stock/news/2450640/company-news-for-apr-17-2025",
      "time_published": "20250417T134100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Companies In The News Article ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.189162,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMD",
          "relevance_score": "0.576289",
          "ticker_sentiment_score": "-0.096075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.576289",
          "ticker_sentiment_score": "0.351501",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PGR",
          "relevance_score": "0.576289",
          "ticker_sentiment_score": "0.135759",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.576289",
          "ticker_sentiment_score": "0.599573",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44227487/abbott-laboratories-options-trading-a-deep-dive-into-market-sentiment",
      "time_published": "20250310T164546",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1741625142_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.22507,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.077845",
          "ticker_sentiment_score": "0.088141",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.565644",
          "ticker_sentiment_score": "0.336021",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.077845",
          "ticker_sentiment_score": "0.088141",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/25/04/44811469/how-to-earn-500-a-month-from-abbott-laboratories-stock-ahead-of-q1-earnings",
      "time_published": "20250415T123537",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "A more conservative goal of $100 monthly dividend income would require 508 shares of Abbott. An investor would need to own $325,274 worth of Abbott Laboratories to generate a monthly dividend income of $500. China's new tariffs just reignited the same market patterns that led to triple- and ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/15/Vials-Of-Liquid-On-A-White-Table-And-The.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.27275,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BAC",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.093846",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.55992",
          "ticker_sentiment_score": "0.435422",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Are Abbott Laboratories Shares Trading Lower? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/24/07/39846741/why-are-abbott-laboratories-shares-trading-lower",
      "time_published": "20240718T185118",
      "authors": [
        "Vaishali Prayag"
      ],
      "summary": "Shares of Abbott Laboratories ABT are trading lower on Thursday following the company's second-quarter 2024 financial results. What's Going On: Abbott reported second-quarter sales of $10.377 billion, slightly beating the $10.371 billion estimate. EPS came in at $1.14, surpassing analyst ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Photo-by-solarseven-on-Shutterstock.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.272131,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.558244",
          "ticker_sentiment_score": "0.384685",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Stocks That Are Passive Income Machines to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/09/11/2-stocks-that-are-passive-income-machines-to-buy-a/",
      "time_published": "20240911T105900",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "You can take these dividends straight to the bank.",
      "banner_image": "https://g.foolcdn.com/editorial/images/789836/doctor-holding-elderly-patients-hand.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        }
      ],
      "overall_sentiment_score": 0.213804,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.515636",
          "ticker_sentiment_score": "0.377301",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.37552",
          "ticker_sentiment_score": "0.323864",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "This House of Representative Just Bought Up To $390K In Abbott Laboratories Stock - Abbott Laboratories  ( NYSE:ABT ) , Amazon.com  ( NASDAQ:AMZN ) ",
      "url": "https://www.benzinga.com/insights/government/25/04/44816766/this-house-of-representative-just-bought-up-to-390k-in-abbott-laboratories-stock",
      "time_published": "20250415T150013",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Records from April 14, 2025 indicate that Representative Byron Donalds of Florida made a purchase of Abbott Laboratories ABT, valued between $26,026 and $390,000, with the transaction dated April 14, 2025 and filed in April. As of now, Abbott Laboratories shares are trading down 0.46% at $126.78.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        }
      ],
      "overall_sentiment_score": 0.175538,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.500753",
          "ticker_sentiment_score": "0.285964",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GDDY",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CZBS",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FIZN",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2025/03/26/2-dividend-stocks-defying-the-market-dip-to-buy/",
      "time_published": "20250326T103000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie ( NYSE: ABBV ) and Abbott Laboratories ( NYSE: ABT ) .",
      "banner_image": "https://media.ycharts.com/charts/a183efe154e8c69ba4b94229ff633e9c.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.230732,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.39736",
          "ticker_sentiment_score": "0.18105",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.484798",
          "ticker_sentiment_score": "0.340425",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?",
      "url": "https://www.fool.com/investing/2024/09/16/abbott-laboratories-best-segment-just-got-even-bet/",
      "time_published": "20240916T091200",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "The company continues to flex its innovative muscles.",
      "banner_image": "https://g.foolcdn.com/editorial/images/790441/diabetes-patient-adjusting-device.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        }
      ],
      "overall_sentiment_score": 0.283356,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.48268",
          "ticker_sentiment_score": "0.351664",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories  ( ABT )  Is a Trending Stock: Facts to Know Before Betting on It",
      "url": "https://www.zacks.com/stock/news/2245920/abbott-laboratories-abt-is-a-trending-stock-facts-to-know-before-betting-on-it",
      "time_published": "20240326T130009",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.212924,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.475838",
          "ticker_sentiment_score": "0.096839",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/07/18/2-dividend-stocks-to-buy-and-hold-forever/",
      "time_published": "20240718T100100",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These stocks don't appeal only to dividend seekers.",
      "banner_image": "https://media.ycharts.com/charts/3b4d5c477812803f75516e8f312c00b2.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.433261,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.543004",
          "ticker_sentiment_score": "0.529633",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.464633",
          "ticker_sentiment_score": "0.545317",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.",
      "url": "https://www.fool.com/investing/2025/02/13/want-decades-of-passive-income-2-stocks-to-buy-now/",
      "time_published": "20250213T113500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off. These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient businesses to sustain dividend ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/806721/physician-shaking-patients-hand.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.321625,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.053271",
          "ticker_sentiment_score": "0.158701",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.452384",
          "ticker_sentiment_score": "0.578013",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.053271",
          "ticker_sentiment_score": "0.037804",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 2 Stocks to Buy Now.",
      "url": "https://www.fool.com/investing/2024/03/22/want-decades-of-passive-income-2-stocks-to-buy-now/",
      "time_published": "20240322T082500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.",
      "banner_image": "https://media.ycharts.com/charts/f446e49093d77d67a17c38a637be54f2.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.26315,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ISRG",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "0.188654",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.448316",
          "ticker_sentiment_score": "0.330782",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.448316",
          "ticker_sentiment_score": "0.347852",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946305/abbott-laboratories-attractive-valuation-ranks-it-among-top-large-cap-medtech-compa",
      "time_published": "20240919T190319",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Piper Sandler initiated coverage on Abbott Laboratories ABT, noting the company as a versatile large-cap with an attractive valuation. Abbott has a diversified business model with solid distribution across segments ( medtech, diagnostics, nutrition, pharmaceuticals ) and geography.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/19/untitled_4.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.20466,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RBGLY",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "-0.195087",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.440549",
          "ticker_sentiment_score": "0.261473",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.092927",
          "ticker_sentiment_score": "-0.136368",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/04/38290833/abbott-labs-q1-revenue-jumps-on-strong-medical-devices-sales-company-boosts-annual-guidance",
      "time_published": "20240417T124216",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Wednesday, Abbott Laboratories ABT reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported sales increased by 2.2%, which includes the anticipated decline in COVID-19 testing-related revenue ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.258151,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.431065",
          "ticker_sentiment_score": "-0.04899",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond",
      "url": "https://www.fool.com/investing/2024/12/19/2-top-dividend-stocks-to-buy-and-hold-through-2025/",
      "time_published": "20241219T110000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. Whatever the answer is, it probably won't be dividend investing.",
      "banner_image": "https://g.foolcdn.com/editorial/images/800762/nurse-holding-patients-hands.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        }
      ],
      "overall_sentiment_score": 0.334899,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.448842",
          "ticker_sentiment_score": "0.366317",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.40375",
          "ticker_sentiment_score": "0.40553",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Beaten-Down Dividend Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/04/28/2-beaten-down-dividend-stocks-to-buy-and-hold-fore/",
      "time_published": "20240428T114500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These companies aren't in danger of becoming has-beens.",
      "banner_image": "https://media.ycharts.com/charts/ff86d4effb822b188bf8b9f6bfe360a3.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972756"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.277201,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AAPL",
          "relevance_score": "0.478332",
          "ticker_sentiment_score": "0.331114",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.399911",
          "ticker_sentiment_score": "0.321287",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose - Canada Goose Hldgs  ( NYSE:GOOS ) ",
      "url": "https://www.benzinga.com/news/24/05/38939482/jim-cramer-calls-this-healthcare-stock-a-worthy-spec-recommends-avoiding-canada-goose",
      "time_published": "20240521T124412",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer recommended buying Dutch Bros Inc. BROS. On May 7, Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance. \"The outlook is fabulous.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/Shanghai-china-sep-9th-2023-Canada-Goose.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.157627,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MGTX",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.022322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BROS",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.585463",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NTNX",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "-0.007153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOS",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.235115",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance",
      "url": "https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-q1-2024-earnings/",
      "time_published": "20240417T115200",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "Abbott stock see-sawed early Wednesday after the giant health care company reported adjusted income of 98 cents a share on $10 billion in first-quarter sales. The Street projected earnings of 95 cents a share and $9.88 billion in sales, according to FactSet.",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.334599,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.373057",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.350658",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades' - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/08/40506059/abbott-laboratories-nu-holdings-and-more-on-cnbcs-final-trades",
      "time_published": "20240822T124821",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Halftime Report Final Trades,\" Karen Firestone of Aureus Asset Management said Abbott Laboratories ABT has a strong pipeline and the stock is starting to move. On July 18, Abbott reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/22/untitled_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.265802,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.392948",
          "ticker_sentiment_score": "0.552851",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NU",
          "relevance_score": "0.696319",
          "ticker_sentiment_score": "0.060157",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTS",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Price Over Earnings Overview: Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/news/24/10/41358117/price-over-earnings-overview-abbott-laboratories",
      "time_published": "20241016T141543",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "In the current session, the stock is trading at $118.67, after a 2.26% increase. Over the past month, Abbott Laboratories Inc. ABT stock increased by 3.30%, and in the past year, by 24.34%.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1729088141_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.040606,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.390904",
          "ticker_sentiment_score": "0.104761",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy for Decades of Passive Income",
      "url": "https://www.fool.com/investing/2025/07/06/2-dividend-stocks-to-buy-for-decades-of-passive-in/",
      "time_published": "20250706T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "In 2013, AbbVie ( NYSE: ABBV ) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories ( NYSE: ABT ) . Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F823870%2Fdoctor-with-patient-talking.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.375049,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.430251",
          "ticker_sentiment_score": "0.441601",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.386626",
          "ticker_sentiment_score": "0.479903",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/news/24/03/37961350/performance-comparison-abbott-laboratories-and-competitors-in-health-care-equipment-amp-supplies-in",
      "time_published": "20240327T150022",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Abbott Laboratories ABT and its primary competitors in the ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.2412,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.38489",
          "ticker_sentiment_score": "0.243522",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Recent Filing Shows That Rep. Josh Gottheimer Sold Over $32K Worth of Abbott Laboratories Stock - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/government/25/04/44764851/recent-filing-shows-that-rep-josh-gottheimer-sold-over-32k-worth-of-abbott-laboratories-stock",
      "time_published": "20250411T150016",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "A April filing shows that Representative Josh Gottheimer reported a sale in Abbott Laboratories ABT, valued between $32,032 and $480,000. The transaction date is listed as April 10, 2025, with the report published on April 10, 2025. At present, Abbott Laboratories shares are trading up 1.07% at ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        }
      ],
      "overall_sentiment_score": 0.198473,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.380978",
          "ticker_sentiment_score": "0.2639",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "A Look Into Abbott Laboratories Inc's Price Over Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/news/25/04/45048272/a-look-into-abbott-laboratories-incs-price-over-earnings",
      "time_published": "20250428T180037",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "In the current market session, Abbott Laboratories Inc. ABT share price is at $129.36, after a 0.40% spike. Moreover, over the past month, the stock fell by 1.77%, but in the past year, increased by 22.07%.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1745863234_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.045479,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.373378",
          "ticker_sentiment_score": "0.076057",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Tumble Nearly 8% In Pre-Market After US Jury Charges $495M Penalty For Disease Causing Baby Formula - Abbott Laboratories  ( NYSE:ABT ) , Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/general/biotech/24/07/40006590/abbott-laboratories-tumble-nearly-8-in-pre-market-after-us-jury-charges-495m-penalty-for-disease-",
      "time_published": "20240729T103046",
      "authors": [
        "Benzinga Neuro"
      ],
      "summary": "In a significant blow, Abbott Laboratories ABT saw its shares nosedive following a U.S. jury's ruling that found Abbott's formula was responsible for a girl developing a severe bowel disease, leading to a hefty $495 million penalty.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": -0.113315,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.371523",
          "ticker_sentiment_score": "-0.060196",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "-0.01988",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41389304/abbott-labs-path-to-double-digit-earnings-growth-in-2025-this-analyst-is-optimistic",
      "time_published": "20241017T184219",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99246"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.260445,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.369319",
          "ticker_sentiment_score": "0.167217",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/24/10/41228094/this-abbott-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday",
      "time_published": "20241008T130330",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer analyst Suraj Kalia initiated coverage on Abbott Laboratories ABT with an Outperform rating and ...",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51-1024x504.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.317175,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.367865",
          "ticker_sentiment_score": "0.457017",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.064667",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FXNC",
          "relevance_score": "0.367865",
          "ticker_sentiment_score": "0.463202",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "-0.094415",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCAX",
          "relevance_score": "0.367865",
          "ticker_sentiment_score": "-0.202607",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "RCUS",
          "relevance_score": "0.367865",
          "ticker_sentiment_score": "0.139662",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HWM",
          "relevance_score": "0.367865",
          "ticker_sentiment_score": "0.467303",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensign Expands Footprint With Buyout of Eight Healthcare Facilities",
      "url": "https://www.zacks.com/stock/news/2387090/ensign-expands-footprint-with-buyout-of-eight-healthcare-facilities",
      "time_published": "20241223T174300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ENSG agrees to buy eight healthcare facilities from Providence Home and Community Care, expanding its footprint.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.360586,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.362858",
          "ticker_sentiment_score": "0.145033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CDNA",
          "relevance_score": "0.294093",
          "ticker_sentiment_score": "0.147108",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DOCS",
          "relevance_score": "0.294093",
          "ticker_sentiment_score": "0.097908",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ENSG",
          "relevance_score": "0.490988",
          "ticker_sentiment_score": "0.662178",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Healthcare Stocks For Your Mid-July 2024 Watchlist",
      "url": "https://stockmarket.com/featured/2-healthcare-stocks-for-your-mid-july-2024-watchlist-2024-07-18",
      "time_published": "20240718T133821",
      "authors": [
        "Josh Dylan"
      ],
      "summary": "The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market's performance is influenced by economic conditions, company earnings, and global events.",
      "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/08/ABT-stock.jpg",
      "source": "StockMarket.com",
      "category_within_source": "n/a",
      "source_domain": "stockmarket.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998645"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999975"
        }
      ],
      "overall_sentiment_score": 0.226047,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HCSG",
          "relevance_score": "0.073773",
          "ticker_sentiment_score": "0.082986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.288893",
          "ticker_sentiment_score": "0.311273",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.356609",
          "ticker_sentiment_score": "0.25405",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/24/09/40937700/this-abbott-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday",
      "time_published": "20240919T124213",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler analyst Adam Maeder initiated coverage on Abbott Laboratories ABT with an Overweight rating ...",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.282128,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.348919",
          "ticker_sentiment_score": "-0.063093",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.348919",
          "ticker_sentiment_score": "0.272987",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HLX",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.175155",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NOG",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.211272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TPB",
          "relevance_score": "0.348919",
          "ticker_sentiment_score": "0.419196",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Massive Insider Trade At Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/news/24/05/38847898/massive-insider-trade-at-abbott-laboratories",
      "time_published": "20240515T150238",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Revealing a significant insider sell on May 14, Robert E. Funck Jr., Executive Vice President at Abbott Laboratories ABT, as per the latest SEC filing. What Happened: Jr.'s recent move involves selling 10,097 shares of Abbott Laboratories. This information is documented in a Form 4 filing with ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.996718"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        }
      ],
      "overall_sentiment_score": 0.219457,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.341699",
          "ticker_sentiment_score": "0.452044",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-",
      "time_published": "20241016T130823",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.390542,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SSTK",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.339356",
          "ticker_sentiment_score": "-0.171509",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Is Abbott Laboratories Stock a Buy?",
      "url": "https://www.fool.com/investing/2024/10/17/is-abbott-laboratories-stock-a-buy/",
      "time_published": "20241017T113000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "The healthcare stock is lagging the market this year.",
      "banner_image": "https://media.ycharts.com/charts/cf84002912a2a573df271a6031049b41.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.162632,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TRMNF",
          "relevance_score": "0.057907",
          "ticker_sentiment_score": "-0.062322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.115509",
          "ticker_sentiment_score": "0.091057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.337044",
          "ticker_sentiment_score": "0.349383",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's why we're buying more of this healthcare stock after its Friday sell-off",
      "url": "https://www.cnbc.com/2024/03/15/why-were-buying-more-of-this-healthcare-stock-after-friday-sell-off.html",
      "time_published": "20240315T145017",
      "authors": [
        "Zev Fima"
      ],
      "summary": "When news breaks and hits the stock price - but likely not the earnings number - you're getting an actual discount.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107281361-1691075973723-gettyimages-1229154325-Rafael_Henrique-17102020-1485.jpeg?v=1709224685&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.268191,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.33628",
          "ticker_sentiment_score": "0.272254",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Buy Rated Stocks to Consider as Earnings Approach",
      "url": "https://www.zacks.com/commentary/2254910/3-buy-rated-stocks-to-consider-as-earnings-approach",
      "time_published": "20240413T005700",
      "authors": [
        "Shaun Pruitt"
      ],
      "summary": "Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default94.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998311"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.242905,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IBKR",
          "relevance_score": "0.411848",
          "ticker_sentiment_score": "0.265562",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.33514",
          "ticker_sentiment_score": "0.295935",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.484191",
          "ticker_sentiment_score": "0.369789",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "P/E Ratio Insights for Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/news/24/10/41462513/pe-ratio-insights-for-abbott-laboratories",
      "time_published": "20241022T173046",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "In the current market session, Abbott Laboratories Inc. ABT stock price is at $116.19, after a 0.68% decrease. However, over the past month, the company's stock increased by 2.51%, and in the past year, by 24.17%.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1729618243_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.130125,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.334762",
          "ticker_sentiment_score": "0.123989",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Amazon, Abbott Laboratories And 2 Other Stocks Insiders Are Selling - Amazon.com  ( NASDAQ:AMZN ) ",
      "url": "https://www.benzinga.com/news/24/05/38730179/amazon-abbott-laboratories-and-2-other-stocks-insiders-are-selling",
      "time_published": "20240509T123558",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The Nasdaq 100 closed slightly lower on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/09/amazon-fans-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.14526,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DTST",
          "relevance_score": "0.085936",
          "ticker_sentiment_score": "0.02927",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.111122",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZM",
          "relevance_score": "0.410505",
          "ticker_sentiment_score": "0.197013",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.253866",
          "ticker_sentiment_score": "0.271349",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "STX",
          "relevance_score": "0.253866",
          "ticker_sentiment_score": "0.113431",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's Going On With Abbott Laboratories Stock On Friday? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/large-cap/24/03/37755685/whats-going-on-with-abbott-laboratories-stock-on-friday",
      "time_published": "20240315T174845",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "An Illinois jury has issued a verdict compelling Reckitt Benckiser Group Plc's RBGLY RBGPF Mead Johnson to pay $60 million to the mother of a premature infant who tragically succumbed to necrotizing enterocolitis ( NEC ) after being fed the company's Enfamil baby formula.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Port-Charlotte--Florida---February-15--2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.051073,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.333257",
          "ticker_sentiment_score": "0.205394",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.22595",
          "ticker_sentiment_score": "-0.060798",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/25/01/43131874/abbott-q4-sales-fall-short-of-estimates-issues-q1-profit-guidance-lower-than-street-view",
      "time_published": "20250122T151748",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Abbott reported Q4 sales of $11 billion missing the consensus; adjusted EPS was $1.34, matching analyst estimates Medical Device sales surged 13.7% to $5.05 billion, with FreeStyle Libre and AVEIR driving growth. Get the Real Story Behind Every Major Earnings Report",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/22/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.365353,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SSTK",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "-0.103671",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/large-cap/24/09/40738686/abbott-laboratories-recalls-some-sensors-for-its-popular-freestyle-libre-3-glucose-monitoring-syst",
      "time_published": "20240905T184524",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Thursday, Abbott Laboratories ABT said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.046575,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.324495",
          "ticker_sentiment_score": "0.087574",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer - Abbott Laboratories  ( NYSE:ABT ) , Cummins  ( NYSE:CMI ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/04/38216143/jim-cramer-calls-cummins-terrific-recommends-selling-this-chinese-auto-manufacturer",
      "time_published": "20240412T124301",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he likes New Fortress Energy Inc. NFE, but \"right now Wes Edens [co-founder of Fortress Investment Group and founder of New Fortress Energy] is kind of just hurt by the president.\"",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/12/cummins-logo-signage-social.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.261859,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.321673",
          "ticker_sentiment_score": "0.207805",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NFE",
          "relevance_score": "0.510588",
          "ticker_sentiment_score": "-0.026784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PNC",
          "relevance_score": "0.419733",
          "ticker_sentiment_score": "-0.011724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NIO",
          "relevance_score": "0.419733",
          "ticker_sentiment_score": "-0.091001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CMI",
          "relevance_score": "0.419733",
          "ticker_sentiment_score": "0.707746",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.217834",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41380804/these-analysts-increase-their-forecasts-on-abbott-laboratories-after-better-than-expected-q3-earnin",
      "time_published": "20241017T131442",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday. The company posted sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Abbott's adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-1024x512.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.307297,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.163909",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.320974",
          "ticker_sentiment_score": "0.696511",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Congressional Trading Report: Rep. Thomas Kean Bought Over $1K In Abbott Laboratories Stock - Abbott Laboratories  ( NYSE:ABT ) , Canadian Pacific Kansas  ( NYSE:CP ) ",
      "url": "https://www.benzinga.com/insights/government/25/01/43168307/congressional-trading-report-rep-thomas-kean-bought-over-1k-in-abbott-laboratories-stock",
      "time_published": "20250123T170134",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "January 22, 2025 records indicate that Representative Thomas Kean filed a purchase of Abbott Laboratories ABT, valued between $1,001 and $15,000. According to the January filing, the transaction occurred on January 22, 2025. Currently, Abbott Laboratories shares are trading up 2.78% at $121.05.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.15956,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AON",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LBTYA",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.257512",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PDRDF",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "A Look Into Abbott Laboratories Inc's Price Over Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/news/24/10/41232001/a-look-into-abbott-laboratories-incs-price-over-earnings",
      "time_published": "20241008T150026",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "In the current market session, Abbott Laboratories Inc. ABT share price is at $114.38, after a 0.90% increase. Moreover, over the past month, the stock decreased by 2.33%, but in the past year, spiked by 24.15%.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1728399623_0_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.222972,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.317527",
          "ticker_sentiment_score": "0.098827",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings - Abbott Laboratories  ( NYSE:ABT ) , Biomerica  ( NASDAQ:BMRA ) ",
      "url": "https://www.benzinga.com/25/04/44840040/nasdaq-down-over-2-abbott-laboratories-posts-upbeat-earnings",
      "time_published": "20250416T140606",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday. The Dow traded down 0.67% to 40,099.73 while the NASDAQ dipped 2.12% to 16,466.96. The S&P 500 also fell, dropping, 1.27% to 5,327.95. Energy shares surged by 1.4% on Wednesday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/16/WallStreet-Banks-Shutterstock.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.155803,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OST",
          "relevance_score": "0.239698",
          "ticker_sentiment_score": "0.185038",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.31583",
          "ticker_sentiment_score": "0.105311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMRA",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "-0.257548",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ZEO",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.390107",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TGL",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "0.195286",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.228039",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ICAD",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "0.295655",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "5 Stocks to Watch for Earnings This Week",
      "url": "https://www.zacks.com/stock/news/2400635/5-stocks-to-watch-for-earnings-this-week",
      "time_published": "20250121T154900",
      "authors": [
        "Tracey Ryniec"
      ],
      "summary": "Zacks Stock Strategist, Tracey Ryniec, discusses 5 stock charts, including Netflix.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default315.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.062031,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.374875",
          "ticker_sentiment_score": "0.215056",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.304114",
          "ticker_sentiment_score": "0.074631",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAL",
          "relevance_score": "0.442339",
          "ticker_sentiment_score": "0.075072",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.442339",
          "ticker_sentiment_score": "0.09709",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNP",
          "relevance_score": "0.442339",
          "ticker_sentiment_score": "-0.234951",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday - D.R. Horton  ( NYSE:DHI ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39831466/d-r-horton-netflix-and-3-stocks-to-watch-heading-into-thursday",
      "time_published": "20240718T070512",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects D.R. Horton, Inc. DHI to report quarterly earnings at $3.77 per share on revenue of $9.77 billion before the opening bell, according to data ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/DR-Horton.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997335"
        }
      ],
      "overall_sentiment_score": 0.339832,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.43852",
          "ticker_sentiment_score": "0.372902",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.301315",
          "ticker_sentiment_score": "0.247786",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.301315",
          "ticker_sentiment_score": "0.250759",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.43852",
          "ticker_sentiment_score": "0.670141",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Got $200? 2 Healthcare Stocks to Buy and Hold Forever.",
      "url": "https://www.fool.com/investing/2024/04/11/got-200-2-healthcare-stocks-to-buy-and-hold/",
      "time_published": "20240411T101500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These companies provide stability, reliability, and passive income.",
      "banner_image": "https://media.ycharts.com/charts/82310276ba6dc41056260e1c00a407ca.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.327868,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.410697",
          "ticker_sentiment_score": "0.393096",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.30021",
          "ticker_sentiment_score": "0.179566",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday",
      "url": "https://www.fool.com/investing/2025/03/27/why-abbott-laboratories-stock-leaped-by-almost-4-o/",
      "time_published": "20250327T225448",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "Abbott Laboratories ( NYSE: ABT ) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. Investors greeted this positively, rewarding the company with a share price gain on the day that approached 4%.",
      "banner_image": "https://g.foolcdn.com/editorial/images/812838/two-people-participating-in-a-telehealth-session.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.321391,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.295867",
          "ticker_sentiment_score": "0.643095",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/large-cap/24/07/39673676/similac-baby-formula-maker-abbott-and-reckitt-face-hundreds-of-baby-formula-lawsuits",
      "time_published": "20240708T183901",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Abbott Laboratories ABT is set to face trial on Monday over allegations that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease known as necrotizing enterocolitis ( NEC ) . This is the second trial out of hundreds of similar ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/08/Similac.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.226478,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.295867",
          "ticker_sentiment_score": "-0.024613",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.199859",
          "ticker_sentiment_score": "-0.074046",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "We're buying a health-care stock that should be higher after reporting a strong quarter",
      "url": "https://www.cnbc.com/2024/04/17/were-buying-a-health-care-stock-that-should-be-higher-after-reporting-a-strong-quarter.html",
      "time_published": "20240417T124634",
      "authors": [
        "Jeff Marks"
      ],
      "summary": "It's the third time in recent weeks that we've added to our position in the medical device maker.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107380826-1709261160392-gettyimages-146355972-e592be27-397e-433b-ae59-1c3cc44b6a8f.jpeg?v=1713281268&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.972756"
        }
      ],
      "overall_sentiment_score": 0.27593,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.295867",
          "ticker_sentiment_score": "0.254712",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday - Abbott Laboratories  ( NYSE:ABT ) , U.S. Bancorp  ( NYSE:USB ) ",
      "url": "https://www.benzinga.com/news/earnings/24/04/38284954/abbott-laboratories-u-s-bancorp-and-3-stocks-to-watch-heading-into-wednesday",
      "time_published": "20240417T060622",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Abbott Laboratories ABT to report quarterly earnings at 95 cents per share on revenue of $9.88 billion before the opening bell, according to ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/abbott_laboratories_-_logo.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972476"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.183452,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TRV",
          "relevance_score": "0.29234",
          "ticker_sentiment_score": "0.404164",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.29234",
          "ticker_sentiment_score": "0.420657",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.426225",
          "ticker_sentiment_score": "-0.090258",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OTRK",
          "relevance_score": "0.426225",
          "ticker_sentiment_score": "-0.149526",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/general/biotech/24/07/39861919/abbott-labs-makes-marketing-push-for-new-glucose-monitors-targets-health-conscious-consumers",
      "time_published": "20240719T151041",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Abbott Laboratories ABT CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/19/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.308181,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.194242",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.194242",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.287762",
          "ticker_sentiment_score": "0.117819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Abbott Laboratories Stock Was a Winner on Wednesday",
      "url": "https://www.fool.com/investing/2024/10/16/why-abbott-laboratories-stock-was-a-winner-on-wedn/",
      "time_published": "20241016T224153",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "Investors bumped its shares higher following a decent, if unspectacular, earnings report.",
      "banner_image": "https://g.foolcdn.com/editorial/images/794367/child-receiving-a-vaccination-shot-from-a-healthcare-professional.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.367497,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.2872",
          "ticker_sentiment_score": "0.528368",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "5 Top Stock Charts for This Week",
      "url": "https://www.zacks.com/stock/news/2448823/5-top-stock-charts-for-this-week",
      "time_published": "20250415T004200",
      "authors": [
        "Tracey Ryniec"
      ],
      "summary": "Tracey Ryniec talks about a new strategy for Q1 earnings season, including impacts of the tariffs, on ABT, TSM, AXP, MAN, and DHI.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default276.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998626"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.064414,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.14923",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.006387",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.134059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.134059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.477986",
          "ticker_sentiment_score": "0.056352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MAN",
          "relevance_score": "0.416844",
          "ticker_sentiment_score": "-0.265628",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.145145",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Class Action Against Abbott's Glucerna Products Proceeds in Federal Court - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/general/biotech/24/06/39233852/class-action-against-abbotts-glucerna-products-proceeds-in-federal-court",
      "time_published": "20240607T181749",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "A California federal judge has reportedly allowed litigation to proceed against Abbott Laboratories ABT regarding its Glucerna shakes and nutritional powders. The lawsuit claims these products, marketed as suitable for people with diabetes, contain harmful ingredients. U.S. District Judge P.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.004838,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.281153",
          "ticker_sentiment_score": "0.02091",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare",
      "url": "https://www.zacks.com/stock/news/2240735/zacks-investment-ideas-feature-highlights-tenet-healthcare-and-hca-healthcare",
      "time_published": "20240314T130200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995973"
        }
      ],
      "overall_sentiment_score": 0.33877,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.097794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.193772",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.280938",
          "ticker_sentiment_score": "0.295843",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "FDA Approves Abbott's Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/markets/equities/24/04/38053214/fda-approves-abbotts-heart-valve-repair-device-for-patients-at-risk-of-complicationsdeath-during",
      "time_published": "20240402T170012",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Tuesday, the FDA approved Abbott Laboratories' ABT first-of-its-kind TriClip transcatheter edge-to-edge repair ( TEER ) system that's specifically designed to treat tricuspid regurgitation ( TR ) , or a leaky tricuspid valve.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Monitoring-Of-Patients-Heart-In-Intensiv.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.244161,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.28008",
          "ticker_sentiment_score": "0.190289",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Pearson  ( NYSE:PSO ) ",
      "url": "https://www.benzinga.com/news/24/07/40009533/abbott-integra-lifesciences-and-other-big-stocks-moving-lower-in-mondays-pre-market-session",
      "time_published": "20240729T122400",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday. Shares of Abbott Laboratories ABT fell in today's pre-market trading after the company was ordered to pay $495 million in damages in its baby formula case.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/movers-image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.071322,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PDD",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.343019",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "GPRK",
          "relevance_score": "0.405651",
          "ticker_sentiment_score": "-0.322771",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ICL",
          "relevance_score": "0.405651",
          "ticker_sentiment_score": "-0.07281",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.133591",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMMP",
          "relevance_score": "0.405651",
          "ticker_sentiment_score": "-0.023426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IART",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.146374",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EZPW",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.133591",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NAMS",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.363985",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Berkshire Hathaway, Chipotle, More NYSE Stocks Hit With Trading Halts Triggered By Technical Issues - Abbott Laboratories  ( NYSE:ABT ) , Ault Disruptive Tech  ( AMEX:ADRT ) ",
      "url": "https://www.benzinga.com/markets/equities/24/06/39138985/berkshire-hathaway-chipotle-more-nyse-stocks-hit-with-trading-halts-triggered-by-technical-issue",
      "time_published": "20240603T143746",
      "authors": [
        "Piero Cingari"
      ],
      "summary": "Multiple stocks on the New York Stock Exchange experienced sudden trading halts after 9:40 a.m. ET Monday due to technical issues. The unexpected pauses in trading were triggered by a technical issue categorized under the \"Limit Up/Limit Down\" code, which is typically used to curb excessive ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/NYSE.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999767"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": -0.182235,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "GOLD",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.279667",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.279667",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "DXYZ",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.279667",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.268877",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NMG",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.279667",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SMR",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "-0.279667",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CMG",
          "relevance_score": "0.405651",
          "ticker_sentiment_score": "-0.047001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? 'Something May Be Wrong Here' - Abbott Laboratories  ( NYSE:ABT ) , Casella Waste Sys  ( NASDAQ:CWST ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/01/43230206/jim-cramer-is-worried-about-this-consumer-cyclical-stock-7-yield-something-may-be-wrong-",
      "time_published": "20250127T132914",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Nu Holdings is a \"really hard\" company, says Cramer. He prefers SOFI. Jim Cramer cannot sanction buying TETRA Technologies. Get Pro-Level Earnings Insights Before the Market Moves On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he is worried about The Wendy's Company WEN.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/27/Jim-Cramer-Photo-by-s-bukley-on-Shutters.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.104337,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WEN",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "-0.013233",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "0.28755",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.046681",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.011767",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WM",
          "relevance_score": "0.18602",
          "ticker_sentiment_score": "-0.106281",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NU",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.170251",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TTI",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SOFI",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "0.040479",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CWST",
          "relevance_score": "0.18602",
          "ticker_sentiment_score": "-0.106281",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's Growth and Dividends Make It a Smart Portfolio Pick - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41382172/abbotts-growth-and-dividends-make-it-a-smart-portfolio-pick",
      "time_published": "20241017T165711",
      "authors": [
        "MarketBeat"
      ],
      "summary": "There are many reasons to own Abbott Laboratories ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among ...",
      "banner_image": "https://www.marketbeat.com/logos/articles/med_20241016081501_chart-abt-10162024.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.287987,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.275246",
          "ticker_sentiment_score": "0.200371",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Better Buy: Abbott Laboratories vs. Intuitive Surgical",
      "url": "https://www.fool.com/investing/2024/07/26/better-buy-abbott-laboratories-vs-intuitive-surgic/",
      "time_published": "20240726T092700",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "The medical technology business has been good for both companies, but which is right for your portfolio?",
      "banner_image": "https://g.foolcdn.com/editorial/images/784235/investor-calculator-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.207029,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.268",
          "ticker_sentiment_score": "0.309649",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.049981",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.368383",
          "ticker_sentiment_score": "0.271892",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.049981",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "We're buying more of this health-care company amid an overdone sell-off",
      "url": "https://www.cnbc.com/2024/03/21/were-buying-more-of-this-health-care-company-amid-an-overdone-sell-off.html",
      "time_published": "20240321T130905",
      "authors": [
        "Jeff Marks"
      ],
      "summary": "The company has lost billions in market capitalization over the past few trading sessions.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107357257-1704980167454-gettyimages-1923334243-em025859_2024011024645207.jpeg?v=1711024629&w=1920&h=1080",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.075114,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.080992",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.268",
          "ticker_sentiment_score": "0.27434",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.080992",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "-0.06",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zacks Investment Ideas feature highlights: Abbott Laboratories, Equifax and SL Green Realty",
      "url": "https://www.zacks.com/stock/news/2351607/zacks-investment-ideas-feature-highlights-abbott-laboratories-equifax-and-sl-green-realty",
      "time_published": "20241016T140300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott Laboratories, Equifax and SL Green Realty are part of the Zacks Investment Ideas article.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999986"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.36574,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EFX",
          "relevance_score": "0.391923",
          "ticker_sentiment_score": "0.420868",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.267559",
          "ticker_sentiment_score": "0.341842",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SLG",
          "relevance_score": "0.330876",
          "ticker_sentiment_score": "0.357156",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?",
      "url": "https://www.zacks.com/stock/news/2570806/abts-freestyle-libre-3-plus-now-available-in-canada-stock-to-rise",
      "time_published": "20250710T122100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.246531,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.262805",
          "ticker_sentiment_score": "0.333737",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.211652",
          "ticker_sentiment_score": "0.066637",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.111998",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.0215",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday - HomeStreet  ( NASDAQ:HMST ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41350412/morgan-stanley-abbott-laboratories-and-3-stocks-to-watch-heading-into-wednesday",
      "time_published": "20241016T063406",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Morgan Stanley MS to report quarterly earnings at $1.58 per share on revenue of $14.41 billion before the opening bell, according to data from ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/morgan-stanley-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999336"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.34662,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IBKR",
          "relevance_score": "0.38489",
          "ticker_sentiment_score": "-0.086984",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.38489",
          "ticker_sentiment_score": "0.513186",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.262522",
          "ticker_sentiment_score": "0.322708",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Excellent Dividend Stocks to Buy With Less Than $200",
      "url": "https://www.fool.com/investing/2024/09/28/2-excellent-dividend-stocks-to-buy-with-less-than/",
      "time_published": "20240928T090000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.",
      "banner_image": "https://media.ycharts.com/charts/f09d2b0e2d98551346d9b46063a4402f.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.244485,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.25726",
          "ticker_sentiment_score": "0.311586",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.306325",
          "ticker_sentiment_score": "0.184425",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Jim Cramer: Abbott Laboratories 'Legal Stuff' Is Behind Them - Archer Aviation  ( NYSE:ACHR ) , Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-",
      "time_published": "20241211T140622",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Occidental Petroleum OXY is one of his \"least favorite oils.\"",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/11/jim-cramer-shutterstock.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.133721,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OXY",
          "relevance_score": "0.488007",
          "ticker_sentiment_score": "-0.391283",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "ACHR",
          "relevance_score": "0.377142",
          "ticker_sentiment_score": "0.412809",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "COO",
          "relevance_score": "0.377142",
          "ticker_sentiment_score": "0.225036",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.256989",
          "ticker_sentiment_score": "0.090066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "-0.102167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.377142",
          "ticker_sentiment_score": "0.21559",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMS",
          "relevance_score": "0.377142",
          "ticker_sentiment_score": "-0.16448",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ET",
          "relevance_score": "0.377142",
          "ticker_sentiment_score": "0.580752",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
      "url": "https://www.fool.com/investing/2025/04/28/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
      "time_published": "20250428T114700",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/816017/person-smiling-and-looking-at-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        }
      ],
      "overall_sentiment_score": 0.360652,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.375879",
          "ticker_sentiment_score": "0.383007",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.29689",
          "ticker_sentiment_score": "0.312283",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.256089",
          "ticker_sentiment_score": "0.245564",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories, Travelers Companies And 3 Stocks To Watch Heading Into Wednesday - Abbott Laboratories  ( NYSE:ABT ) , ASML Holding  ( NASDAQ:ASML ) ",
      "url": "https://www.benzinga.com/25/04/44831969/abbott-laboratories-travelers-companies-and-3-stocks-to-watch-heading-into-wednesday",
      "time_published": "20250416T072824",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Abbott Laboratories ABT to report quarterly earnings at $1.07 per share on revenue of $10.40 billion before the opening bell, according to ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/16/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.995921"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.2611,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TRV",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.30923",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PGR",
          "relevance_score": "0.375251",
          "ticker_sentiment_score": "0.477245",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.293187",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.375251",
          "ticker_sentiment_score": "0.068602",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales - Abbott Laboratories  ( NYSE:ABT ) , Absci  ( NASDAQ:ABSI ) ",
      "url": "https://www.benzinga.com/news/earnings/25/01/43141158/crude-oil-edges-lower-abbott-laboratories-posts-weak-sales",
      "time_published": "20250122T193904",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday. The Dow traded up 0.27% to 44,146.86 while the NASDAQ rose 1.29% to 20,010.85. The S&P 500 also rose, gaining, 0.70% to 6,091.74. Information technology shares surged by 2.5% on ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/22/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.213871,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.011508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LSTA",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "-0.102479",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABSI",
          "relevance_score": "0.086556",
          "ticker_sentiment_score": "0.195151",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IPA",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.238386",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGYS",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.24114",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BLBX",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.377728",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HEPA",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.159483",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/general/health-care/25/04/44838946/abbott-labs-clocks-q1-profit-beat-ceo-says-diversification-and-execution-enable-navigation-du",
      "time_published": "20250416T134428",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Q1 sales rose 7.2% to $10.36 billion; adjusted EPS of $1.09 beat the consensus of $1.07 and topped the guidance range. Medical Device sales hit $4.89 billion, up 9.9%, led by FreeStyle Libre and heart-related product growth.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/16/Oct-15--2019-Sunnyvale-----Ca-----Usa---_3.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.342145,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.254973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?",
      "url": "https://www.zacks.com/stock/news/2332712/abbotts-lingo-cgm-system-gains-us-availability-stock-to-gain",
      "time_published": "20240906T133700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.293906,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TMDX",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.144392",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.253514",
          "ticker_sentiment_score": "0.293932",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "0.12946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.057773",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.253514",
          "ticker_sentiment_score": "0.197138",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Roche  ( RHHBY )  Launches AI-Based Predictive CGM Accu-Chek",
      "url": "https://www.zacks.com/stock/news/2239783/roche-rhhby-launches-ai-based-predictive-cgm-accu-chek",
      "time_published": "20240313T115600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.333849,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.239508",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.252332",
          "ticker_sentiment_score": "0.355314",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.127795",
          "ticker_sentiment_score": "0.123507",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "We're adding to our geopolitical hedge and a struggling health-care stock",
      "url": "https://www.cnbc.com/2024/05/29/were-adding-to-our-geopolitical-hedge-and-a-struggling-health-care-stock.html",
      "time_published": "20240529T133450",
      "authors": [
        "Jeff Marks"
      ],
      "summary": "We're adding to our lone oil stock and an out-of-favor medical-technology company.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107394152-1711627809352-gettyimages-2118602274-01-bb2_1227-_05c3dsrv.jpeg?v=1716987437&w=1920&h=1080",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.363646,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.251247",
          "ticker_sentiment_score": "0.29865",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRO",
          "relevance_score": "0.085022",
          "ticker_sentiment_score": "0.16501",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.085022",
          "ticker_sentiment_score": "0.16501",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CTRA",
          "relevance_score": "0.330654",
          "ticker_sentiment_score": "0.364603",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Abbott, Taiwan Semiconductor, American Express, ManpowerGroup and D.R. Horton",
      "url": "https://www.zacks.com/stock/news/2448891/the-zacks-analyst-blog-abbott-taiwan-semiconductor-american-express-manpowergroup-and-dr-horton",
      "time_published": "20250415T112500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott, Taiwan Semiconductor, American Express, ManpowerGroup and D.R. Horton are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/70438.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998626"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.023966,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "0.148149",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.003777",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "0.133117",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "0.133117",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.47672",
          "ticker_sentiment_score": "0.033941",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MAN",
          "relevance_score": "0.423504",
          "ticker_sentiment_score": "-0.163807",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.189175",
          "ticker_sentiment_score": "-0.03397",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?",
      "url": "https://www.fool.com/investing/2024/08/12/abbott-laboratories-stock-could-soar-to-143-accord/",
      "time_published": "20240813T002900",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "An unexpected diabetes partnership with Medtronic bodes well for Abbott's biggest growth driver.",
      "banner_image": "https://g.foolcdn.com/editorial/images/786808/investment-presentation2-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.247093,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "-0.109967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.249873",
          "ticker_sentiment_score": "0.221881",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.217437",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.201105",
          "ticker_sentiment_score": "0.176356",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.040944",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Molson Coors, CenterPoint Energy, WEC Energy, Abbott Laboratories and HCA Healthcare",
      "url": "https://www.zacks.com/stock/news/2441614/the-zacks-analyst-blog-highlights-molson-coors-centerpoint-energy-wec-energy-abbott-laboratories-and-hca-healthcare",
      "time_published": "20250408T101300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Molson Coors, CenterPoint Energy, WEC Energy, Abbott Laboratories and HCA Healthcare are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bc/2889.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.246146,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TAP",
          "relevance_score": "0.247208",
          "ticker_sentiment_score": "0.273487",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.247208",
          "ticker_sentiment_score": "0.244412",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CNP",
          "relevance_score": "0.306198",
          "ticker_sentiment_score": "0.420523",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WEC",
          "relevance_score": "0.247208",
          "ticker_sentiment_score": "0.260143",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.247208",
          "ticker_sentiment_score": "0.175161",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Medical Devices ETF Hits 52-Week High: Stocks to Watch",
      "url": "https://www.zacks.com/commentary/2240185/medical-devices-etf-hits-52-week-high-stocks-to-watch",
      "time_published": "20240313T163800",
      "authors": [
        "Bryan Hayes"
      ],
      "summary": "Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        }
      ],
      "overall_sentiment_score": 0.341039,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.306198",
          "ticker_sentiment_score": "0.121662",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.306198",
          "ticker_sentiment_score": "0.243875",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.247208",
          "ticker_sentiment_score": "0.366443",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Columbus Day: Is Stock Market Open Today? - Abbott Laboratories  ( NYSE:ABT ) , Bank of America  ( NYSE:BAC ) ",
      "url": "https://www.benzinga.com/news/24/10/41309748/columbus-day-is-stock-market-open-today",
      "time_published": "20241014T104616",
      "authors": [
        "Benzinga Neuro"
      ],
      "summary": "As Columbus Day approaches, investors and market participants are preparing for a unique trading environment. This U.S. holiday, observed on Monday, October 14, 2024, will see a mix of open and closed financial markets, impacting trading activities.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Market-Update.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999696"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.173887,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.10352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.10352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.22275",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.10352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.10352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.10352",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Stock Gains Following FDA Approval of the Tendyne System",
      "url": "https://www.zacks.com/stock/news/2478135/abbott-stock-gains-following-fda-approval-of-the-tendyne-system",
      "time_published": "20250528T132200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/667.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.296642,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PAHC",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.111778",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STE",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.158344",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.243498",
          "ticker_sentiment_score": "0.159893",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services",
      "url": "https://www.zacks.com/stock/news/2251993/the-zacks-analyst-blog-highlights-t-mobile-us-abbott-laboratories-palo-alto-networks-enterprise-products-partners-and-the-pnc-financial-services",
      "time_published": "20240408T131300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e3/536.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.294667,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TMUS",
          "relevance_score": "0.243498",
          "ticker_sentiment_score": "0.147942",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.243498",
          "ticker_sentiment_score": "0.24056",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PNC",
          "relevance_score": "0.123209",
          "ticker_sentiment_score": "0.034191",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PANW",
          "relevance_score": "0.243498",
          "ticker_sentiment_score": "0.07784",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39831467/abbott-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-a",
      "time_published": "20240718T070512",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18. Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.10 per share, up from $1.08 per share in the year-ago period.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/untitled.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.119396,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.15245",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.082227",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.073049",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday - Interactive Brokers Gr  ( NASDAQ:IBKR ) , Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/25/01/43119868/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-wednesday",
      "time_published": "20250122T065559",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Abbott Laboratories ABT to report quarterly earnings at $1.34 per share on revenue of $11.01 billion before the opening bell, according to ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/22/10-Netflix-Holiday-Episodes-To-Keep-You-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998932"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.353013,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.457566",
          "ticker_sentiment_score": "0.117026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBKR",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.48231",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "0.273619",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.470511",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.407205",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39853970/dow-plunges-over-500-points-following-unexpected-surge-in-us-jobless-claims",
      "time_published": "20240719T064810",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the \"Neutral\" zone on Thursday. U.S. stocks closed lower on Thursday, with the Dow Jones index falling more than 500 points during the session.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/19/Stocks-Photo-by-Phongphan-on-Shutterstoc.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.201381,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SLB",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "-0.135115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "-0.328443",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "-0.210339",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SSTK",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAL",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "-0.210339",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.331738",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Unstoppable Dividend Stocks to Buy Right Now",
      "url": "https://www.fool.com/investing/2024/08/25/3-unstoppable-dividend-stocks-to-buy-right-now/",
      "time_published": "20240825T223000",
      "authors": [
        "and Prosper Junior Bakiny",
        "Keith Speights",
        "David Jagielski"
      ],
      "summary": "These stocks are the A-team for income investors.",
      "banner_image": "https://g.foolcdn.com/editorial/images/788183/two-people-looking-at-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.382955,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.282777",
          "ticker_sentiment_score": "0.365654",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.282777",
          "ticker_sentiment_score": "0.335334",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.237204",
          "ticker_sentiment_score": "0.186795",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41351053/abbott-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-a",
      "time_published": "20241016T075353",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Abbott Laboratories ABT will release earnings results for its third quarter, before the opening bell on Wednesday, Oct. 16. Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.2 per share, up from $1.14 per share in the year-ago period.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Stock-market-analysts.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.185746,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Defensive Stocks to Buy for a Safe Portfolio Amid Tariff-Led Mayhem",
      "url": "https://www.zacks.com/stock/news/2441093/5-defensive-stocks-to-buy-for-a-safe-portfolio-amid-tariff-led-mayhem",
      "time_published": "20250407T121400",
      "authors": [
        "Nalak Das"
      ],
      "summary": "Five defensive stocks to buy at this soaring volatility are TAP, CNP, WEC, BSX, HCA.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3f/49151.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99793"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.244238,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TAP",
          "relevance_score": "0.232598",
          "ticker_sentiment_score": "0.314467",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.232598",
          "ticker_sentiment_score": "0.281762",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CNP",
          "relevance_score": "0.296264",
          "ticker_sentiment_score": "0.48666",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WEC",
          "relevance_score": "0.232598",
          "ticker_sentiment_score": "0.304849",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.232598",
          "ticker_sentiment_score": "0.206494",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone - Abbott Laboratories  ( NYSE:ABT ) , D.R. Horton  ( NYSE:DHI ) ",
      "url": "https://www.benzinga.com/markets/25/01/43120493/dow-jumps-over-500-points-as-trump-takes-office-investor-sentiment-improves-but-greed-index-remains-in-fe",
      "time_published": "20250122T075527",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed further improvement in overall market sentiment, but the index remained in the \"Fear\" zone on Tuesday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/22/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.053455,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WBD",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "-0.187517",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMM",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.596664",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone - Abbott Laboratories  ( NYSE:ABT ) , D.R. Horton  ( NYSE:DHI ) ",
      "url": "https://www.benzinga.com/news/25/01/43120493/dow-jumps-over-500-points-as-trump-takes-office-investor-sentiment-improves-but-greed-index-remains",
      "time_published": "20250122T075526",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed further improvement in overall market sentiment, but the index remained in the \"Fear\" zone on Tuesday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/22/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.053455,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WBD",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "-0.187517",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMM",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.596664",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investor Optimism Decreases; Dow Ends 6-Session Losing Streak - Abbott Laboratories  ( NYSE:ABT ) , Bank of America  ( NYSE:BAC ) ",
      "url": "https://www.benzinga.com/news/earnings/24/04/38284995/investor-optimism-decreases-dow-ends-6-session-losing-streak",
      "time_published": "20240417T060633",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index remaining in the \"Fear\" zone on Tuesday. U.S. stocks closed mixed on Tuesday amid increased geopolitical concerns. The Dow Jones index, meanwhile, snapped its six-session losing streak.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/image27.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.207898,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "WBD",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "-0.386828",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.357554",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.357554",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Cisco Systems, Abbott Laboratories and Coca-Cola",
      "url": "https://www.zacks.com/stock/news/2404121/the-zacks-analyst-blog-highlights-cisco-systems-abbott-laboratories-and-coca-cola",
      "time_published": "20250127T184800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Cisco Systems, Abbott Laboratories and Coca-Cola are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/405.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.301479,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.364987",
          "ticker_sentiment_score": "0.197488",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.22421",
          "ticker_sentiment_score": "0.059058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.22421",
          "ticker_sentiment_score": "0.059058",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dependable Dividend Stocks That Can Pay You for Life",
      "url": "https://www.fool.com/investing/2025/03/07/2-dependable-dividend-stocks-that-can-pay-you-for/",
      "time_published": "20250307T131500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how juicy its dividend yield.",
      "banner_image": "https://media.ycharts.com/charts/b01ddcc5c0be9b8f0ef7223fcd303537.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.365534,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.381255",
          "ticker_sentiment_score": "0.225983",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.163119",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "S&P 500 Hits New Record As Netflix Reports Strong Results: Investor Sentiment Improves But Greed Index Remains In 'Fear' Zone - Abbott Laboratories  ( NYSE:ABT ) , American Airlines Gr  ( NASDAQ:AAL ) ",
      "url": "https://www.benzinga.com/25/01/43152748/sp-500-hits-new-record-fear-among-us-investors-eases-but-fear-greed-index-remains-in-fear-zone",
      "time_published": "20250123T073919",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed further improvement in overall market sentiment, while the index remained in the \"Fear\" zone on Wednesday. U.S. stocks settled higher on Wednesday, with the S&P 500 surging to a new all-time high during the session. Netflix Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/23/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.096132,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.08063",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "-0.188034",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.08063",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAL",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNP",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.08063",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst - Abbott Laboratories  ( NYSE:ABT ) , Anteris Technologies  ( NASDAQ:AVR ) ",
      "url": "https://www.benzinga.com/trading-ideas/movers/25/01/42859544/anteris-technologies-positioned-to-capture-4-5-of-us-transcatheter-valve-replacement-market-",
      "time_published": "20250107T194528",
      "authors": [
        "Nabaparna Bhattacharya"
      ],
      "summary": "Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. AVR with a Positive rating and a forecast of $22. The analyst notes that Anteris Technologies' DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement ( BEV TAVR ) ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/07/Anteris-Structural-Heart-PMS-White.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.171107,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.193042",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.193949",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.328819",
          "ticker_sentiment_score": "0.120943",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVR",
          "relevance_score": "0.428632",
          "ticker_sentiment_score": "-0.161193",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "3 Top-Rated Stocks to Watch as Earnings Approach: ABT, EFX, SLG",
      "url": "https://www.zacks.com/commentary/2350839/3-top-rated-stocks-to-watch-as-earnings-approach-abt-efx-slg",
      "time_published": "20241015T200000",
      "authors": [
        "Shaun Pruitt"
      ],
      "summary": "Sporting a Zacks Rank #2 (Buy), here are three top-rated stocks that investors will want to consider as their Q3 results approach on Wednesday, October 16.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/65212.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999986"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.36588,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EFX",
          "relevance_score": "0.361802",
          "ticker_sentiment_score": "0.452204",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.222157",
          "ticker_sentiment_score": "0.382708",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock - Apple  ( NASDAQ:AAPL ) , Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/government/25/05/45380795/recent-filing-shows-that-rep-bruce-westerman-sold-over-137k-worth-of-apple-stock",
      "time_published": "20250513T150056",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "An official report on May 12, 2025 reveals Representative Bruce Westerman's recent sale of Apple AAPL stock, valued between $137,095 and $1,530,000. The transaction took place on May 12, 2025, as per the May filing. At this time, Apple shares are trading up 0.22% at $211.25.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998356"
        }
      ],
      "overall_sentiment_score": 0.17554,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AAPL",
          "relevance_score": "0.324495",
          "ticker_sentiment_score": "0.234658",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.219809",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition",
      "url": "https://www.zacks.com/stock/news/2328328/abt-expands-pure-bliss-line-of-products-for-advanced-infant-nutrition",
      "time_published": "20240828T134100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.448968,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TMDX",
          "relevance_score": "0.219312",
          "ticker_sentiment_score": "0.152684",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.219312",
          "ticker_sentiment_score": "0.225107",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.055492",
          "ticker_sentiment_score": "0.120871",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.165409",
          "ticker_sentiment_score": "0.060544",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.272181",
          "ticker_sentiment_score": "0.208561",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.055492",
          "ticker_sentiment_score": "0.485272",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Kings to Buy for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2024/11/22/2-dividend-kings-to-buy-for-passive-income/",
      "time_published": "20241122T172100",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Dividend Kings are among the best income stocks on the market. Any corporation capable of raising its payouts for 50 consecutive years -- the requirement to become a Dividend King -- has an incredibly strong business capable of navigating company-specific challenges and economic peaks and ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/798548/person-drinking-bottled-drink-with-a-straw.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        }
      ],
      "overall_sentiment_score": 0.199478,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.270373",
          "ticker_sentiment_score": "0.08229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.217834",
          "ticker_sentiment_score": "0.109531",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Healthcare Stocks to Buy Hand Over Fist in June",
      "url": "https://www.fool.com/investing/2024/06/12/2-healthcare-stocks-to-buy-hand-over-fist-in-june/",
      "time_published": "20240612T114500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "They both have pretty impressive pasts, and their prospects look just as bright.",
      "banner_image": "https://media.ycharts.com/charts/19bc1a080c6f69546fc44ee4ad147602.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.341233,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.217346",
          "ticker_sentiment_score": "0.360761",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.217346",
          "ticker_sentiment_score": "0.338294",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Recent Report Shows That Sen. Shelley M Capito Sold Up to $75K Worth of Comcast Stock - Abbott Laboratories  ( NYSE:ABT ) , Accenture  ( NYSE:ACN ) ",
      "url": "https://www.benzinga.com/insights/government/25/03/44191997/recent-report-shows-that-sen-shelley-m-capito-sold-up-to-75k-worth-of-comcast-stock",
      "time_published": "20250307T150037",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "March 6, 2025 records indicate that Senator Shelley M Capito filed a sale of Comcast CMCSA, valued between $5,005 and $75,000. According to the March filing, the transaction occurred on March 6, 2025. Currently, Comcast shares are trading up 1.12% at $36.67.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.166402,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCZ",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.185103",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DUK",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACN",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock - Abbott Laboratories  ( NYSE:ABT ) , West Pharmaceutical Servs  ( NYSE:WST ) ",
      "url": "https://www.benzinga.com/insights/government/25/03/44191982/florida-rep-jared-moskowitz-sold-up-to-15k-worth-of-west-pharmaceutical-servs-stock",
      "time_published": "20250307T150020",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "March 6, 2025 records indicate that Representative Jared Moskowitz filed a sale of West Pharmaceutical Servs WST, valued between $1,001 and $15,000. According to the March filing, the transaction occurred on March 6, 2025. Currently, West Pharmaceutical Servs shares are trading down 0.0% at $232.76.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        }
      ],
      "overall_sentiment_score": 0.168695,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Global Expansion in EPD and Innovations Support Abbott Stock",
      "url": "https://www.zacks.com/stock/news/2440033/global-expansion-in-epd-and-innovations-support-abbott-stock",
      "time_published": "20250403T172500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        }
      ],
      "overall_sentiment_score": 0.241811,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.16171",
          "ticker_sentiment_score": "0.059646",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.214462",
          "ticker_sentiment_score": "0.365723",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.16171",
          "ticker_sentiment_score": "0.059646",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.16171",
          "ticker_sentiment_score": "0.059646",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.054236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Expanding Diabetes Business Supports ABT Stock, FX Issues Stay",
      "url": "https://www.zacks.com/stock/news/2417910/expanding-diabetes-business-supports-abt-stock-fx-issues-stay",
      "time_published": "20250219T144100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.24886,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "0.145925",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VCYT",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "0.111308",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "0.062278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.358502",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2024/10/19/want-decades-of-passive-income-2-stocks-to-buy-now/",
      "time_published": "20241019T135700",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These companies' longtime shareholders have generally been rewarded.",
      "banner_image": "https://g.foolcdn.com/editorial/images/794279/physicians-in-an-operating-room.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.300861,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.21258",
          "ticker_sentiment_score": "0.328311",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.263942",
          "ticker_sentiment_score": "0.256908",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Expanding EPD Business Supports ABT Stock Amid Macro Issues",
      "url": "https://www.zacks.com/stock/news/2403997/expanding-epd-business-supports-abt-stock-amid-macro-issues",
      "time_published": "20250127T163300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.246544,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.159922",
          "ticker_sentiment_score": "0.145304",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VCYT",
          "relevance_score": "0.159922",
          "ticker_sentiment_score": "0.110831",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.159922",
          "ticker_sentiment_score": "0.062006",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.212115",
          "ticker_sentiment_score": "0.352275",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.053629",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's Core Businesses Thrive Despite Macroeconomic Issues",
      "url": "https://www.zacks.com/stock/news/2327754/abbotts-core-businesses-thrive-despite-macroeconomic-issues",
      "time_published": "20240827T150200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.168472,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EXAS",
          "relevance_score": "0.210274",
          "ticker_sentiment_score": "0.113441",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.052841",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.210274",
          "ticker_sentiment_score": "0.232255",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What Does the Market Think About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/02/44049685/what-does-the-market-think-about-abbott-laboratories",
      "time_published": "20250228T170045",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 21.7% since its last report. The company recently reported that it has 22.31 million shares sold short, which is 1.29% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1740762042_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.287757,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.148634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/02/43622364/looking-into-abbott-laboratoriess-recent-short-interest",
      "time_published": "20250211T133242",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 4.82% since its last report. The company recently reported that it has 14.97 million shares sold short, which is 0.87% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1739280759_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.287757,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.148634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/12/42730500/how-is-the-market-feeling-about-abbott-laboratories",
      "time_published": "20241230T193018",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has fallen 11.39% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.7% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1735587015_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.262256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.079385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Peering Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/12/42364441/peering-into-abbott-laboratoriess-recent-short-interest",
      "time_published": "20241206T143027",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has fallen 14.63% since its last report. The company recently reported that it has 12.05 million shares sold short, which is 0.7% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1733495423_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.262256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.079385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Does 'Very Well,' Cramer's Favorite? Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories",
      "time_published": "20241017T124934",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said AbbVie Inc. ABBV is doing \"very, very well.\" However, he added that Abbott Laboratories ABT remains his favorite in the group right now. AbbVie was founded in 2013 when it became a separate company from Abbott.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.262289,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.086907",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SG",
          "relevance_score": "0.404563",
          "ticker_sentiment_score": "0.141787",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CORZQ",
          "relevance_score": "0.309539",
          "ticker_sentiment_score": "0.340065",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ORCL",
          "relevance_score": "0.493128",
          "ticker_sentiment_score": "0.534909",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.493128",
          "ticker_sentiment_score": "0.041475",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLOV",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.155277",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GXO",
          "relevance_score": "0.404563",
          "ticker_sentiment_score": "0.345606",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/10/41215818/how-is-the-market-feeling-about-abbott-laboratories",
      "time_published": "20241007T200018",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 4.05% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.77% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1728331215_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.287757,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.148634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/08/40628656/looking-into-abbott-laboratoriess-recent-short-interest",
      "time_published": "20240829T153019",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has fallen 7.59% since its last report. The company recently reported that it has 12.68 million shares sold short, which is 0.73% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1724945416_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.262256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.079385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Peering Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/07/39986383/peering-into-abbott-laboratoriess-recent-short-interest",
      "time_published": "20240726T144524",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has fallen 17.33% since its last report. The company recently reported that it has 10.75 million shares sold short, which is 0.62% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1722005121_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.262256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.079385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/07/39716022/looking-into-abbott-laboratoriess-recent-short-interest",
      "time_published": "20240710T181513",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has fallen 20.24% since its last report. The company recently reported that it has 11.62 million shares sold short, which is 0.67% of all regular shares that are available for trading.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.262256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.079385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/05/38613561/how-is-the-market-feeling-about-abbott-laboratories",
      "time_published": "20240503T131513",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has fallen 7.69% since its last report. The company recently reported that it has 14.48 million shares sold short, which is 0.84% of all regular shares that are available for trading.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.262256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.079385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/03/37991355/how-is-the-market-feeling-about-abbott-laboratories",
      "time_published": "20240328T180023",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 12.16% since its last report. The company recently reported that it has 14.29 million shares sold short, which is 0.83% of all regular shares that are available for trading.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.287757,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.148634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know - NVIDIA  ( NASDAQ:NVDA ) , Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/25/05/45189546/jensen-huang-magic-johnson-patrick-dempsey-linda-yaccarino-and-more-bigwigs-headline-milken-global-conference-202",
      "time_published": "20250505T101044",
      "authors": [
        "Ananya Gairola"
      ],
      "summary": "The Milken Institute's 28th annual Global Conference began on Sunday and will run through May 7 at the Beverly Hilton in Los Angeles.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/05/Jensen-Huang-Nvidias-Founder--President-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.110552,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.068516",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.068516",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRMND",
          "relevance_score": "0.105141",
          "ticker_sentiment_score": "0.125375",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "-0.321078",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Badger Meter Gears Up to Report Q1 Earnings: What's in the Offing?",
      "url": "https://www.zacks.com/stock/news/2448941/badger-meter-gears-up-to-report-q1-earnings-whats-in-the-offing",
      "time_published": "20250415T123900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BMI's performance is likely to have benefited from demand for its solutions. However, the uncertain macro backdrop, higher costs and competition are concerns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.223701,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.192871",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WTII",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.11202",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.097165",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMI",
          "relevance_score": "0.356317",
          "ticker_sentiment_score": "0.258167",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "STLD",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.082691",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio?",
      "url": "https://www.fool.com/investing/2025/05/03/2-stocks-2-decades-200-is-this-the-long-term-divid/",
      "time_published": "20250503T122000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Investing in excellent dividend stocks can be a great strategy to mitigate risk and boost long-term returns. Companies that can dispense regular payouts to their shareholders -- especially those that have done so for a long time -- generally have stable and steadily growing businesses that can ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/816660/person-drinking-bottled-drink-with-a-straw.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.972756"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.321086,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.402135",
          "ticker_sentiment_score": "0.383381",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "0.156492",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes",
      "url": "https://www.zacks.com/stock/news/2455126/epd-growth-in-emerging-market-supports-abbott-stock-amid-macro-woes",
      "time_published": "20250424T153900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        }
      ],
      "overall_sentiment_score": 0.257428,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.097266",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.354414",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.156461",
          "ticker_sentiment_score": "0.106687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.087329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients - DexCom  ( NASDAQ:DXCM ) ",
      "url": "https://www.benzinga.com/news/large-cap/24/08/40556465/dexcoms-stelo-device-brings-affordable-continuous-glucose-monitoring-to-type-2-diabetes-patients",
      "time_published": "20240826T153906",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "In March, the FDA approved DexCom Inc's DXCM Stelo Glucose Biosensor System as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) . The Dexcom Stelo Glucose Biosensor System is an integrated CGM ( iCGM ) intended for people 18 and older who do not use insulin.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/biotech-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.187903,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.705377",
          "ticker_sentiment_score": "0.4255",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.206685",
          "ticker_sentiment_score": "0.163215",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' - Abbott Laboratories  ( NYSE:ABT ) , Emerson Electric  ( NYSE:EMR ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/04/38155367/jim-cramer-was-upset-at-this-hostile-takeover-but-they-fixed-the-situation-stocks-been-a",
      "time_published": "20240409T131029",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he prefers Abbott Laboratories ABT over Penumbra, Inc. PEN. \"I still fear it after the environmental damage. I am concerned that you can't really put a price on it,\" Cramer said when asked about Hawaiian Electric Industries, Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/09/shutterstock_2246181693.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.083032,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EE",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "-0.019508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAWEL",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.012065",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "-0.106949",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBSW",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "0.120339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "F",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "-0.09122",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GM",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "-0.09122",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEN",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "-0.154852",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "0.466411",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "EMR",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "-0.207998",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "HE",
          "relevance_score": "0.103778",
          "ticker_sentiment_score": "-0.092462",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?",
      "url": "https://www.zacks.com/stock/news/2514587/abts-i-stat-tbi-test-receives-approval-in-canada-stock-to-rise",
      "time_published": "20250619T121800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ed/4119.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.128734,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.204936",
          "ticker_sentiment_score": "0.238131",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.204936",
          "ticker_sentiment_score": "0.066655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.204936",
          "ticker_sentiment_score": "0.096017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "0.022377",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/06/46148813/how-is-the-market-feeling-about-abbott-laboratories",
      "time_published": "20250627T180045",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 3.45% since its last report. The company recently reported that it has 20.80 million shares sold short, which is 1.2% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.292022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.145272",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Peering Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/06/45837368/peering-into-abbott-laboratoriess-recent-short-interest",
      "time_published": "20250609T140036",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 5.74% since its last report. The company recently reported that it has 22.26 million shares sold short, which is 1.29% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.292022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.145272",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What Does the Market Think About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/03/44419809/what-does-the-market-think-about-abbott-laboratories",
      "time_published": "20250320T153028",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Abbott Laboratories's ABT short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.93 million shares sold short, which is 1.33% of all regular shares that are available for trading.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742484625_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.292022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.145272",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "EPD Expansion Supports Abbot Stock, Macro Issues Prevail",
      "url": "https://www.zacks.com/stock/news/2428446/epd-expansion-supports-abbot-stock-macro-issues-prevail",
      "time_published": "20250311T154300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        }
      ],
      "overall_sentiment_score": 0.233272,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.153145",
          "ticker_sentiment_score": "0.053624",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.358047",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "0.051215",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Growing Biosimilars Business, New Partnerships Support ABT Stock",
      "url": "https://www.zacks.com/stock/news/2388694/growing-biosimilars-business-new-partnerships-support-abt-stock",
      "time_published": "20241227T134600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.221679,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "0.056567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RMD",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "0.056567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.264128",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.161439",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.153145",
          "ticker_sentiment_score": "0.076075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt",
      "url": "https://www.zacks.com/stock/news/2356127/growing-biosimilars-business-supports-abt-stock-macro-issues-hurt",
      "time_published": "20241023T162000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.224871,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BAX",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "0.054426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "0.054426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.325366",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.157435",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "0.054426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dow Falls Over 150 Points Even As Citi, Bank Of America Earnings Beat Expectations: Greed Index Remains In 'Extreme Fear' Zone - Abbott Laboratories  ( NYSE:ABT ) , Bank of America  ( NYSE:BAC ) ",
      "url": "https://www.benzinga.com/25/04/44832047/dow-falls-over-150-points-fear-among-us-investors-increases-fear-greed-index-remains-in-extreme-fear-zone",
      "time_published": "20250416T074726",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed an increase in the overall fear level, while the index remained in the \"Extreme Fear\" zone on Tuesday. U.S. stocks settled lower on Tuesday, with the Dow Jones index falling more than 150 points during the session as investors assessed recent earnings ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/16/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.118469,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WBD",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "-0.31782",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.202366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PGR",
          "relevance_score": "0.202366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.202366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.202366",
          "ticker_sentiment_score": "0.282262",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.202366",
          "ticker_sentiment_score": "0.282262",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues",
      "url": "https://www.zacks.com/stock/news/2377105/growing-epd-business-supports-abt-stock-amid-macroeconomic-issues",
      "time_published": "20241129T151500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.252174,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.100518",
          "ticker_sentiment_score": "0.054133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.199447",
          "ticker_sentiment_score": "0.338788",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GMED",
          "relevance_score": "0.100518",
          "ticker_sentiment_score": "0.054133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.050359",
          "ticker_sentiment_score": "0.157271",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.150278",
          "ticker_sentiment_score": "0.115502",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.050359",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Apple and Nvidia fight Wednesday's stock market decline. Here is what's supporting them",
      "url": "https://www.cnbc.com/2024/05/29/apple-nvidia-fight-wednesday-stock-market-decline-what-is-supporting-them.html",
      "time_published": "20240529T155952",
      "authors": [
        "Morgan Chittum"
      ],
      "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/102963707-GettyImages-468159964.jpg?v=1716996029&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990893"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.099035,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.111216",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.294682",
          "ticker_sentiment_score": "0.090894",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.066724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTRA",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.066724",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain - Labcorp Holdings  ( NYSE:LH ) ",
      "url": "https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str",
      "time_published": "20240826T173631",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Labcorp Holdings Inc LH is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly detected virus strain outside Africa.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/Congo-Worst-Affected.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.016672,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DGX",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "-0.157634",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "-0.157634",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BVNKF",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq Sees Worst Session Since 2022 As Chip Stocks Tumble After Trump's Taiwan Remarks and Biden's Potential Restrictions - Netflix  ( NASDAQ:NFLX ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39831773/nasdaq-sees-worst-session-since-2022-as-chip-stocks-tumble-after-trumps-taiwan-remarks-and-bidens-p",
      "time_published": "20240718T072749",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the \"Neutral\" zone on Wednesday. U.S. stocks closed mixed on Wednesday, with the Nasdaq Composite recording its worst session since Dec. 2022.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Semiconductor-Shutterstock.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.08678,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.099476",
          "ticker_sentiment_score": "-0.307907",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SYF",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.247269",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FIVE",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.247269",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "-0.157012",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains",
      "url": "https://www.zacks.com/stock/news/2434127/watch-these-5-ai-powered-healthcare-bigwigs-for-portfolio-gains",
      "time_published": "20250324T124500",
      "authors": [
        "Nalak Das"
      ],
      "summary": "Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/1670.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.457455,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.291182",
          "ticker_sentiment_score": "0.319607",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.228533",
          "ticker_sentiment_score": "0.218254",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.21992",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.164356",
          "ticker_sentiment_score": "0.351742",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.164356",
          "ticker_sentiment_score": "0.36473",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone - NVIDIA  ( NASDAQ:NVDA ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41350830/nasdaq-dips-1-amid-plunge-in-chipmaker-stocks-fear-greed-index-moves-to-greed-zone",
      "time_published": "20241016T071326",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the \"Greed\" zone on Tuesday. U.S. stocks settled lower on Tuesday, with the Dow Jones index falling more than 300 points during the session. ASML Holding N.V.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.168187,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "-0.129737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.194351",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMD",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "-0.129737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.099066",
          "ticker_sentiment_score": "-0.362329",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.194351",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "-0.129737",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is UNH Stock Soaring After Earnings?",
      "url": "https://www.kiplinger.com/investing/stocks/why-is-unh-stock-soaring-after-earnings",
      "time_published": "20240416T153055",
      "authors": [
        "Joey Solitro"
      ],
      "summary": "UnitedHealth Group ( UNH ) stock is soaring over 5% in Tuesday's session after the company beat both earnings and revenue estimates for its fiscal 2024 first quarter. UNH stock can certainly use the boost considering it was down 15% for the year-to-date heading into today's trading.",
      "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
      "source": "Kiplinger",
      "category_within_source": "n/a",
      "source_domain": "www.kiplinger.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99992"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.360075,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PLD",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBKR",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.543004",
          "ticker_sentiment_score": "0.372026",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T",
      "url": "https://www.zacks.com/stock/news/2477955/the-zacks-analyst-blog-highlights-coca-cola-abbott-laboratories-and-att",
      "time_published": "20250528T095100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Coca-Cola, Abbott and AT&T shine in Zacks' latest reports, with each outperforming peers year-to-date despite headwinds in key segments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a5/1022.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.351959,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.195287",
          "ticker_sentiment_score": "0.054519",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "T",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.19271",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.195287",
          "ticker_sentiment_score": "0.054519",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Magnificent Stocks That Are Passive Income Machines",
      "url": "https://www.fool.com/investing/2025/05/17/3-magnificent-stocks-that-are-passive-income-machi/",
      "time_published": "20250517T104000",
      "authors": [
        "and Prosper Junior Bakiny",
        "Keith Speights",
        "David Jagielski"
      ],
      "summary": "Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this \"easy\" money.Three Motley Fool contributors believe they have found some great dividend stocks that fit the bill.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F818484%2Fpassive-income.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.344075,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SPGI",
          "relevance_score": "0.04872",
          "ticker_sentiment_score": "0.134965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.286082",
          "ticker_sentiment_score": "0.268248",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.193078",
          "ticker_sentiment_score": "0.227804",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.286082",
          "ticker_sentiment_score": "0.358714",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology",
      "url": "https://www.zacks.com/stock/news/2437520/the-zacks-analyst-blog-highlights-mcdonalds-abbott-laboratories-oreilly-automotive-and-mind-technology",
      "time_published": "20250331T131900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.278776,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.19231",
          "ticker_sentiment_score": "0.059895",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDNDF",
          "relevance_score": "0.144853",
          "ticker_sentiment_score": "0.091874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ORLY",
          "relevance_score": "0.23907",
          "ticker_sentiment_score": "0.114524",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MIND",
          "relevance_score": "0.284972",
          "ticker_sentiment_score": "0.172317",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MCD",
          "relevance_score": "0.19231",
          "ticker_sentiment_score": "0.059895",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cramer's week ahead: Major banks, Taiwan Semi and Netflix report as earnings season gets into full swing",
      "url": "https://www.cnbc.com/2024/10/11/cramers-week-ahead-taiwan-semi-netflix-goldman-sachs-citi-earnings.html",
      "time_published": "20241011T224251",
      "authors": [],
      "summary": "Charles Schwab, Bank of America, Johnson & Johnson, Walgreens, UnitedHealth Group Morgan Stanley, Procter & Gamble and Abbott Laboratories all report earnings.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        }
      ],
      "overall_sentiment_score": 0.097428,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "-0.089474",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.231841",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.131823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.131823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.184864",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "-0.154208",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SLB",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.010048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.131823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "-0.132152",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.184864",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.010048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.010048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.110539",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These Dividend Stocks Are an Investor's Best Friend",
      "url": "https://www.fool.com/investing/2024/05/16/these-dividend-stocks-are-an-investors-best-friend/",
      "time_published": "20240516T120000",
      "authors": [
        "George Budwell"
      ],
      "summary": "These two healthcare stocks are well-known for their top-tier dividend programs.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F777461%2Fdividends.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        }
      ],
      "overall_sentiment_score": 0.427908,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.310843",
          "ticker_sentiment_score": "0.411438",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.18967",
          "ticker_sentiment_score": "0.209958",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market",
      "url": "https://www.zacks.com/stock/news/2401598/abbott-q4-earnings-meet-margins-down-stock-falls-in-pre-market",
      "time_published": "20250122T184600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT delivers a strong underlying base business performance for the fourth quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.205544,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VCYT",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.103322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.188781",
          "ticker_sentiment_score": "0.06129",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.096913",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.030886",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Stock Gains on Q3 Earnings Beat, Margins Expand",
      "url": "https://www.zacks.com/stock/news/2351773/abbott-stock-gains-on-q3-earnings-beat-margins-expand",
      "time_published": "20241016T175700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT delivers a strong underlying base business performance in the third quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/50/73256.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.261953,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AVIR",
          "relevance_score": "0.113956",
          "ticker_sentiment_score": "0.029633",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.188781",
          "ticker_sentiment_score": "0.13471",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.038101",
          "ticker_sentiment_score": "0.044002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AHCO",
          "relevance_score": "0.113956",
          "ticker_sentiment_score": "-0.001115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADUS",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.100758",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's why we scooped up additional shares of these 2 lagging health-care stocks",
      "url": "https://www.cnbc.com/2024/05/09/why-jim-cramer-bought-more-shares-of-these-2-lagging-health-care-stocks.html",
      "time_published": "20240509T155434",
      "authors": [
        "Morgan Chittum"
      ],
      "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107372340-1707755955868-gettyimages-1665282931-porzycki-armphoto230914_npsnU.jpeg?v=1707756116&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        }
      ],
      "overall_sentiment_score": 0.201412,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "0.130721",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Growth Stocks to Buy and Hold",
      "url": "https://www.fool.com/investing/2025/07/12/3-dividend-growth-stocks-to-buy-and-hold/",
      "time_published": "20250712T104000",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "What's better than a great dividend? A great dividend that's growing.Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are healthcare stocks. Here's why they picked Abbott Laboratories ( NYSE: ABT ) , AbbVie ( NYSE: ABBV ) , and Eli ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F824621%2Fwoman-smiling-laptop.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.351968,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "0.287057",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.321273",
          "ticker_sentiment_score": "0.245366",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.1871",
          "ticker_sentiment_score": "0.096222",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.094204",
          "ticker_sentiment_score": "0.111698",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott India appoints Maithilee Pathare Mistry as CFO - ETCFO",
      "url": "https://cfo.economictimes.indiatimes.com/news/leadership/abbott-india-appoints-maithilee-mistry-as-cfo/120483529",
      "time_published": "20250421T102201",
      "authors": [
        "ETCFO",
        "ETCFO Staff"
      ],
      "summary": "Abbott India has appointed Maithilee Pathare Mistry as Chief Financial Officer, effective May 6, 2025. A finance veteran with over 25 years of experience, she succeeds Sridhar Kadangode following his resignation in February.",
      "banner_image": "https://img.etb2bimg.com/files/cp/upload-1716885663-etcfo-default.webp",
      "source": "Economic Times",
      "category_within_source": "Top Stories",
      "source_domain": "cfo.economictimes.indiatimes.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.081601,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.028728",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.004546",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lutikizumab Clinical Trials Approved Bispecific Antibodies Market Insight",
      "url": "https://www.benzinga.com/pressreleases/24/03/g37768775/lutikizumab-clinical-trials-approved-bispecific-antibodies-market-insight",
      "time_published": "20240317T170809",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.14381,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.120262",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.043688",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds",
      "url": "https://www.zacks.com/stock/news/2479589/abbott-benefits-from-libre-biosimilars-amid-fx-cost-headwinds",
      "time_published": "20250530T140900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.283436,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PAHC",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.10098",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.312204",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.230454",
          "ticker_sentiment_score": "0.153511",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBH",
          "relevance_score": "0.093289",
          "ticker_sentiment_score": "0.086623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights NVIDIA, Abbott Laboratories, Linde and Tredegar",
      "url": "https://www.zacks.com/stock/news/2466194/the-zacks-analyst-blog-highlights-nvidia-abbott-laboratories-linde-and-tredegar",
      "time_published": "20250509T140100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "NVIDIA, Abbott Laboratories, Linde and Tredegar are part of the Zacks top Analyst ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.254093,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLFD",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.160654",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LIN",
          "relevance_score": "0.093289",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.093289",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.296587",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRBO",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.217491",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TG",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.032354",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Q1 Earnings Beat, Sales Miss, Stock Falls in Pre-Market",
      "url": "https://www.zacks.com/stock/news/2450204/abbott-q1-earnings-beat-sales-miss-stock-falls-in-pre-market",
      "time_published": "20250416T170700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT delivers a strong underlying base business performance for the first quarter of 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.198399,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VEEV",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.094566",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.026362",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.088626",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ICON  ( ICLR )  Q2 Earnings Surpass Estimates, Margins Expand",
      "url": "https://www.zacks.com/stock/news/2310091/icon-iclr-q2-earnings-surpass-estimates-margins-expand",
      "time_published": "20240726T130900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/64950.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999974"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.163325,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICLR",
          "relevance_score": "0.244723",
          "ticker_sentiment_score": "0.105121",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.184834",
          "ticker_sentiment_score": "0.097579",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.244723",
          "ticker_sentiment_score": "0.077916",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.303175",
          "ticker_sentiment_score": "0.135724",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week",
      "url": "https://www.investors.com/stock-lists/sector-leaders/dexcom-stock-dxcm-diabetes-insulin/",
      "time_published": "20240419T123000",
      "authors": [
        "Investor's Business Daily",
        "VIDYA RAMAKRISHNAN"
      ],
      "summary": "Dexcom Stock Is In Buy Zone Ahead Of Earnings Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-02-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        }
      ],
      "overall_sentiment_score": 0.327633,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "0.135154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.440549",
          "ticker_sentiment_score": "0.428074",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "0.135154",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results - Abbott Laboratories  ( NYSE:ABT ) , 180 Life Sciences  ( NASDAQ:ATNF ) ",
      "url": "https://www.benzinga.com/markets/equities/24/10/41357767/us-stocks-mixed-abbott-reports-better-than-expected-q3-results",
      "time_published": "20241016T140317",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 20 points on Wednesday. The Dow traded up 0.05% to 42,762.18 while the NASDAQ fell 0.06% to 18,305.30. The S&P 500 also fell, dropping, 0.07% to 5,811.21. Financials shares jumped by 0.7% on Wednesday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Wall-Street.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.070997,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.270773",
          "ticker_sentiment_score": "0.515132",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SVCO",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "-0.136284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STEC",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.296266",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.508569",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ATNF",
          "relevance_score": "0.270773",
          "ticker_sentiment_score": "0.139623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VS",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.413506",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "GE HealthCare's Latest Product Launch to Boost Cardiology Care",
      "url": "https://www.zacks.com/stock/news/2437417/ge-healthcares-latest-product-launch-to-boost-cardiology-care",
      "time_published": "20250331T134500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.297049,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.226583",
          "ticker_sentiment_score": "0.22632",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MMSI",
          "relevance_score": "0.091684",
          "ticker_sentiment_score": "0.130645",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.182162",
          "ticker_sentiment_score": "0.093698",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.182162",
          "ticker_sentiment_score": "0.168822",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Page 40320 of",
      "url": "https://www.financialexpress.com/about-news/page/40320/",
      "time_published": "20240415T081446",
      "authors": [],
      "summary": "Ambuja Realty Group has entered into the education sector, taking over Institute of Technology and Marine Engineering, although it would\u2026 Most human resource managers try to serenade the 18-25 year olds, the Generation Y, by either money or promise of\u2026",
      "banner_image": "https://www.financialexpress.com/wp-content/themes/ie-network-theme/assets/src/img/default-img-fe.jpg",
      "source": "The Financial Express",
      "category_within_source": "n/a",
      "source_domain": "www.financialexpress.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.086064,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.179788",
          "ticker_sentiment_score": "0.303128",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRYPTO:NANO",
          "relevance_score": "0.179788",
          "ticker_sentiment_score": "-0.125738",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?",
      "url": "https://www.zacks.com/stock/news/2484246/emerging-markets-power-boston-scientific-will-the-growth-trend-continue",
      "time_published": "20250604T130400",
      "authors": [
        "Sridatri Sarkar"
      ],
      "summary": "BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/aa/957.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.400586,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.237551",
          "ticker_sentiment_score": "0.278907",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.503559",
          "ticker_sentiment_score": "0.470989",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.179343",
          "ticker_sentiment_score": "0.304018",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Relatively Safe Stocks to Buy Right Now",
      "url": "https://www.fool.com/investing/2025/03/29/3-relatively-safe-stocks-to-buy-right-now/",
      "time_published": "20250329T104500",
      "authors": [
        "and Prosper Junior Bakiny",
        "David Jagielski",
        "Keith Speights"
      ],
      "summary": "Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions.Three Motley Fool contributors think they've found relatively safe stocks to buy right now with major market indexes remaining near correction ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/812763/woman-with-fingers-crossed-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.255753,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.388209",
          "ticker_sentiment_score": "0.081397",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.178459",
          "ticker_sentiment_score": "0.197083",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.388209",
          "ticker_sentiment_score": "0.264782",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Is Abbott Stock Trading Higher On Thursday? - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/general/health-care/25/01/43174107/why-is-abbott-stock-trading-higher-on-thursday",
      "time_published": "20250123T200128",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Abbott's Q4 sales reached $10.97 billion, growing 7.2% YoY but falling short of expectations. Stifel and Piper Sandler analysts maintain positive ratings and price forecasts of $135 and $133, respectively. Get the Real Story Behind Every Major Earnings Report",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/23/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.433093,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "-0.140028",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What to Expect From Badger Meter Stock Ahead of its Q3 Earnings",
      "url": "https://www.zacks.com/stock/news/2349679/what-to-expect-from-badger-meter-stock-ahead-of-its-q3-earnings",
      "time_published": "20241014T113900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BMI's third-quarter performance is likely to have benefited from increased demand for its digital smart water solutions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99989"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.329038,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.200877",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.200877",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.161286",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMI",
          "relevance_score": "0.3986",
          "ticker_sentiment_score": "0.402596",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Nasdaq Dips 3% Amid Plunge In Nvidia, AMD: Greed Index Remains In 'Extreme Fear' Zone - Abbott Laboratories  ( NYSE:ABT ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",
      "url": "https://www.benzinga.com/25/04/44857684/nasdaq-dips-3-amid-plunge-in-nvidia-amd-shares-fear-among-us-investors-increases-fear-greed-index-remains-in-extr",
      "time_published": "20250417T074140",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "The CNN Money Fear and Greed index showed a further increase in the overall fear level, while the index remained in the \"Extreme Fear\" zone on Wednesday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/17/Fear-and-Greed.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.155301,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.262052",
          "ticker_sentiment_score": "-0.227868",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.459738",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AMD",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "-0.169171",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.088799",
          "ticker_sentiment_score": "-0.296752",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.459738",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Growth Beasts That Have Raised Their Payouts for a Combined 165 Years",
      "url": "https://www.fool.com/investing/2025/01/02/3-dividend-growth-beasts-that-have-raised-their/",
      "time_published": "20250102T130000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Want some solid dividend growth stocks with incredible track records of increasing their payouts? Here's a list of stocks that have been raising their dividend payments consistently for more than 50 consecutive years.",
      "banner_image": "https://g.foolcdn.com/editorial/images/801754/a-person-holding-cash.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.32648,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TGT",
          "relevance_score": "0.396798",
          "ticker_sentiment_score": "0.378628",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.176964",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HRL",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.20937",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "-0.074396",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Veracyte  ( VCYT )  Q2 Earnings Beat Estimates, '24 Sales View Up",
      "url": "https://www.zacks.com/stock/news/2319283/veracyte-vcyt-q2-earnings-beat-estimates-24-sales-view-up",
      "time_published": "20240808T130900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999919"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.133744,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VCYT",
          "relevance_score": "0.444595",
          "ticker_sentiment_score": "0.423453",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.175009",
          "ticker_sentiment_score": "0.098057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.231884",
          "ticker_sentiment_score": "0.081532",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.287537",
          "ticker_sentiment_score": "0.13421",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2024/08/03/2-unstoppable-dividend-stocks-to-buy-if-a-sell-off/",
      "time_published": "20240803T104500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Dividend stocks are great. cheap dividend stocks are better.",
      "banner_image": "https://g.foolcdn.com/editorial/images/785210/person-sitting-at-a-desk-looking-at-two-monitors.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.993856"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.307438,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.173645",
          "ticker_sentiment_score": "0.177066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.298957",
          "ticker_sentiment_score": "0.125028",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Unstoppable Dividend Stocks That Will Pay You for Life",
      "url": "https://www.fool.com/investing/2025/02/03/2-unstoppable-dividend-stocks-that-will-pay-you/",
      "time_published": "20250203T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings.These companies have ...",
      "banner_image": "https://media.ycharts.com/charts/0ae74fdb02b3766b354ad04d5fcd3aa5.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.229153,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "FMBRY",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "0.22101",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.390613",
          "ticker_sentiment_score": "0.2227",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.132362",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On",
      "url": "https://www.zacks.com/stock/news/2442878/will-trump-tariffs-make-or-break-healthcare-space-3-stocks-to-rely-on",
      "time_published": "20250409T190000",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.255142,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMRN",
          "relevance_score": "0.29689",
          "ticker_sentiment_score": "0.315313",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UHS",
          "relevance_score": "0.336852",
          "ticker_sentiment_score": "0.393316",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.172404",
          "ticker_sentiment_score": "0.122234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.043421",
          "ticker_sentiment_score": "-0.095618",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Philips  ( PHG )  Q2 Earnings Rise, Revenues Fall Year Over Year",
      "url": "https://www.zacks.com/stock/news/2312228/philips-phg-q2-earnings-rise-revenues-fall-year-over-year",
      "time_published": "20240730T161200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        }
      ],
      "overall_sentiment_score": 0.250265,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AKRO",
          "relevance_score": "0.227538",
          "ticker_sentiment_score": "0.204661",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.171688",
          "ticker_sentiment_score": "0.170319",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMED",
          "relevance_score": "0.171688",
          "ticker_sentiment_score": "0.170319",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PHG",
          "relevance_score": "0.227538",
          "ticker_sentiment_score": "0.297915",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Citi elevates GE Healthcare to a top pick. Here's why we're not buying more shares just yet",
      "url": "https://www.cnbc.com/2024/05/22/citi-names-ge-healthcare-a-top-pick-jim-cramers-thoughts-on-the-call.html",
      "time_published": "20240522T154045",
      "authors": [
        "Morgan Chittum"
      ],
      "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107417472-1716238810469-gettyimages-2153880447-dsc05750_une9fz1g.jpeg?v=1716238843&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Earnings",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.195086,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.254751",
          "ticker_sentiment_score": "0.159742",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.171485",
          "ticker_sentiment_score": "0.118183",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.171485",
          "ticker_sentiment_score": "0.118183",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TJX",
          "relevance_score": "0.254751",
          "ticker_sentiment_score": "0.159742",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso",
      "url": "https://www.zacks.com/stock/news/2309168/the-zacks-analyst-blog-highlights-sap-abbott-laboratories-citigroup-team-and-vaso",
      "time_published": "20240725T135300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SAP, Abbott Laboratories, Citigroup, Team and Vaso are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/33/496.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.291697,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.171181",
          "ticker_sentiment_score": "0.055949",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.171181",
          "ticker_sentiment_score": "0.110416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAP",
          "relevance_score": "0.171181",
          "ticker_sentiment_score": "0.01834",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TISI",
          "relevance_score": "0.254307",
          "ticker_sentiment_score": "0.179541",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "We're looking to buy more of this health care stock after an overblown selloff",
      "url": "https://www.cnbc.com/2024/03/19/were-looking-to-buy-more-of-this-health-care-stock-after-a-big-selloff.html",
      "time_published": "20240319T154340",
      "authors": [
        "Morgan Chittum"
      ],
      "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107389439-17108587581710858755-33780250380-1080pnbcnews.jpg?v=1710858758&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.031392,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.252114",
          "ticker_sentiment_score": "0.025426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.169676",
          "ticker_sentiment_score": "0.018764",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.252114",
          "ticker_sentiment_score": "0.025426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.085324",
          "ticker_sentiment_score": "0.013629",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Growth Stocks You Can Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/10/26/3-dividend-growth-stocks-you-can-buy-and-hold-fore/",
      "time_published": "20241026T113000",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "These healthcare stocks have fantastic dividend track records.",
      "banner_image": "https://g.foolcdn.com/editorial/images/795225/couple-looking-at-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.320127,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.328455",
          "ticker_sentiment_score": "0.280552",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.151135",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.289381",
          "ticker_sentiment_score": "0.406408",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings - Abbott Laboratories  ( NYSE:ABT ) , Edible Garden AG  ( NASDAQ:EDBL ) ",
      "url": "https://www.benzinga.com/news/earnings/24/04/38293458/dow-surges-200-points-abbott-laboratories-posts-upbeat-earnings",
      "time_published": "20240417T140753",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.55% to 38,006.47 while the NASDAQ rose 0.24% to 15,903.38. The S&P 500 also rose, gaining, 0.40% to 5,071.74.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/image38.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        }
      ],
      "overall_sentiment_score": 0.212521,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SBFM",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.293909",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EDBL",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.291227",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VIAO",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.35634",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.446615",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "INVO",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.289886",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IZM",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.362906",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy With $500 and Hold Forever",
      "url": "https://www.fool.com/investing/2025/05/23/2-dividend-stocks-to-buy-with-500-and-hold-forever/",
      "time_published": "20250523T103000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Broader equities have been volatile this year, but that's par for the course. The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest. However, times like these might help remind us that some corporations are more resilient than others.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F818808%2Fpet-owners-walking-their-dog.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        }
      ],
      "overall_sentiment_score": 0.293562,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZTS",
          "relevance_score": "0.539569",
          "ticker_sentiment_score": "0.422311",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.167032",
          "ticker_sentiment_score": "0.227894",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ELAN",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "0.140031",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "0.223099",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues",
      "url": "https://www.zacks.com/stock/news/2396748/quidelortho-stock-down-despite-solid-preliminary-q4-revenues",
      "time_published": "20250114T164900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "QDEL's preliminary fourth-quarter revenues align with the company's expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.222796,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.246999",
          "ticker_sentiment_score": "0.096782",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.246999",
          "ticker_sentiment_score": "0.149649",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QDEL",
          "relevance_score": "0.470894",
          "ticker_sentiment_score": "0.33763",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Abbott's Formula Selloff Could Be A Buying Opportunity, Says Analyst",
      "url": "https://www.investors.com/news/technology/abbott-stock-infant-formula-similac-lawsuits/",
      "time_published": "20240315T163313",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "Abbott Stock Dives As Fellow Formula Maker Fined $60 Million Following Infant Death Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        }
      ],
      "overall_sentiment_score": -0.096686,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.029786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.083541",
          "ticker_sentiment_score": "-0.026914",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.06886",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.06886",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.246999",
          "ticker_sentiment_score": "-0.305291",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Q1 Earnings Review",
      "url": "https://www.zacks.com/stock/news/2257009/q1-earnings-review",
      "time_published": "20240417T150400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq. the blue-chip Dow outperformed the field yesterday, closing +0.17%. Major indices are all lower over the past month, from -1.7% ( tech-heavy Nasdaq ) to -2.9% ( ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.096465,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LVS",
          "relevance_score": "0.165598",
          "ticker_sentiment_score": "0.026869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.165598",
          "ticker_sentiment_score": "0.026869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSX",
          "relevance_score": "0.165598",
          "ticker_sentiment_score": "0.026869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.165598",
          "ticker_sentiment_score": "0.143135",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.165598",
          "ticker_sentiment_score": "0.026869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLG",
          "relevance_score": "0.165598",
          "ticker_sentiment_score": "0.026869",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "U.S. Department of Health and Human Services Designates Four Nutrients of Public Health Concern Validating Glucose Health, Inc.  ( OTC: GLUC )  Patent Pending Soluble Fiber-Based Nutrition Formulation",
      "url": "https://www.globenewswire.com/news-release/2025/06/30/3107320/0/en/U-S-Department-of-Health-and-Human-Services-Designates-Four-Nutrients-of-Public-Health-Concern-Validating-Glucose-Health-Inc-OTC-GLUC-Patent-Pending-Soluble-Fiber-Based-Nutrition-F.html",
      "time_published": "20250630T103000",
      "authors": [
        "Glucose Health"
      ],
      "summary": "BENTONVILLE, Ark., June 30, 2025 ( GLOBE NEWSWIRE ) -- Glucose Health, Inc. ( OTC: GLUC ) , a publicly traded company specializing in diabetic nutrition and soluble fiber-based nutrition products, today commented on the U.S. Department of Health and Human Services ( HHS ) and U.S.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d47e41d4-d807-43aa-95a4-73f35ecf06a9",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.184183,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GLUC",
          "relevance_score": "0.5341",
          "ticker_sentiment_score": "0.254492",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.165031",
          "ticker_sentiment_score": "0.209066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "0.278888",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.165031",
          "ticker_sentiment_score": "0.138832",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer: It's not too late to buy this portfolio health-care stock after Friday's selloff",
      "url": "https://www.cnbc.com/2024/03/18/jim-cramer-its-not-too-late-to-buy-abbott-stock-after-friday-selloff.html",
      "time_published": "20240318T155552",
      "authors": [
        "Morgan Chittum"
      ],
      "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107248804-1685557819267-gettyimages-1494887228-dsc_6170_tmhhfzze.jpeg?v=1710774347&w=600&h=300&vtcrop=y",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.169597,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.082111",
          "ticker_sentiment_score": "0.073757",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.133805",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.163354",
          "ticker_sentiment_score": "0.099411",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.163354",
          "ticker_sentiment_score": "0.099411",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.163354",
          "ticker_sentiment_score": "0.099411",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.082111",
          "ticker_sentiment_score": "0.073757",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants",
      "url": "https://www.zacks.com/stock/news/2276402/the-zacks-analyst-blog-highlights-stocks-recently-featured-in-the-blog-include-unitedhealth-danaher-abbott-and-ark-restaurants",
      "time_published": "20240521T105900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.217868,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.162073",
          "ticker_sentiment_score": "0.054406",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARKR",
          "relevance_score": "0.266828",
          "ticker_sentiment_score": "0.113503",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.162073",
          "ticker_sentiment_score": "0.054406",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.266828",
          "ticker_sentiment_score": "0.130703",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Exact Sciences  ( EXAS )  Q2 Loss Narrower Than Expected, Sales Beat",
      "url": "https://www.zacks.com/stock/news/2314363/exact-sciences-exas-q2-loss-narrower-than-expected-sales-beat",
      "time_published": "20240801T130300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999986"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.049769,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.161349",
          "ticker_sentiment_score": "0.092816",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.458708",
          "ticker_sentiment_score": "0.036738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.213988",
          "ticker_sentiment_score": "0.073201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.265666",
          "ticker_sentiment_score": "0.156757",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Markets Try to Shake Off April Blues",
      "url": "https://www.zacks.com/stock/news/2256979/markets-try-to-shake-off-april-blues",
      "time_published": "20240417T143200",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/17/1181.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.986413"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.091707,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LVS",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.026278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.026278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSX",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.026278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.140005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.026278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLG",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.026278",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday - Abbott Laboratories  ( NYSE:ABT ) , Exelixis  ( NASDAQ:EXEL ) ",
      "url": "https://www.benzinga.com/analyst-ratings/price-target/25/01/43225208/abbott-to-rally-over-26-here-are-10-top-analyst-forecasts-for-monday",
      "time_published": "20250127T124926",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley slashed the price target for Intellia Therapeutics, Inc. NTLA from $56 to $11.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/27/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.779048"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.161536,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PTLO",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.227172",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "-0.010912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.454174",
          "ticker_sentiment_score": "-0.06902",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMC",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.220463",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.31282",
          "ticker_sentiment_score": "0.013962",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.125452",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNG",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "-0.11391",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.166281",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "QRVO",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.08054",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RLI",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.005494",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTLA",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "-0.099058",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Exact Sciences Q2 Loss Narrower Than Expected, Sales Beat - Abbott Laboratories  ( NYSE:ABT ) , Exact Sciences  ( NASDAQ:EXAS ) ",
      "url": "https://www.benzinga.com/general/biotech/24/08/40103157/exact-sciences-q2-loss-narrower-than-expected-sales-beat",
      "time_published": "20240801T171128",
      "authors": [
        "Zacks"
      ],
      "summary": "Exact Sciences Corporation EXAS reported a net loss of 9 cents per share in second-quarter 2024, narrower than the year-ago loss of 45 cents per share. The figure beat the Zacks Consensus Estimate of a loss of 37 cents per share.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/70/1722514623.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999953"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.073563,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.117293",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.454174",
          "ticker_sentiment_score": "0.033488",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.211652",
          "ticker_sentiment_score": "0.083887",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.262805",
          "ticker_sentiment_score": "0.204739",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights like Amazon.com, Procter & Gamble, Abbott and NVE",
      "url": "https://www.zacks.com/stock/news/2367214/the-zacks-analyst-blog-highlights-like-amazoncom-procter-gamble-abbott-and-nve",
      "time_published": "20241108T131300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Amazon.com, Procter & Gamble, Abbott and NVE are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/92/486.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.355336,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVEC",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.12615",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.157827",
          "ticker_sentiment_score": "0.056099",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.404563",
          "ticker_sentiment_score": "0.170267",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "5 MedTech Stocks That Are Poised to Beat the Market in 2025",
      "url": "https://www.zacks.com/stock/news/2389368/5-medtech-stocks-that-are-poised-to-beat-the-market-in-2025",
      "time_published": "20241230T140000",
      "authors": [
        "Harshit Gupta"
      ],
      "summary": "Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.385053,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SEM",
          "relevance_score": "0.026184",
          "ticker_sentiment_score": "0.106426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.156123",
          "ticker_sentiment_score": "0.102626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.25726",
          "ticker_sentiment_score": "0.324922",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.232315",
          "ticker_sentiment_score": "0.289554",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.181721",
          "ticker_sentiment_score": "0.195863",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.207127",
          "ticker_sentiment_score": "0.223503",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories",
      "url": "https://www.zacks.com/stock/news/2386077/the-zacks-analyst-blog-highlights-veracyte-omnicell-masimo-and-abbott-laboratories",
      "time_published": "20241220T100800",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Veracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.339274,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VCYT",
          "relevance_score": "0.246895",
          "ticker_sentiment_score": "0.274978",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.21686",
          "ticker_sentiment_score": "0.258668",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.21686",
          "ticker_sentiment_score": "0.311144",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.155853",
          "ticker_sentiment_score": "0.186016",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.1108",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "U.S. Department of Health and Human Services Designates Four Nutrients of Public Health Concern Validating Glucose Health, Inc.  ( OTC: GLUC )  Patent Pending Soluble Fiber-Based Nutrition Formulation - Glucose Health  ( OTC:GLUC ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g46164505/u-s-department-of-health-and-human-services-designates-four-nutrients-of-public-health-concern-val",
      "time_published": "20250630T103000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "BENTONVILLE, Ark., June 30, 2025 ( GLOBE NEWSWIRE ) -- Glucose Health, Inc. GLUC, a publicly traded company specializing in diabetic nutrition and soluble fiber-based nutrition products, today commented on the U.S. Department of Health and Human Services ( HHS ) and U.S.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.200378,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GLUC",
          "relevance_score": "0.50325",
          "ticker_sentiment_score": "0.236857",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.153961",
          "ticker_sentiment_score": "0.193689",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.229149",
          "ticker_sentiment_score": "0.256346",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.153961",
          "ticker_sentiment_score": "0.131522",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Waters  ( WAT )  Q2 Earnings & Sales Beat Estimates, Fall Y/Y",
      "url": "https://www.zacks.com/stock/news/2313398/waters-wat-q2-earnings-sales-beat-estimates-fall-yy",
      "time_published": "20240731T173300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998311"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.026135,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKRO",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.188221",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.086416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WAT",
          "relevance_score": "0.780721",
          "ticker_sentiment_score": "0.048059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMED",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.158626",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Abbott Laboratories  ( NYSE:ABT ) , Danaher  ( NYSE:DHR ) ",
      "url": "https://www.benzinga.com/news/25/07/46296955/meta-platforms-to-rally-around-9-here-are-10-top-analyst-forecasts-for-tuesday",
      "time_published": "20250708T140356",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group slashed Danaher Corporation DHR price target from $230 to $226.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/08/Meta-Platforms-Inc--META.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.779048"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.222672,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EYE",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.121709",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KLAC",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.078648",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.151315",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.145489",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.091092",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KALV",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.096002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDDT",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.108002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWX",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.315155",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.43852",
          "ticker_sentiment_score": "0.08535",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "-0.014269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KEY",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.220493",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.146927",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.",
      "url": "https://www.fool.com/investing/2024/08/17/looking-for-safe-dividend-income-these-3-stocks-ha/",
      "time_published": "20240817T131000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "These stocks pay above-average yields, and their dividend income could rise higher in the future.",
      "banner_image": "https://g.foolcdn.com/editorial/images/786768/a-couple-reviewing-a-statement.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99977"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.196584,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.193316",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.051441",
          "ticker_sentiment_score": "-0.033003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "T",
          "relevance_score": "0.301315",
          "ticker_sentiment_score": "0.16261",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.21912",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Reasons to Retain ABT Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2385655/reasons-to-retain-abt-stock-in-your-portfolio-now",
      "time_published": "20241219T131500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986413"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.360348,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.124026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.153145",
          "ticker_sentiment_score": "0.356386",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GMED",
          "relevance_score": "0.153145",
          "ticker_sentiment_score": "0.15305",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.143928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Envista  ( NVST )  Q2 Earnings & Revenues Miss, Margins Fall",
      "url": "https://www.zacks.com/stock/news/2319365/envista-nvst-q2-earnings-revenues-miss-margins-fall",
      "time_published": "20240808T151300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999994"
        }
      ],
      "overall_sentiment_score": 0.0,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.153145",
          "ticker_sentiment_score": "0.089803",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.075002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.252463",
          "ticker_sentiment_score": "0.120812",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVST",
          "relevance_score": "0.393462",
          "ticker_sentiment_score": "-0.177577",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Abbott Snags U.S. Clearance To Enter The Obesity Arena",
      "url": "https://www.investors.com/news/technology/abbott-stock-continuous-glucose-monitor-obesity/",
      "time_published": "20240610T120000",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "Abbott Laboratories ( ABT ) gained U.S. clearance Monday for a pair of new continuous glucose monitors. The news could push Abbott stock closer to a breakout. The Food and Drug Administration signed off on Lingo and Libre Rio - vastly expanding Abbott's market in the U.S.",
      "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/Stock-abbott-06-company.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.172692,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "0.223415",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.152983",
          "ticker_sentiment_score": "0.041407",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.152983",
          "ticker_sentiment_score": "0.136172",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker",
      "url": "https://www.zacks.com/stock/news/2385071/abt-stock-up-on-first-successful-lbbap-procedures-with-aveir-pacemaker",
      "time_published": "20241218T124800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99489"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.2947,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.152178",
          "ticker_sentiment_score": "0.119091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PAHC",
          "relevance_score": "0.101797",
          "ticker_sentiment_score": "0.056463",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.152178",
          "ticker_sentiment_score": "0.15022",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.152178",
          "ticker_sentiment_score": "0.117733",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Omnicell  ( OMCL )  Q2 Earnings Top Estimates, Margins Down",
      "url": "https://www.zacks.com/stock/news/2315347/omnicell-omcl-q2-earnings-top-estimates-margins-down",
      "time_published": "20240802T132300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.135229,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OMCL",
          "relevance_score": "0.435177",
          "ticker_sentiment_score": "0.356106",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.152178",
          "ticker_sentiment_score": "0.088171",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.201944",
          "ticker_sentiment_score": "0.11831",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.250902",
          "ticker_sentiment_score": "0.120207",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott  ( ABT )  Faces Low Testing Demand, Currency Headwinds",
      "url": "https://www.zacks.com/stock/news/2251992/abbott-abt-faces-low-testing-demand-currency-headwinds",
      "time_published": "20240408T141000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        }
      ],
      "overall_sentiment_score": 0.167989,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.012465",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.054698",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.054698",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.201105",
          "ticker_sentiment_score": "0.044891",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday - Meta Platforms  ( NASDAQ:META ) ",
      "url": "https://www.benzinga.com/news/24/10/41379312/meta-to-rally-around-13-here-are-10-top-analyst-forecasts-for-thursday",
      "time_published": "20241017T123657",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Clear Secure, Inc. YOU price target from $40 to $45. Needham analyst Joshua Reilly ...",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-1024x524.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999967"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.312302,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JKHY",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.203024",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.148941",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYF",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.294915",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.149656",
          "ticker_sentiment_score": "0.138204",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHUN",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.173021",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.149656",
          "ticker_sentiment_score": "0.138204",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OI",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.037284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DASH",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.203024",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LII",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.325416",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SR",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.005213",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott  ( ABT )  Q2 Earnings Surpass Estimates, Margins Expand",
      "url": "https://www.zacks.com/stock/news/2304588/abbott-abt-q2-earnings-surpass-estimates-margins-expand",
      "time_published": "20240718T143200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.269866,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PODD",
          "relevance_score": "0.149192",
          "ticker_sentiment_score": "0.035238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.149192",
          "ticker_sentiment_score": "0.102358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMED",
          "relevance_score": "0.185876",
          "ticker_sentiment_score": "0.071584",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.149192",
          "ticker_sentiment_score": "0.06811",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's in Store for Abbott Laboratories  ( ABT )  in Q1 Earnings?",
      "url": "https://www.zacks.com/stock/news/2254571/whats-in-store-for-abbott-laboratories-abt-in-q1-earnings",
      "time_published": "20240412T135100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.234768,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EW",
          "relevance_score": "0.148502",
          "ticker_sentiment_score": "0.104611",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.148502",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWAV",
          "relevance_score": "0.148502",
          "ticker_sentiment_score": "0.008976",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HITI",
          "relevance_score": "0.148502",
          "ticker_sentiment_score": "0.047734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Stock Hurt by Macroeconomic Issues & FX Headwind",
      "url": "https://www.zacks.com/stock/news/2338593/abbott-stock-hurt-by-macroeconomic-issues-fx-headwind",
      "time_published": "20240919T144900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        }
      ],
      "overall_sentiment_score": 0.11017,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AXGN",
          "relevance_score": "0.148121",
          "ticker_sentiment_score": "0.053956",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMDX",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.154104",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.148121",
          "ticker_sentiment_score": "-0.054784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KIDS",
          "relevance_score": "0.291182",
          "ticker_sentiment_score": "0.099287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.049629",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Retain ABT Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2404305/reasons-to-retain-abt-stock-in-your-portfolio-now",
      "time_published": "20250128T111800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.315421,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.137201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VCYT",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.068997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.01917",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.394909",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook",
      "url": "https://www.zacks.com/stock/news/2396403/dexcom-stock-up-following-strong-preliminary-q4-results-2025-outlook",
      "time_published": "20250114T131100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.234274,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.220141",
          "ticker_sentiment_score": "0.136518",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.358669",
          "ticker_sentiment_score": "0.467618",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.220141",
          "ticker_sentiment_score": "-0.027756",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years",
      "url": "https://www.fool.com/investing/2024/11/14/3-ultra-safe-dividend-stocks-that-have-been-paying/",
      "time_published": "20241114T111900",
      "authors": [
        "David Jagielski"
      ],
      "summary": "These are income stocks you can buy and hold forever.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797238/a-couple-looking-at-a-statement.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        }
      ],
      "overall_sentiment_score": 0.286386,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.33628",
          "ticker_sentiment_score": "0.287248",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.243864",
          "ticker_sentiment_score": "0.150183",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.196658",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Quest Diagnostics  ( DGX )  Tops Q2 Earnings, Raises 2024 Outlook",
      "url": "https://www.zacks.com/stock/news/2306998/quest-diagnostics-dgx-tops-q2-earnings-raises-2024-outlook",
      "time_published": "20240723T140500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.24009,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "III",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.050118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.465478",
          "ticker_sentiment_score": "0.576238",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.196212",
          "ticker_sentiment_score": "0.083694",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.075299",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips",
      "url": "https://www.zacks.com/stock/news/2270202/the-zacks-analyst-blog-highlights-tesla-johnson-johnson-netflix-abbott-and-conocophillips",
      "time_published": "20240508T101800",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/04/590.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.285535,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.190577",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.146469",
          "ticker_sentiment_score": "0.037354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.218161",
          "ticker_sentiment_score": "0.049508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.146469",
          "ticker_sentiment_score": "0.037354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.288044",
          "ticker_sentiment_score": "0.050653",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DXCM's Access Gains and Operational Strength Offset Margin Pressures",
      "url": "https://www.zacks.com/stock/news/2519590/dxcms-access-gains-and-operational-strength-offset-margin-pressures",
      "time_published": "20250620T132500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d8/68148.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        }
      ],
      "overall_sentiment_score": 0.332334,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.109289",
          "ticker_sentiment_score": "0.166535",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.536334",
          "ticker_sentiment_score": "0.390901",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.145364",
          "ticker_sentiment_score": "0.183508",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold",
      "url": "https://www.fool.com/investing/2024/09/13/3-ultra-safe-dividend-stocks-for-retirees-to-buy/",
      "time_published": "20240913T130000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "These stocks have increased their payouts for decades.",
      "banner_image": "https://g.foolcdn.com/editorial/images/789982/two-people-shaking-hands-at-a-meeting.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.752319"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.349319,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENB",
          "relevance_score": "0.239541",
          "ticker_sentiment_score": "0.224229",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.145145",
          "ticker_sentiment_score": "0.338722",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ICNB",
          "relevance_score": "0.048621",
          "ticker_sentiment_score": "0.143933",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.239541",
          "ticker_sentiment_score": "0.319766",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Reasons to Add ABT Stock to Your Portfolio Right Now",
      "url": "https://www.zacks.com/stock/news/2440400/reasons-to-add-abt-stock-to-your-portfolio-right-now",
      "time_published": "20250404T120900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        }
      ],
      "overall_sentiment_score": 0.420045,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PAHC",
          "relevance_score": "0.191929",
          "ticker_sentiment_score": "0.166346",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.144563",
          "ticker_sentiment_score": "0.410414",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.144563",
          "ticker_sentiment_score": "0.056948",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.144563",
          "ticker_sentiment_score": "0.104238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.048425",
          "ticker_sentiment_score": "0.027989",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tandem Diabetes  ( TNDM )  Q2 Earnings Beat, '24 View Raised",
      "url": "https://www.zacks.com/stock/news/2316187/tandem-diabetes-tndm-q2-earnings-beat-24-view-raised",
      "time_published": "20240805T134700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.047205,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.086685",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.191549",
          "ticker_sentiment_score": "0.070202",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.191549",
          "ticker_sentiment_score": "-0.119718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.115235",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Myriad Genetics  ( MYGN )  Q2 Earnings Surpass, '24 Outlook Raised",
      "url": "https://www.zacks.com/stock/news/2318906/myriad-genetics-mygn-q2-earnings-surpass-24-outlook-raised",
      "time_published": "20240808T121600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/62145.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.118173,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "QGEN",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "0.109992",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.142284",
          "ticker_sentiment_score": "0.049033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.142284",
          "ticker_sentiment_score": "0.056416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.234911",
          "ticker_sentiment_score": "0.084146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYGN",
          "relevance_score": "0.367412",
          "ticker_sentiment_score": "0.265993",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "BBNX Stock May Gain From Abbott Deal to Advance iLet Integration",
      "url": "https://www.zacks.com/stock/news/2535909/bbnx-stock-may-gain-from-abbott-deal-to-advance-ilet-integration",
      "time_published": "20250623T152000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        }
      ],
      "overall_sentiment_score": 0.329872,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "0.087078",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.259901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ITGR",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.007598",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BBNX",
          "relevance_score": "0.560957",
          "ticker_sentiment_score": "0.505019",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch - Costco Wholesale  ( NASDAQ:COST ) , Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/government/regulations/25/01/43011207/fda-bans-red-dye-no-3-effective-january-2027-cites-cancer-risks-food-stocks-to-watch",
      "time_published": "20250115T174101",
      "authors": [
        "Maureen Meehan"
      ],
      "summary": "\"If you can't put it on your skin why would you eat it?\" says one expert. \"We don't need bright red candies.\" Ferrara and General Mills have indicated their readiness to meet the new standards. Ferrara has already begun reformulating products. The U.S.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/15/Top-View-Of-Sweets--Candy--Red-Sugar-Can.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.033914,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GIS",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "-0.04225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HESG",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "0.009091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RTA1:MU",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "-0.05481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "-0.068886",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "-0.068886",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TAK",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "-0.068886",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott  ( ABT )  Q1 Earnings Beat Estimates, Margins Contract",
      "url": "https://www.zacks.com/stock/news/2256957/abbott-abt-q1-earnings-beat-estimates-margins-contract",
      "time_published": "20240417T141300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.221765,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "INSP",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.034626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.032987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.095681",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.032981",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Penumbra  ( PEN )  Tops on Q2 Earnings, Lowers Sales View",
      "url": "https://www.zacks.com/stock/news/2313226/penumbra-pen-tops-on-q2-earnings-lowers-sales-view",
      "time_published": "20240731T140300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.120127,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.446742",
          "ticker_sentiment_score": "0.293596",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.141171",
          "ticker_sentiment_score": "0.084405",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.141171",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.233108",
          "ticker_sentiment_score": "0.11153",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Myriad Genetics Q2 Earnings Surpass, '24 Outlook Raised - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
      "url": "https://www.benzinga.com/news/mid-cap/24/08/40254297/myriad-genetics-q2-earnings-surpass-24-outlook-raised",
      "time_published": "20240808T153009",
      "authors": [
        "Zacks"
      ],
      "summary": "Myriad Genetics, Inc. MYGN reported adjusted earnings of 5 cents per share in the second quarter of 2024 compared to the Zacks Consensus Estimate of a loss of 1 cent per share. The reported figure also compares to a loss of 8 cents per share in the year-ago quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/42/1723113961.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.141797,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "QGEN",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.109982",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.061009",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.072041",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.232661",
          "ticker_sentiment_score": "0.107877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYGN",
          "relevance_score": "0.364053",
          "ticker_sentiment_score": "0.271557",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Molina Healthcare Q3 Earnings Beat Estimates on Growing Premiums",
      "url": "https://www.zacks.com/stock/news/2357177/molina-healthcare-q3-earnings-beat-estimates-on-growing-premiums",
      "time_published": "20241024T173700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "MOH's third-quarter results benefit from growing membership and rising premiums, partially offset by rising expenses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999974"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.214636,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EHC",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.109797",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.060813",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.080372",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MOH",
          "relevance_score": "0.319488",
          "ticker_sentiment_score": "0.24323",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ABT Stock Gains Following the Positive TRILUMINATE Trial Results",
      "url": "https://www.zacks.com/stock/news/2437910/abt-stock-gains-following-the-positive-triluminate-trial-results",
      "time_published": "20250401T112200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/667.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972476"
        }
      ],
      "overall_sentiment_score": 0.245188,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.052214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.245445",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.052214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.052214",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Amedisys  ( AMED )  Q2 Earnings Top Estimates, Gross Margin Down",
      "url": "https://www.zacks.com/stock/news/2309700/amedisys-amed-q2-earnings-top-estimates-gross-margin-down",
      "time_published": "20240726T115300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.213154,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.048508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.055812",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMED",
          "relevance_score": "0.480769",
          "ticker_sentiment_score": "0.449157",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.230454",
          "ticker_sentiment_score": "0.082855",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.345981",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Community Health Q3 Earnings Miss on Lower Adjusted Admissions",
      "url": "https://www.zacks.com/stock/news/2357173/community-health-q3-earnings-miss-on-lower-adjusted-admissions",
      "time_published": "20241024T172900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "CYH's third-quarter earnings suffer a setback due to lower admissions and patient days. Improved occupancy levels and reimbursement rates partially offset the negatives.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999919"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.113941,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.138997",
          "ticker_sentiment_score": "0.08491",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CYH",
          "relevance_score": "0.273807",
          "ticker_sentiment_score": "-0.029018",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.138997",
          "ticker_sentiment_score": "0.087349",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MOH",
          "relevance_score": "0.138997",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Globus Medical  ( GMED )  Q2 Earnings Top Estimates, '24 View Up",
      "url": "https://www.zacks.com/stock/news/2318208/globus-medical-gmed-q2-earnings-top-estimates-24-view-up",
      "time_published": "20240807T142600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.240271,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.13873",
          "ticker_sentiment_score": "0.084822",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.184246",
          "ticker_sentiment_score": "0.068211",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMED",
          "relevance_score": "0.316555",
          "ticker_sentiment_score": "0.337845",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.229149",
          "ticker_sentiment_score": "0.111726",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Kings That Would Have Doubled Your Money in 5 Years",
      "url": "https://www.fool.com/investing/2024/11/08/2-dividend-kings-that-would-have-doubled-your-mone/",
      "time_published": "20241108T100000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.",
      "banner_image": "https://g.foolcdn.com/editorial/images/796253/investor-calculating-stock-returns-on-a-calculator.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.348232,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VZIO",
          "relevance_score": "0.069495",
          "ticker_sentiment_score": "0.16787",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.514619",
          "ticker_sentiment_score": "0.373076",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.141165",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.514619",
          "ticker_sentiment_score": "0.396988",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Pitney Bowes  ( NYSE:PBI ) ",
      "url": "https://www.benzinga.com/news/24/07/40005612/why-pitney-bowes-shares-are-trading-higher-by-over-12-here-are-20-stocks-moving-premarket",
      "time_published": "20240729T092634",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Shares of Pitney Bowes Inc. PBI shares rose sharply in today's pre-market trading following a report indicating that the company has sold a part of its e-commerce business to Stord. Pitney Bowes shares jumped 12.5% to $7.58 in pre-market trading. Here are some other stocks moving in pre-market ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/movers-image.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.167147,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERO",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.133618",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BFI",
          "relevance_score": "0.206392",
          "ticker_sentiment_score": "0.359973",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TIVC",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.4676",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "LGVN",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.206754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.122943",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNAZ",
          "relevance_score": "0.206392",
          "ticker_sentiment_score": "0.253925",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TGOPF",
          "relevance_score": "0.069495",
          "ticker_sentiment_score": "0.16182",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VTVT",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.024929",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "YIBO",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.135926",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NUZE",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.214077",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PBI",
          "relevance_score": "0.206392",
          "ticker_sentiment_score": "0.181544",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AVXL",
          "relevance_score": "0.206392",
          "ticker_sentiment_score": "-0.017104",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CGTX",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.190882",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GVH",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.175764",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TGL",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.080912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LUXH",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.137382",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHIO",
          "relevance_score": "0.206392",
          "ticker_sentiment_score": "-0.392891",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "EZPW",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.238465",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "INVO",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "-0.057457",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CVS Health  ( CVS )  Beats Q2 Earnings, Narrows '24 EPS Outlook",
      "url": "https://www.zacks.com/stock/news/2317864/cvs-health-cvs-beats-q2-earnings-narrows-24-eps-outlook",
      "time_published": "20240807T130200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/59/54380.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.217831,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.47672",
          "ticker_sentiment_score": "0.431392",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.138198",
          "ticker_sentiment_score": "0.048257",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.138198",
          "ticker_sentiment_score": "0.055523",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.138198",
          "ticker_sentiment_score": "0.072502",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tech Stocks Stall, Small Caps Surge As Regional Banks Rally, Airlines Rocket: What's Driving Markets Wednesday? - Alcoa  ( NYSE:AA ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41364779/tech-stocks-stall-small-caps-surge-as-regional-banks-rally-airlines-rocket-whats-driving-markets-we",
      "time_published": "20241016T174441",
      "authors": [
        "Piero Cingari"
      ],
      "summary": "Small-cap stocks outperformed large caps in Wednesday's session, with the Russell 2000 Index surging to test July 2024 highs on the back of expectations for interest rate cuts and a strong rally in regional banks. Financial stocks continued their upward momentum, buoyed by strong earnings reports.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Wall-Street_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.072849,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AA",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.272029",
          "ticker_sentiment_score": "0.039477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBKR",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "-0.510392",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "CFG",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.272029",
          "ticker_sentiment_score": "0.102717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSX",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.069294",
          "ticker_sentiment_score": "0.020963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "-0.367202",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "DFS",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STLD",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.233239",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "IDEXX  ( IDXX )  Q2 Earnings Miss Estimates, 2024 View Down",
      "url": "https://www.zacks.com/stock/news/2317144/idexx-idxx-q2-earnings-miss-estimates-2024-view-down",
      "time_published": "20240806T134700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.165677,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IDXX",
          "relevance_score": "0.227859",
          "ticker_sentiment_score": "0.021967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.137934",
          "ticker_sentiment_score": "0.084561",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.183198",
          "ticker_sentiment_score": "0.067927",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.227859",
          "ticker_sentiment_score": "0.111222",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Stock Ahead of Q4 Earnings Results: Smart Buy or Risky Move?",
      "url": "https://www.zacks.com/stock/news/2400013/abbott-stock-ahead-of-q4-earnings-results-smart-buy-or-risky-move",
      "time_published": "20250120T160700",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "Abbott's Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand in the fourth quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.290802,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.103628",
          "ticker_sentiment_score": "0.07872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.137868",
          "ticker_sentiment_score": "0.152669",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "National Vision  ( EYE )  Tops Q2 Earnings, Lowers '24 Outlook",
      "url": "https://www.zacks.com/stock/news/2318931/national-vision-eye-tops-q2-earnings-lowers-24-outlook",
      "time_published": "20240808T122500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        }
      ],
      "overall_sentiment_score": 0.119821,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EYE",
          "relevance_score": "0.474321",
          "ticker_sentiment_score": "0.181635",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.137409",
          "ticker_sentiment_score": "0.046903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.137409",
          "ticker_sentiment_score": "0.054146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.137409",
          "ticker_sentiment_score": "0.030029",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "-0.059161",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Globus Medical Q2 Earnings Top Estimates, '24 View Up - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
      "url": "https://www.benzinga.com/news/earnings/24/08/40225737/globus-medical-q2-earnings-top-estimates-24-view-up",
      "time_published": "20240807T184856",
      "authors": [
        "Zacks"
      ],
      "summary": "Globus Medical, Inc. GMED reported second-quarter 2024 adjusted earnings per share of 75 cents, which beat the Zacks Consensus Estimate by 10.3%. The figure increased 19% year over year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/29/1723034409.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.256128,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.137409",
          "ticker_sentiment_score": "0.107432",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.079314",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMED",
          "relevance_score": "0.313674",
          "ticker_sentiment_score": "0.351828",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.227007",
          "ticker_sentiment_score": "0.143283",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "IDEXX Q2 Earnings Miss Estimates, 2024 View Down - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
      "url": "https://www.benzinga.com/news/earnings/24/08/40193340/idexx-q2-earnings-miss-estimates-2024-view-down",
      "time_published": "20240806T181753",
      "authors": [
        "Zacks"
      ],
      "summary": "IDEXX Laboratories, Inc. IDXX posted second-quarter 2024 earnings per share of $2.44, down 8.6% year over year. The figure missed the Zacks Consensus Estimate by 14.9%. Comparable constant-currency EPS of $3.02 improved 14.8% year over year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/11/1722950838.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.184287,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IDXX",
          "relevance_score": "0.22574",
          "ticker_sentiment_score": "0.021924",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.136629",
          "ticker_sentiment_score": "0.107109",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.181477",
          "ticker_sentiment_score": "0.07899",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.22574",
          "ticker_sentiment_score": "0.142648",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus",
      "url": "https://www.zacks.com/stock/news/2443431/abbotts-q1-earnings-coming-up-medical-devices-arm-in-focus",
      "time_published": "20250410T125200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/69315.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999974"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.211451,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.068502",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.068502",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.136499",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.102595",
          "ticker_sentiment_score": "0.059805",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HCA Healthcare Beats on Q3 Earnings, Reaffirms 2024 EPS View",
      "url": "https://www.zacks.com/stock/news/2358015/hca-healthcare-beats-on-q3-earnings-reaffirms-2024-eps-view",
      "time_published": "20241025T162500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "HCA's quarterly results benefit from improved admissions and inpatient surgeries, partially offset by the impact of hurricanes and rising salaries and benefits expenses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998947"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.186393,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.053876",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.055078",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.47037",
          "ticker_sentiment_score": "0.366842",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MOH",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Research Reports for Abbott, BlackRock & ConocoPhillips",
      "url": "https://www.zacks.com/research-daily/2375844/top-research-reports-for-abbott-blackrock-conocophillips",
      "time_published": "20241127T182400",
      "authors": [
        "Sheraz Mian"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BlackRock, Inc. (BLK) and ConocoPhillips (COP), as well as two micro-cap stocks, NetSol Technologies, Inc. (NTWK) and Optex Systems Holdings, Inc (OPXS).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.225532,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OPXS",
          "relevance_score": "0.135729",
          "ticker_sentiment_score": "0.109151",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.135729",
          "ticker_sentiment_score": "0.109151",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.267559",
          "ticker_sentiment_score": "0.164947",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NTWK",
          "relevance_score": "0.135729",
          "ticker_sentiment_score": "0.109151",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "STERIS  ( STE )  Q1 Earnings Beat Estimates, Operating Margin Falls",
      "url": "https://www.zacks.com/stock/news/2318207/steris-ste-q1-earnings-beat-estimates-operating-margin-falls",
      "time_published": "20240807T142600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.165856,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.135602",
          "ticker_sentiment_score": "0.083803",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.180124",
          "ticker_sentiment_score": "0.067101",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.224072",
          "ticker_sentiment_score": "0.109744",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STE",
          "relevance_score": "0.391583",
          "ticker_sentiment_score": "0.262974",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Chemed  ( CHE )  Q2 Earnings Miss Estimates, Margins Expand",
      "url": "https://www.zacks.com/stock/news/2308654/chemed-che-q2-earnings-miss-estimates-margins-expand",
      "time_published": "20240725T124900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/69315.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.106087,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CHE",
          "relevance_score": "0.468807",
          "ticker_sentiment_score": "0.303396",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.135602",
          "ticker_sentiment_score": "0.047776",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.135602",
          "ticker_sentiment_score": "0.054969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.224072",
          "ticker_sentiment_score": "0.081006",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Charles River  ( CRL )  Q2 Earnings Beat Estimates, 2024 View Down",
      "url": "https://www.zacks.com/stock/news/2318347/charles-river-crl-q2-earnings-beat-estimates-2024-view-down",
      "time_published": "20240807T173000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.101913,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.135094",
          "ticker_sentiment_score": "0.08364",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRL",
          "relevance_score": "0.223248",
          "ticker_sentiment_score": "0.184974",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.179454",
          "ticker_sentiment_score": "0.066922",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.223248",
          "ticker_sentiment_score": "0.109422",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Iridium Gearing Up to Report Q3 Earnings: Here's What to Expect",
      "url": "https://www.zacks.com/stock/news/2349984/iridium-gearing-up-to-report-q3-earnings-heres-what-to-expect",
      "time_published": "20241014T141500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Iridium's third-quarter performance is likely to have benefited from momentum in commercial service revenues and increasing subscriber base.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999953"
        }
      ],
      "overall_sentiment_score": 0.21766,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IRDM",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.186377",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.134841",
          "ticker_sentiment_score": "0.170189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.134841",
          "ticker_sentiment_score": "0.170189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.134841",
          "ticker_sentiment_score": "0.136455",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Add Cencora Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2443097/heres-why-you-should-add-cencora-stock-to-your-portfolio-now",
      "time_published": "20250410T112500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999974"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.27958,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "0.051124",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "0.095388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "0.051124",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "0.042076",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "0.114187",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.388209",
          "ticker_sentiment_score": "0.338801",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pre-Markets Open in The Red",
      "url": "https://www.zacks.com/stock/news/2450022/pre-markets-open-in-the-red",
      "time_published": "20250416T145400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pre-market futures are still in the red at this hour, but threaten to break out into positive territory compared with where we were overnight. We're also bifurcated presently: -40 points, roughly, on both the Dow and S&P 500, but -260 points on he tech-heavy Nasdaq.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/2160.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        }
      ],
      "overall_sentiment_score": 0.134312,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.200134",
          "ticker_sentiment_score": "-0.031836",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.134214",
          "ticker_sentiment_score": "0.0741",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALV",
          "relevance_score": "0.134214",
          "ticker_sentiment_score": "0.137988",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.134214",
          "ticker_sentiment_score": "-0.024395",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "4 Healthcare Technology Innovators to Invest in Before the New Year",
      "url": "https://www.zacks.com/stock/news/2385834/4-healthcare-technology-innovators-to-invest-in-before-the-new-year",
      "time_published": "20241219T155600",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/74133.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.348246,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VCYT",
          "relevance_score": "0.231963",
          "ticker_sentiment_score": "0.310525",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.199584",
          "ticker_sentiment_score": "0.310856",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.199584",
          "ticker_sentiment_score": "0.360889",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "0.240358",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.033609",
          "ticker_sentiment_score": "0.111803",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senhwa Biosciences Announces Jason Huang, MD as New Chief Medical Officer",
      "url": "https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-jason-huang-md-as-new-chief-medical-officer-302143219.html",
      "time_published": "20240513T110000",
      "authors": [
        "Inc.",
        "Senhwa Biosciences"
      ],
      "summary": "NEW TAIPEI CITY, May 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. ( TPEx: 6492 ) , announced the appointment of Jason Huang, M.D., former Regional Therapeutic Area Expert ( RTAE ) , Janssen, a subsidiary of Johnson and Johnson, as the company's chief medical officer.",
      "banner_image": "https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.285702,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "0.175549",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF  ( RSPH ) ?",
      "url": "https://www.zacks.com/stock/news/2431195/should-you-invest-in-the-invesco-sp-500-equal-weight-health-care-etf-rsph",
      "time_published": "20250318T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default259.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.317752,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.071096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.071096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.071096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.198493",
          "ticker_sentiment_score": "0.174797",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Neogen  ( NEOG )  Q4 Earnings Miss Estimates, Margins Crash",
      "url": "https://www.zacks.com/stock/news/2312689/neogen-neog-q4-earnings-miss-estimates-margins-crash",
      "time_published": "20240731T120700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.073871,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.047322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEOG",
          "relevance_score": "0.461132",
          "ticker_sentiment_score": "0.197987",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.054447",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.220008",
          "ticker_sentiment_score": "0.07983",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2381261/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20241210T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.220947,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.070801",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.070801",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.196877",
          "ticker_sentiment_score": "0.141519",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.070801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2448173/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20250414T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.223702,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SEM",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.027021",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2413318/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20250211T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.202767,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SEM",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.027021",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2248126/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20240401T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default354.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.193607,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "0.149109",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.070705",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2381887/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20241211T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.198159,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SEM",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.026984",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.070609",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.070609",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.070609",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cramer's week ahead: Earnings from JPMorgan, Netflix, Goldman Sachs and PepsiCo",
      "url": "https://www.cnbc.com/2025/07/11/cramers-week-ahead-earnings-from-jpmorgan-netflix-goldman-sachs-and-pepsico.html",
      "time_published": "20250711T225755",
      "authors": [],
      "summary": "CNBC's Jim Cramer's on Friday told investors what to follow next week as earnings season kicks off.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        }
      ],
      "overall_sentiment_score": 0.146135,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.194763",
          "ticker_sentiment_score": "-0.108292",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "-0.089584",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "0.077671",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.152432",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "0.126013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "0.126013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "0.126013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.194763",
          "ticker_sentiment_score": "0.220757",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "-0.022464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.194763",
          "ticker_sentiment_score": "0.195512",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.17934",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.17934",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.194763",
          "ticker_sentiment_score": "-0.108292",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2450394/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20250417T102002",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.187099,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.07042",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.07042",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.194763",
          "ticker_sentiment_score": "0.117513",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.07042",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems",
      "url": "https://www.zacks.com/stock/news/2376789/the-zacks-analyst-blog-abbott-blackrock-conocophillips-netsol-and-optex-systems",
      "time_published": "20241129T070000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f8/614.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.218022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OPXS",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.257668",
          "ticker_sentiment_score": "0.086903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTWK",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bio-Rad  ( BIO )  Q2 Earnings Surpass Estimates, Guidance Lowered",
      "url": "https://www.zacks.com/stock/news/2315332/bio-rad-bio-q2-earnings-surpass-estimates-guidance-lowered",
      "time_published": "20240802T141600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.076476,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BIO",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.142112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130453",
          "ticker_sentiment_score": "0.081001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.130453",
          "ticker_sentiment_score": "0.055082",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.215702",
          "ticker_sentiment_score": "0.10484",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ResMed's  ( RMD )  Q4 Earnings Surpass Estimates, Margins Expand",
      "url": "https://www.zacks.com/stock/news/2314987/resmeds-rmd-q4-earnings-surpass-estimates-margins-expand",
      "time_published": "20240802T121100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.225684,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.486464",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130453",
          "ticker_sentiment_score": "0.046852",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.130453",
          "ticker_sentiment_score": "0.053906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.215702",
          "ticker_sentiment_score": "0.078587",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Labcorp  ( LH )  Q2 Earnings Surpass Estimates, Margins Increase",
      "url": "https://www.zacks.com/stock/news/2314219/labcorp-lh-q2-earnings-surpass-estimates-margins-increase",
      "time_published": "20240801T134700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.118859,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.130453",
          "ticker_sentiment_score": "0.046852",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.130453",
          "ticker_sentiment_score": "0.053906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LH",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.163058",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.215702",
          "ticker_sentiment_score": "0.078587",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "0JDB",
          "relevance_score": "0.087185",
          "ticker_sentiment_score": "0.121346",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2509884/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20250618T102007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.182348,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.194242",
          "ticker_sentiment_score": "0.11726",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2347943/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20241009T102007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.177529,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SEM",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.026877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2315697/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20240805T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.24763,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLK",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.031022",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEM",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.026877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Abbott  ( ABT )  is Placed Ahead of Q2 Earnings Release",
      "url": "https://www.zacks.com/stock/news/2300076/heres-how-abbott-abt-is-placed-ahead-of-q2-earnings-release",
      "time_published": "20240711T142800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/91/54133.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.273834,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENOV",
          "relevance_score": "0.065061",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.12969",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.097457",
          "ticker_sentiment_score": "-0.001059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.097457",
          "ticker_sentiment_score": "0.033653",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Magnificent Dividend Growth Stocks to Buy Now",
      "url": "https://www.fool.com/investing/2024/06/11/2-magnificent-dividend-growth-stocks-to-buy-now/",
      "time_published": "20240611T134500",
      "authors": [
        "George Budwell"
      ],
      "summary": "These two dividend growth stocks are potent capital appreciation vehicles.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780175%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        }
      ],
      "overall_sentiment_score": 0.487967,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TGT",
          "relevance_score": "0.536866",
          "ticker_sentiment_score": "0.637757",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.38089",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ResMed's Q4 Earnings Surpass Estimates, Margins Expand - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
      "url": "https://www.benzinga.com/general/biotech/24/08/40131230/resmeds-q4-earnings-surpass-estimates-margins-expand",
      "time_published": "20240802T170825",
      "authors": [
        "Zacks"
      ],
      "summary": "ResMed Inc.'s RMD adjusted earnings per share in the fourth quarter of fiscal 2024 were $2.08, up 30% year over year. The metric beat the Zacks Consensus Estimate by 2.5%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/37/1722586174.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999996"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.241642,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.335709",
          "ticker_sentiment_score": "0.497288",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.129284",
          "ticker_sentiment_score": "0.058357",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.129284",
          "ticker_sentiment_score": "0.068909",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.2138",
          "ticker_sentiment_score": "0.100853",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zimmer Biomet  ( ZBH )  Beats on Q2 Earnings, Cuts Revenue View",
      "url": "https://www.zacks.com/stock/news/2318276/zimmer-biomet-zbh-beats-on-q2-earnings-cuts-revenue-view",
      "time_published": "20240807T161300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2f/61766.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.184883,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZBH",
          "relevance_score": "0.411848",
          "ticker_sentiment_score": "0.377584",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.129052",
          "ticker_sentiment_score": "0.081752",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.171485",
          "ticker_sentiment_score": "0.066199",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CBRE",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.169205",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.213423",
          "ticker_sentiment_score": "0.105594",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2505844/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20250617T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default126.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.252587,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SEM",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.026704",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.069872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.069872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.069872",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2249507/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20240403T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default211.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.216422,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLK",
          "relevance_score": "0.064449",
          "ticker_sentiment_score": "0.031013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEM",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.026704",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.069872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.069872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.069872",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?",
      "url": "https://www.zacks.com/stock/news/2393808/abbott-stock-trades-at-a-discounted-pb-value-to-buy-or-not-to-buy",
      "time_published": "20250108T153500",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.441148,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.128363",
          "ticker_sentiment_score": "0.125008",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.042953",
          "ticker_sentiment_score": "0.190205",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.128363",
          "ticker_sentiment_score": "0.186122",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.128363",
          "ticker_sentiment_score": "0.186122",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.085782",
          "ticker_sentiment_score": "0.150627",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
      "url": "https://www.zacks.com/stock/news/2282436/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
      "time_published": "20240603T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for IHI ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.245387,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLK",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.031012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEM",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.02667",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.069783",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.069783",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.128135",
          "ticker_sentiment_score": "0.069783",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Henry Schein  ( HSIC )  Q2 Earnings Surpass, 2024 Guidance Slashed",
      "url": "https://www.zacks.com/stock/news/2316783/henry-schein-hsic-q2-earnings-surpass-2024-guidance-slashed",
      "time_published": "20240806T125700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/64446.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        }
      ],
      "overall_sentiment_score": 0.142587,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.042723",
          "ticker_sentiment_score": "0.126446",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.127682",
          "ticker_sentiment_score": "0.046372",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.127682",
          "ticker_sentiment_score": "0.053353",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSIC",
          "relevance_score": "0.546745",
          "ticker_sentiment_score": "0.314544",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "0.077287",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Labcorp  ( LH )  Q2 Earnings Surpass Estimates  ( revised ) ",
      "url": "https://www.zacks.com/stock/news/2314612/labcorp-lh-q2-earnings-surpass-estimates-revised",
      "time_published": "20240801T190200",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.114505,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.126561",
          "ticker_sentiment_score": "0.046181",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.126561",
          "ticker_sentiment_score": "0.053134",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LH",
          "relevance_score": "0.168197",
          "ticker_sentiment_score": "0.159768",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.076763",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "0JDB",
          "relevance_score": "0.084572",
          "ticker_sentiment_score": "0.120656",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Retail Sales, Q1 Earnings Show Signs of \"Pull Forward\"",
      "url": "https://www.zacks.com/stock/news/2449989/retail-sales-q1-earnings-show-signs-of-pull-forward",
      "time_published": "20250416T142800",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "A trade tariff casualty - NVIDIA - is sending the Nasdaq lower than the other major indexes ahead of the open.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/100361.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        }
      ],
      "overall_sentiment_score": 0.129436,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "0.081706",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.066883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALV",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.122791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.063634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends",
      "url": "https://www.fool.com/investing/2025/03/20/heres-how-many-shares-of-abbvie-you-need-to-own-to/",
      "time_published": "20250320T133100",
      "authors": [
        "Selena Maranjian"
      ],
      "summary": "So, you want to invest in AbbVie ( NYSE: ABBV ) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy? The answer requires a little simple math.Shares of AbbVie were recently trading for $212 apiece, ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F811522%2Fdisabled-senior-man-in-wheelchair-indoors-playing-with-a-pet-dog.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.25891,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.730954",
          "ticker_sentiment_score": "0.40853",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.213298",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Integra's  ( IART )  Q2 Earnings and Revenues Top, Margins Down",
      "url": "https://www.zacks.com/stock/news/2312264/integras-iart-q2-earnings-and-revenues-top-margins-down",
      "time_published": "20240730T164900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.191094,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IART",
          "relevance_score": "0.206862",
          "ticker_sentiment_score": "0.156992",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.125025",
          "ticker_sentiment_score": "0.075924",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.125025",
          "ticker_sentiment_score": "0.051685",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.206862",
          "ticker_sentiment_score": "0.101462",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years",
      "url": "https://www.fool.com/investing/2024/07/25/3-high-yielding-dividend-stocks-that-can-help-bank/",
      "time_published": "20240725T110000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "These stocks provide good yields and they don't come with much risk.",
      "banner_image": "https://g.foolcdn.com/editorial/images/784054/elderly-person-holding-money.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998356"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.369701,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HD",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "0.413776",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.264488",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2359699/angiodynamics-stock-plunges-138-in-three-months-whats-next",
      "time_published": "20241029T144300",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.185902,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BSX",
          "relevance_score": "0.123951",
          "ticker_sentiment_score": "0.119904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.123951",
          "ticker_sentiment_score": "0.119904",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Beta Bionics  ( NASDAQ:BBNX ) , Insulet  ( NASDAQ:PODD ) , DexCom  ( NASDAQ:DXCM ) ",
      "url": "https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45719165/goldman-sachs-bullish-on-dexcom-and-insulet-as-diabetes-tech-surges",
      "time_published": "20250602T121128",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Goldman sets $380 target for Insulet, citing Omnipod's unique design and share capture potential. Dexcom gets $104 target, expected to gain share in non-insulin diabetes segments through 2025. Rebound or breakdown? See how Matt Maley is trading June's market volatility, live this Wednesday, June ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/02/Santa-Ana--Ca--Usa---May-9--2022-Goldman.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.278346,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PODD",
          "relevance_score": "0.302429",
          "ticker_sentiment_score": "0.253538",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.359014",
          "ticker_sentiment_score": "0.249218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "-0.089319",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BBNX",
          "relevance_score": "0.184363",
          "ticker_sentiment_score": "0.017954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.413587",
          "ticker_sentiment_score": "0.369202",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Intuitive Surgical Stock Surges on Q4 Preliminary Revenue Beat",
      "url": "https://www.zacks.com/stock/news/2398030/intuitive-surgical-stock-surges-on-q4-preliminary-revenue-beat",
      "time_published": "20250116T132800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ISRG records significant growth in the top line, driven by higher system placements as well as improved pricing. Procedure volume remains strong.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/1670.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.217572,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.119058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.123209",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.412619",
          "ticker_sentiment_score": "0.22147",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "-0.024175",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years - SPDR S&P 500  ( ARCA:SPY ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39766859/netflix-goldman-sachs-j-j-asml-lead-q2-reports-this-week-as-analysts-see-earnings-growth-accelerati",
      "time_published": "20240715T091317",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "The second-quarter reporting season got off to a rocky start with investors reacting to some big bank earnings. Nevertheless, optimism over a healthy earnings season continues to abound. The Week That Was: Shares of high-profile big banks including JPMorgan Chase & Co. JPM, Citigroup Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/15/earnings.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999813"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.22049,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AA",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALK",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.249464",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.210285",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLB",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "-0.192121",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "DAL",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.089961",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DPZ",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLG",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DFS",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DMPZF",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAL",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.220592",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.18343",
          "ticker_sentiment_score": "-0.265821",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.220592",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "-0.220592",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STLD",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus",
      "url": "https://www.zacks.com/stock/news/2349820/abbotts-q3-earnings-release-coming-up-epd-business-in-focus",
      "time_published": "20241014T132800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.282462,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.061394",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.122425",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.061394",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.061394",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views - Abbott Laboratories  ( NYSE:ABT ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39846457/nasdaq-down-over-100-points-abbott-laboratories-earnings-beat-views",
      "time_published": "20240718T183140",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48. Energy shares jumped by 1.1% on Thursday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Crude-oil-4-logo.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        }
      ],
      "overall_sentiment_score": 0.079768,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "0.112059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LESL",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "0.019092",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "-0.143033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "0.327852",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COMM",
          "relevance_score": "0.182047",
          "ticker_sentiment_score": "0.165862",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CHUY",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "0.272802",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "-0.068001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APH",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "0.115015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CURV",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "-0.077378",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DRI",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "0.23819",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EA",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "-0.143033",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ICUI Stock Gains Following Latest FDA Approvals for Precision IV Pumps",
      "url": "https://www.zacks.com/stock/news/2442089/icui-stock-gains-following-latest-fda-approvals-for-precision-iv-pumps",
      "time_published": "20250408T160400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ICU Medical aims to enable healthcare systems to customize infusion setups, optimizing device footprint without compromising performance or safety.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.333424,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ICUI",
          "relevance_score": "0.600121",
          "ticker_sentiment_score": "0.483095",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.181591",
          "ticker_sentiment_score": "0.104992",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.240489",
          "ticker_sentiment_score": "0.097105",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "UnitedHealth Q3 Earnings Beat on Domestic Commercial Business",
      "url": "https://www.zacks.com/stock/news/2350974/unitedhealth-q3-earnings-beat-on-domestic-commercial-business",
      "time_published": "20241015T164200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "UNH's third-quarter earnings benefit on the back of client wins in the Optum Rx sub-unit, partly offset by an elevated operating expense level.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.168296,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EHC",
          "relevance_score": "0.080865",
          "ticker_sentiment_score": "0.114092",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.121037",
          "ticker_sentiment_score": "0.111373",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CI",
          "relevance_score": "0.080865",
          "ticker_sentiment_score": "0.075284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.221534",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "S&P 500, Nasdaq Futures Point To Higher Open Today: What's Going On? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
      "url": "https://www.benzinga.com/news/earnings/24/04/38288246/wall-street-poised-to-rebound-from-slump-as-earnings-optimism-grows-analyst-eyes-this-s-p-500-level",
      "time_published": "20240417T110902",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "U.S. stocks are priming for a firmer start on Wednesday, potentially striving to inflect higher from the weakness seen so far in April. As some bullish market watchers pointed out there could be an inflection from the second half of April, with earnings potentially serving as an upside catalyst.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/nyse-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.02176,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AA",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DFS",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "-0.142125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LVS",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSX",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FHN",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "-0.142274",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "-0.18681",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine",
      "url": "https://www.zacks.com/stock/news/2292126/the-zacks-analyst-blog-highlights-abbott-laboratories-bp-gilead-sciences-smith-midland-and-crimson-wine",
      "time_published": "20240624T133600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ee/431.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.30321,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PRBZF",
          "relevance_score": "0.040348",
          "ticker_sentiment_score": "0.11887",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.120632",
          "ticker_sentiment_score": "0.046343",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.120632",
          "ticker_sentiment_score": "0.046343",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMID",
          "relevance_score": "0.120632",
          "ticker_sentiment_score": "0.046343",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSSMY",
          "relevance_score": "0.120632",
          "ticker_sentiment_score": "0.062462",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.",
      "url": "https://www.fool.com/investing/2025/02/01/want-1-million-in-retirement-2-stocks-to-buy-now-a/",
      "time_published": "20250201T110500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Many people set a goal to save $1 million for retirement. This amount may or may not be sufficient in today's economy, but it's at least a good start. And to get there, investing in stocks is an excellent strategy.",
      "banner_image": "https://g.foolcdn.com/editorial/images/805108/pharmacist-talking-to-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.358763,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.295155",
          "ticker_sentiment_score": "0.423669",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.350564",
          "ticker_sentiment_score": "0.309291",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.115699",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pre Q3 Earnings: Is Hologic  ( HOLX )  Stock a Portfolio Must-Have?",
      "url": "https://www.zacks.com/stock/news/2303276/pre-q3-earnings-is-hologic-holx-stock-a-portfolio-must-have",
      "time_published": "20240717T131000",
      "authors": [
        "Moumi Mondal"
      ],
      "summary": "Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/13457.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.429434,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HOLX",
          "relevance_score": "0.350564",
          "ticker_sentiment_score": "0.552948",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.283946",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.283946",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.04028",
          "ticker_sentiment_score": "0.016971",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bruker  ( BRKR )  Q2 Earnings Meet Mark, '24 Revenue Outlook Raised",
      "url": "https://www.zacks.com/stock/news/2317698/bruker-brkr-q2-earnings-meet-mark-24-revenue-outlook-raised",
      "time_published": "20240807T113200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.189476,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BRKR",
          "relevance_score": "0.519739",
          "ticker_sentiment_score": "0.435127",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.12023",
          "ticker_sentiment_score": "0.045146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.12023",
          "ticker_sentiment_score": "0.051942",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.073813",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:NANO",
          "relevance_score": "0.12023",
          "ticker_sentiment_score": "0.170459",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead",
      "url": "https://www.fool.com/investing/2024/09/26/forget-novo-nordisk-buy-this-magnificent-dividend/",
      "time_published": "20240926T123000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Even the mighty Novo Nordisk can't hold a candle to its peer in this area.",
      "banner_image": "https://media.ycharts.com/charts/274fc80dee3744f630d06f23387c1cae.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.318167,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.550151",
          "ticker_sentiment_score": "0.412957",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.12013",
          "ticker_sentiment_score": "0.159675",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MPW",
          "relevance_score": "0.060236",
          "ticker_sentiment_score": "-0.014039",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.294446",
          "ticker_sentiment_score": "0.406178",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WBA",
          "relevance_score": "0.060236",
          "ticker_sentiment_score": "-0.014039",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Align Technology  ( ALGN )  Beats on Q2 Earnings, Lowers '24 Sales View",
      "url": "https://www.zacks.com/stock/news/2309130/align-technology-algn-beats-on-q2-earnings-lowers-24-sales-view",
      "time_published": "20240725T132300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.714479"
        }
      ],
      "overall_sentiment_score": 0.112745,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.119631",
          "ticker_sentiment_score": "0.045052",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.45283",
          "ticker_sentiment_score": "0.278004",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.159043",
          "ticker_sentiment_score": "0.072176",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.198059",
          "ticker_sentiment_score": "0.073536",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Got $500? 2 Healthcare Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2025/06/28/got-500-2-healthcare-stocks-to-buy-and-hold-foreve/",
      "time_published": "20250628T094900",
      "authors": [
        "Keith Speights"
      ],
      "summary": "I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence ( AI ) will replace millions of jobs. But there's one thing I'm quite confident about: We'll still need healthcare products and services ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822817%2Fyoung-woman-smiling-hands-behind-head.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.238245,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.401331",
          "ticker_sentiment_score": "0.173218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.128994",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ResMed Gains 37.8% in a Year: What's Driving the Stock?",
      "url": "https://www.zacks.com/stock/news/2391478/resmed-gains-378-in-a-year-whats-driving-the-stock",
      "time_published": "20250103T132100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/10/83654.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.382459,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.344872",
          "ticker_sentiment_score": "0.475752",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CURN",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "-0.129112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.176717",
          "ticker_sentiment_score": "0.158183",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.176717",
          "ticker_sentiment_score": "0.117135",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco S&P 500 Equal Weight Health Care ETF  ( RSPH )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2441629/is-invesco-sp-500-equal-weight-health-care-etf-rsph-a-strong-etf-right-now",
      "time_published": "20250408T102008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default346.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999336"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.351289,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.06168",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.06168",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.06168",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.300573",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.",
      "url": "https://www.fool.com/investing/2025/01/21/want-decades-of-passive-income-2-stocks-to-buy-now/",
      "time_published": "20250121T110000",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit or lose. But, fortunately, a particular type of stock could make you a winner year after year, ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F804546%2Fgettyimages-1197547531.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        }
      ],
      "overall_sentiment_score": 0.362192,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.148746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.078586",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
      "url": "https://www.fool.com/investing/2024/12/28/2-no-brainer-healthcare-stocks-to-buy-with-1000-ri/",
      "time_published": "20241228T091500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets. In any case, it should have a solid track record of earnings growth and promising long-term prospects.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801546%2Fgettyimages-happy-people-gather-around-a-computer.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999696"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.346621,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ISRG",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.157668",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.13753",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know",
      "url": "https://www.zacks.com/stock/news/2462422/medtechs-adjust-2025-outlook-amid-tariffs-what-investors-need-to-know",
      "time_published": "20250505T190000",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/be/82544.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.188806,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.010247",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.009106",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.039289",
          "ticker_sentiment_score": "0.358649",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.194554",
          "ticker_sentiment_score": "0.180797",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.194554",
          "ticker_sentiment_score": "0.014183",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? - Alcoa  ( NYSE:AA ) ",
      "url": "https://www.benzinga.com/markets/cryptocurrency/24/07/39845998/vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-los",
      "time_published": "20240718T180528",
      "authors": [
        "Piero Cingari"
      ],
      "summary": "It's another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index ( VIX ) , often referred to as the market's fear gauge, spiked over 10%, reaching levels last seen in late April.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Bull-and-bear-stock-market-index.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": -0.061521,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AA",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALK",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "-0.079457",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.175433",
          "ticker_sentiment_score": "-0.06853",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.018315",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.059696",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DPZ",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLG",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "-0.241445",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "DMPZF",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.175433",
          "ticker_sentiment_score": "-0.06853",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTAS",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VIRT",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.040451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "-0.446115",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2465805/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
      "time_published": "20250509T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default246.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999999"
        }
      ],
      "overall_sentiment_score": 0.258672,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.116631",
          "ticker_sentiment_score": "0.060259",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.116631",
          "ticker_sentiment_score": "0.060259",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.174167",
          "ticker_sentiment_score": "0.258301",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.116631",
          "ticker_sentiment_score": "0.060259",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic",
      "url": "https://www.zacks.com/stock/news/2456506/the-zacks-analyst-blog-highlights-abbott-laboratories-boston-scientific-and-medtronic",
      "time_published": "20250428T112600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Abbott Laboratories, Boston Scientific and Medtronic are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        }
      ],
      "overall_sentiment_score": 0.299198,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.154703",
          "ticker_sentiment_score": "0.151402",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.154703",
          "ticker_sentiment_score": "0.151402",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "0.02973",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2024/11/08/want-decades-of-passive-income-2-stocks-to-buy-now/",
      "time_published": "20241108T091500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "You'll also like these stocks for their track record of earnings growth.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F796743%2Fgettyimages-smiling-investor.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.391827,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "0.187391",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "0.282322",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ICUI Stock Declines Despite Plans for Offsetting Tariff Impacts",
      "url": "https://www.zacks.com/stock/news/2442375/icui-stock-declines-despite-plans-for-offsetting-tariff-impacts",
      "time_published": "20250409T103300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ICU Medical unveils a strategic plan to offset new U.S. tariffs, aiming to protect margins and stability amid medtech market volatility and global trade shifts.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/95849.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.074945,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.116161",
          "ticker_sentiment_score": "0.047869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.116161",
          "ticker_sentiment_score": "0.089134",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.116161",
          "ticker_sentiment_score": "0.047869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ICUI",
          "relevance_score": "0.303175",
          "ticker_sentiment_score": "0.152249",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.038843",
          "ticker_sentiment_score": "0.041234",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2425687/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
      "time_published": "20250305T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default160.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999997"
        }
      ],
      "overall_sentiment_score": 0.293553,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.060144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.060144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.060144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.298625",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Integer Holdings Gains 34.4% in One Year: What's Driving the Stock?",
      "url": "https://www.zacks.com/stock/news/2387680/integer-holdings-gains-344-in-one-year-whats-driving-the-stock",
      "time_published": "20241224T172600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        }
      ],
      "overall_sentiment_score": 0.350593,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.056936",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ULBI",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "-0.026014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITGR",
          "relevance_score": "0.618922",
          "ticker_sentiment_score": "0.548739",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "-0.023164",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2462655/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now",
      "time_published": "20250506T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default238.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.287538,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LMT",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.05004",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.05004",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.05004",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2424111/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now",
      "time_published": "20250303T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.321376,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.115509",
          "ticker_sentiment_score": "0.04665",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.115509",
          "ticker_sentiment_score": "0.04665",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2361385/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
      "time_published": "20241031T102007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default41.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999997"
        }
      ],
      "overall_sentiment_score": 0.28471,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.06109",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.06109",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.268594",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.06109",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "QIAGEN  ( QGEN )  Q2 Earnings Surpass Estimates, Margins Crash",
      "url": "https://www.zacks.com/stock/news/2313918/qiagen-qgen-q2-earnings-surpass-estimates-margins-crash",
      "time_published": "20240801T124000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/69315.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.102873,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "QGEN",
          "relevance_score": "0.370969",
          "ticker_sentiment_score": "0.237238",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.043268",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.049947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.065552",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity",
      "url": "https://www.investors.com/research/ibd-stock-of-the-day/dexcom-stock-buy-zone-diabetes-obesity-continuous-glucose-monitors/",
      "time_published": "20240313T160442",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-13-24DXCM.png",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        }
      ],
      "overall_sentiment_score": 0.138038,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.053149",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.10132",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.10132",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "-0.23901",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.531326",
          "ticker_sentiment_score": "0.152339",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.053149",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Reasons to Buy DexCom Stock Like There's No Tomorrow",
      "url": "https://www.fool.com/investing/2024/12/02/3-reasons-to-buy-dexcom-stock-like-no-tomorrow/",
      "time_published": "20241202T141200",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Medical device specialist DexCom ( NASDAQ: DXCM ) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it has encountered are, no doubt, concerning.",
      "banner_image": "https://media.ycharts.com/charts/7f8ec8a1e485b38a87a4fe77ecb4f29e.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.253942,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.719473",
          "ticker_sentiment_score": "0.40289",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.076562",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2380644/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
      "time_published": "20241209T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default270.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        }
      ],
      "overall_sentiment_score": 0.331182,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.060868",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.060868",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.22595",
          "ticker_sentiment_score": "0.276708",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.060868",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hologic  ( HOLX )  Q3 Earnings Surpass Estimates, Margins Rise",
      "url": "https://www.zacks.com/stock/news/2311578/hologic-holx-q3-earnings-surpass-estimates-margins-rise",
      "time_published": "20240730T120800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/91/69871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.110044,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HOLX",
          "relevance_score": "0.295867",
          "ticker_sentiment_score": "0.243183",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.11324",
          "ticker_sentiment_score": "0.042984",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.11324",
          "ticker_sentiment_score": "0.049619",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.187608",
          "ticker_sentiment_score": "0.069124",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand",
      "url": "https://www.zacks.com/stock/news/2397709/nevro-stock-falls-despite-q4-sales-beat-on-strong-scs-demand",
      "time_published": "20250115T172300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.201618,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.168884",
          "ticker_sentiment_score": "0.07236",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.168884",
          "ticker_sentiment_score": "0.112149",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVRO",
          "relevance_score": "0.522854",
          "ticker_sentiment_score": "0.320087",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNXYF",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "0.175976",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA",
      "url": "https://www.zacks.com/stock/news/2387681/glaukos-stock-down-despite-nda-submission-of-epioxa-to-the-fda",
      "time_published": "20241224T173800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GKOS announces New Drug Application submission for its Epioxa to the FDA.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/25271.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.319861,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GKOS",
          "relevance_score": "0.477704",
          "ticker_sentiment_score": "0.359534",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.168884",
          "ticker_sentiment_score": "0.114895",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.168884",
          "ticker_sentiment_score": "-0.022732",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2024/09/25/2-unstoppable-dividend-stocks-to-buy-if-a-selloff/",
      "time_published": "20240925T103500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "These dividend players could lift your portfolio no matter what the market is doing.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791677%2Fgettyimages-an-investor-reads-something-on-his-phone.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.359918,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "0.372902",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Top Dividend Stocks That Could Set You Up for Life",
      "url": "https://www.fool.com/investing/2025/04/09/2-top-dividend-stocks-that-could-set-you-up-for/",
      "time_published": "20250409T110000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.For one, dividend-paying companies tend to be more resilient than their non-dividend-paying peers.",
      "banner_image": "https://media.ycharts.com/charts/d41e49999bc35bce83ff5adf491d2753.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        }
      ],
      "overall_sentiment_score": 0.217191,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.428632",
          "ticker_sentiment_score": "0.260848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.027786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.3796",
          "ticker_sentiment_score": "0.25684",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers  ( HIMS )  Gains 37.7% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2297363/hims-hers-hims-gains-377-in-three-months-whats-next",
      "time_published": "20240705T160400",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.393462,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.325924",
          "ticker_sentiment_score": "0.311663",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "0.099374",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "0.099374",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PACB Stock Declines Despite Promising HiFi Sequencing Findings",
      "url": "https://www.zacks.com/stock/news/2397707/pacb-stock-declines-despite-promising-hifi-sequencing-findings",
      "time_published": "20250115T172000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.235923,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.165788",
          "ticker_sentiment_score": "0.110763",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PACB",
          "relevance_score": "0.219809",
          "ticker_sentiment_score": "-0.026968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.165788",
          "ticker_sentiment_score": "-0.022458",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HealthEquity Gains 46.8% in a Year: What's Driving the Stock?",
      "url": "https://www.zacks.com/stock/news/2388864/healthequity-gains-468-in-a-year-whats-driving-the-stock",
      "time_published": "20241227T145800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "HQY's sustained strength in HSAs raises optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.995921"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.390533,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HQY",
          "relevance_score": "0.421485",
          "ticker_sentiment_score": "0.61197",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.165031",
          "ticker_sentiment_score": "0.110427",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.110462",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.165031",
          "ticker_sentiment_score": "-0.022388",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers  ( HIMS )  Gains 45.8% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2316328/hims-hers-hims-gains-458-in-three-months-whats-next",
      "time_published": "20240805T163000",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/961.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.416961,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.321673",
          "ticker_sentiment_score": "0.361677",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.146481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.146481",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Beaten-Down Dexcom Stock a Buy on the Dip?",
      "url": "https://www.fool.com/investing/2024/07/29/is-beaten-down-dexcom-stock-a-buy-on-the-dip/",
      "time_published": "20240729T095400",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "The market may have overreacted to a disappointing earnings report.",
      "banner_image": "https://g.foolcdn.com/editorial/images/784935/investor-thinking-about-stock-charts-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.990893"
        }
      ],
      "overall_sentiment_score": 0.031669,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "COST",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.142001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.552966",
          "ticker_sentiment_score": "-0.048077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "-0.036252",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?",
      "url": "https://www.zacks.com/stock/news/2401026/tandem-diabetes-gains-457-in-a-year-whats-driving-the-stock",
      "time_published": "20250122T122500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.994953"
        }
      ],
      "overall_sentiment_score": 0.359676,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.163539",
          "ticker_sentiment_score": "0.107077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.163539",
          "ticker_sentiment_score": "0.152798",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.109455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.21686",
          "ticker_sentiment_score": "0.31471",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.294993",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "FeganScott Launches Investigation into Abbott Laboratories Employees Credit Union Data Breach",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41530304/feganscott-launches-investigation-into-abbott-laboratories-employees-credit-union-data-breach",
      "time_published": "20241024T201542",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "CHICAGO, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- Attorneys at the law firm FeganScott have launched an investigation into the Abbott Laboratories Employees Credit Union ( ALEC ) data breach, which, according to company reports, occurred during an August cyberattack against the Illinois-based credit ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.130969,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.109455",
          "ticker_sentiment_score": "0.128512",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.109455",
          "ticker_sentiment_score": "0.082027",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Edwards Lifesciences  ( EW )  Q2 Earnings Meet Mark, Margins Crash",
      "url": "https://www.zacks.com/stock/news/2308693/edwards-lifesciences-ew-q2-earnings-meet-mark-margins-crash",
      "time_published": "20240725T130200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.208082,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EW",
          "relevance_score": "0.285942",
          "ticker_sentiment_score": "0.224531",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.109289",
          "ticker_sentiment_score": "0.043536",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.109289",
          "ticker_sentiment_score": "0.050087",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.109289",
          "ticker_sentiment_score": "0.065393",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.",
      "url": "https://www.fool.com/investing/2024/06/20/want-decades-of-passive-income-2-stocks-to-buy-now/",
      "time_published": "20240620T091500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "These healthcare players offer you dividends and a strong earnings picture.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780947%2Fgettyimages-1188369583.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99793"
        }
      ],
      "overall_sentiment_score": 0.380048,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.109206",
          "ticker_sentiment_score": "0.073797",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.109206",
          "ticker_sentiment_score": "0.164285",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is Abbott Stock Worth Buying at a Discounted P/S Valuation?",
      "url": "https://www.zacks.com/stock/news/2388392/is-abbott-stock-worth-buying-at-a-discounted-ps-valuation",
      "time_published": "20241226T160000",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "Abbott's strong market position, promising growth prospects and consistent share gains make it a compelling pick for investors.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.298173,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.072765",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.072765",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.120185",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics",
      "url": "https://www.zacks.com/stock/news/2394884/pacb-stock-rises-after-the-shipment-of-vega-systems-to-berry-genomics",
      "time_published": "20250110T131400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.325873,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.162437",
          "ticker_sentiment_score": "0.111958",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.108712",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PACB",
          "relevance_score": "0.215415",
          "ticker_sentiment_score": "0.174974",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.162437",
          "ticker_sentiment_score": "-0.022136",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction",
      "url": "https://www.zacks.com/stock/news/2455012/the-zacks-analyst-blog-highlights-coca-cola-abbott-laboratories-rtx-investors-title-and-armanino-foods-of-distinction",
      "time_published": "20250424T132200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a5/1022.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.336225,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.064133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.214937",
          "ticker_sentiment_score": "0.091424",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITIC",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.08765",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RTX",
          "relevance_score": "0.214937",
          "ticker_sentiment_score": "0.110827",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "BAX Stock Declines Despite Latest Product Launch Boosting Patient Care",
      "url": "https://www.zacks.com/stock/news/2448457/bax-stock-declines-despite-latest-product-launch-boosting-patient-care",
      "time_published": "20250414T134800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.296466,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BAX",
          "relevance_score": "0.504646",
          "ticker_sentiment_score": "0.439077",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.214937",
          "ticker_sentiment_score": "0.088802",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LMAT",
          "relevance_score": "0.162073",
          "ticker_sentiment_score": "0.036764",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "EssilorLuxottica to Acquire Pulse Audition: Will the Stock Rise?",
      "url": "https://www.zacks.com/stock/news/2392079/essilorluxottica-to-acquire-pulse-audition-will-the-stock-rise",
      "time_published": "20250106T122300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ESLOY is set to acquire Pulse Audition, an AI-driven tech startup, to strengthen its position in the hearing solution space.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.318995,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.162073",
          "ticker_sentiment_score": "0.109121",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.162073",
          "ticker_sentiment_score": "0.090415",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ESLOF",
          "relevance_score": "0.317527",
          "ticker_sentiment_score": "0.281244",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "TMDX Stock Down Despite Responding to Misleading Short-Seller Report",
      "url": "https://www.zacks.com/stock/news/2400006/tmdx-stock-down-despite-responding-to-misleading-short-seller-report",
      "time_published": "20250120T160000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.037115,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "0.108647",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMDX",
          "relevance_score": "0.750367",
          "ticker_sentiment_score": "-0.024324",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.107736",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "-0.022017",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Elon Musk's X Bolsters Antitrust Lawsuit With Additional Advertisers",
      "url": "https://www.benzinga.com/tech/25/02/43420490/elon-musks-x-bolsters-antitrust-lawsuit-with-additional-advertisers",
      "time_published": "20250201T192023",
      "authors": [
        "Bibhu Pattnaik"
      ],
      "summary": "X intensifies legal battle, targeting global brands in expanded antitrust lawsuit over advertising boycott. High stakes for digital ad industry as X's case challenges major advertisers' collective bargaining power.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/01/Elon-Musks-X-Reveals-Its-Investors-Inclu.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.089888,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.069383",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.091919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PINS",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.091919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.091919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSN",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.091919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DEO",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.101534",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks That Could Pay You for Life",
      "url": "https://www.fool.com/investing/2024/06/16/2-dividend-stocks-that-could-pay-you-for-life/",
      "time_published": "20240616T123000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "There are other reasons to love these businesses, too.",
      "banner_image": "https://media.ycharts.com/charts/3bd652ae2c5fb62c2ed8b70314e36548.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.270085,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "V",
          "relevance_score": "0.411176",
          "ticker_sentiment_score": "0.365463",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.500753",
          "ticker_sentiment_score": "0.307669",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "0.135056",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
      "url": "https://www.benzinga.com/25/01/43122112/us-stocks-likely-to-open-higher-as-president-trump-announces-500-billion-ai-project-oracle-netflix-nvidia-among-s",
      "time_published": "20250122T110259",
      "authors": [
        "Rounak Jain"
      ],
      "summary": "U.S. stocks could open on a positive note on Wednesday, continuing to rally after Donald Trump's inauguration as the 47th President of the U.S. on Monday. Futures point to a second consecutive day of positive start to the Trump presidency.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/22/Wall-Street.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.992549"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.245072,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.261955",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.257561",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.170835",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VST",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.205938",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFTBF",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.225703",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ORCL",
          "relevance_score": "0.362254",
          "ticker_sentiment_score": "0.470894",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARM",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "0.170835",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.053629",
          "ticker_sentiment_score": "0.219829",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WT",
          "relevance_score": "0.053629",
          "ticker_sentiment_score": "0.267905",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Cardiovascular Implants Market Poised For Strong Growth, Reaching $34.5 Billion In 2028: Latest Report Unveils Insights As Per The Business Research Company's Cardiovascular Implants Global Market Report 2024",
      "url": "https://www.benzinga.com/pressreleases/24/03/g37826136/cardiovascular-implants-market-poised-for-strong-growth-reaching-34-5-billion-in-2028-latest-repor",
      "time_published": "20240319T154000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The global cardiovascular implants market is experiencing robust growth, as highlighted in the newest report \"Cardiovascular Implants Market Global Report 2024\", by The Business Research Company.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.353544,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.053509",
          "ticker_sentiment_score": "0.348987",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.053509",
          "ticker_sentiment_score": "0.348987",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.106778",
          "ticker_sentiment_score": "0.321013",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's Why You Should Hold on to Abbott  ( ABT )  Stock for Now",
      "url": "https://www.zacks.com/stock/news/2276548/heres-why-you-should-hold-on-to-abbott-abt-stock-for-now",
      "time_published": "20240521T132900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's (ABT) share recovery in the Nutrition business buoys optimism.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997845"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.258615,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.141935",
          "ticker_sentiment_score": "0.083425",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.106699",
          "ticker_sentiment_score": "0.295713",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.141935",
          "ticker_sentiment_score": "0.079153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HITI",
          "relevance_score": "0.106699",
          "ticker_sentiment_score": "0.059447",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "0.014626",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Omnicell Gains 26.2% in a Year: What's Driving the Stock?",
      "url": "https://www.zacks.com/stock/news/2392090/omnicell-gains-262-in-a-year-whats-driving-the-stock",
      "time_published": "20250106T123900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "OMCL's shares rise on the back of its XT Amplify program gaining market traction with its initial offerings. However, the unfavorable macroeconomic scenario is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.343415,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.158868",
          "ticker_sentiment_score": "0.109043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.158868",
          "ticker_sentiment_score": "0.147334",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMCL",
          "relevance_score": "0.261678",
          "ticker_sentiment_score": "0.314352",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.106305",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA approves two new Abbott over-the-counter continuous glucose monitors",
      "url": "https://www.cnbc.com/2024/06/10/abbott-fda-approval-libre-rio-lingo-cgm-diabetes.html",
      "time_published": "20240610T133103",
      "authors": [
        "Ashley Capoot"
      ],
      "summary": "Abbott has FDA clearance for two new over-the-counter continuous glucose monitoring systems ...",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/106998194-1641558949731-gettyimages-1363222030-em018417_20220106104408207.jpeg?v=1718021922&w=1920&h=1080",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.221106,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.167062",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.137587",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq, S&P 500 Futures Edge Up After Tuesday's Chip Sell-off - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41353878/us-stocks-could-open-narrowly-mixed-after-tuesdays-chip-sell-off-bitcoin-heads-to-68k-oil-slips",
      "time_published": "20241016T112917",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/NYSE.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.021984,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AA",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DFS",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.181143",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.311366",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVCR",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "-0.192479",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "QCOM",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "-0.197541",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "INTC",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "-0.197541",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.181143",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.053035",
          "ticker_sentiment_score": "0.145661",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STLD",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.105836",
          "ticker_sentiment_score": "-0.110592",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock",
      "url": "https://www.zacks.com/stock/news/2399618/completion-of-whole-blood-assets-sale-to-gvs-likely-to-boost-hae-stock",
      "time_published": "20250120T130100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Haemonetics completes the sale of whole blood assets to GVS, S.p.A.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.291934,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "0.059945",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PAHC",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "0.059945",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.105372",
          "ticker_sentiment_score": "0.049493",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.610722",
          "ticker_sentiment_score": "0.499099",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Tempus AI Stock Falls Despite Collaboration Announcement With Genialis",
      "url": "https://www.zacks.com/stock/news/2394252/tempus-ai-stock-falls-despite-collaboration-announcement-with-genialis",
      "time_published": "20250109T133600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.267153,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "0.109751",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.105372",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEM",
          "relevance_score": "0.208914",
          "ticker_sentiment_score": "0.06618",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "-0.021687",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Heart pumps tied to 14 deaths, hundreds of injuries are being recalled",
      "url": "https://www.foxbusiness.com/lifestyle/heart-pumps-tied-14-deaths-injuries-being-recalled",
      "time_published": "20240417T152600",
      "authors": [
        "Daniella Genovese"
      ],
      "summary": "Nearly 14,000 heart pumps tied to hundreds of injuries and more than a dozen deaths are being recalled, according to federal health officials.",
      "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/52fd3ea9-8f05-451e-a69d-df2025d33919/ea2d2479-5dfb-4404-90af-4e1adf516753/1280x720/match/image.jpg",
      "source": "Fox Business News",
      "category_within_source": "n/a",
      "source_domain": "www.foxbusiness.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.049121,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.105141",
          "ticker_sentiment_score": "-0.201491",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Alcon Stock Gains Following UNITY VCS' Approval in Canada",
      "url": "https://www.zacks.com/stock/news/2568746/alcon-stock-gains-following-unity-vcs-approval-in-canada",
      "time_published": "20250709T122900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/25271.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.363295,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALC",
          "relevance_score": "0.531716",
          "ticker_sentiment_score": "0.557114",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "0.065702",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.1568",
          "ticker_sentiment_score": "0.022593",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:NXT",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.11911",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy - Abbott Laboratories  ( NYSE:ABT ) , Amazon.com  ( NASDAQ:AMZN ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/06/46144750/44-public-companies-make-times-most-influential-list-coinbase-ufc-nintendo-netflix-and-m",
      "time_published": "20250627T153958",
      "authors": [
        "Chris Katje"
      ],
      "summary": "Time Magazine put out its annual list of the most influential companies. A look at the publicly traded companies on the list. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving July volatility. See how Chris Capre is trading it-live Wednesday, July 2 at 6 PM ET.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/27/Time-magazine.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.229832,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LTH",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.447276",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FI",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BYDDF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ESLOF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLD",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.053737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DASH",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DUOL",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.053737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EQNR",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.053737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COUR",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.053737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFTBF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BABA",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ENGQF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.049718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.094611",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTDOF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DKS",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MELI",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HYMLF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.049718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GAP",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCZ",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.053737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARM",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LRLCF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.094611",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NET",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.053737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.10238",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Alibaba, Linde, Abbott Laboratories and Value Line",
      "url": "https://www.zacks.com/stock/news/2351703/the-zacks-analyst-blog-highlights-alibaba-linde-abbott-laboratories-and-value-line",
      "time_published": "20241016T150800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Alibaba, Linde, Abbott Laboratories and Value Line are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.347358,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BABA",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIN",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "0.205822",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALU",
          "relevance_score": "0.1568",
          "ticker_sentiment_score": "0.134333",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teleflex  ( TFX )  Tops Q2 Earnings Estimates, Raises 2024 Outlook",
      "url": "https://www.zacks.com/stock/news/2314994/teleflex-tfx-tops-q2-earnings-estimates-raises-2024-outlook",
      "time_published": "20240802T121400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/58862.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.1626,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.104835",
          "ticker_sentiment_score": "0.042952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.104835",
          "ticker_sentiment_score": "0.049414",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.104835",
          "ticker_sentiment_score": "0.064511",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TFX",
          "relevance_score": "0.339511",
          "ticker_sentiment_score": "0.208513",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now",
      "url": "https://www.fool.com/investing/2024/10/18/3-no-brainer-pharmaceutical-stocks-to-buy-with-500/",
      "time_published": "20241018T091000",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "These stocks could deliver big over the long term.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794412%2Fgettyimages-scientists-in-lab01.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998311"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.372282,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.184634",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104683",
          "ticker_sentiment_score": "0.078",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.110364",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.104683",
          "ticker_sentiment_score": "0.200124",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is DexCom a Millionaire-Maker Stock?",
      "url": "https://www.fool.com/investing/2024/09/02/is-dexcom-a-millionaire-maker-stock/",
      "time_published": "20240902T111200",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "The stock has delivered superior returns in the past 19 years.",
      "banner_image": "https://g.foolcdn.com/editorial/images/788047/dexcom-g6-full-family.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        }
      ],
      "overall_sentiment_score": 0.273415,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.035922",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.141586",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104683",
          "ticker_sentiment_score": "0.121976",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.141586",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.642977",
          "ticker_sentiment_score": "0.493744",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Top Stock Reports for NVIDIA, Abbott Laboratories & Linde",
      "url": "https://www.zacks.com/research-daily/2464857/top-stock-reports-for-nvidia-abbott-laboratories-linde",
      "time_published": "20250508T201700",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Abbott Laboratories (ABT) and Linde plc (LIN), as well as a micro-cap stock Tredegar Corp. (TG).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.259518,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLFD",
          "relevance_score": "0.05234",
          "ticker_sentiment_score": "0.161",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LIN",
          "relevance_score": "0.05234",
          "ticker_sentiment_score": "0.166145",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104455",
          "ticker_sentiment_score": "0.339505",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRBO",
          "relevance_score": "0.05234",
          "ticker_sentiment_score": "0.218679",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TG",
          "relevance_score": "0.05234",
          "ticker_sentiment_score": "0.053019",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Got the Market Sell-Off Blues? Do These 3 Things Right Now",
      "url": "https://www.fool.com/investing/2024/08/11/got-the-market-sell-off-blues-do-these-3-things-ri/",
      "time_published": "20240811T112800",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "You aren't powerless in the face of what the market throws at you.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786309%2Finvestor-expresses-regret.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.089522,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.156123",
          "ticker_sentiment_score": "0.01216",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104455",
          "ticker_sentiment_score": "0.124987",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain Integer Holdings Stock in Your Portfolio",
      "url": "https://www.zacks.com/stock/news/2389501/heres-why-you-should-retain-integer-holdings-stock-in-your-portfolio",
      "time_published": "20241230T144600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        }
      ],
      "overall_sentiment_score": 0.297813,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.155786",
          "ticker_sentiment_score": "0.106398",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ULBI",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.186193",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITGR",
          "relevance_score": "0.568148",
          "ticker_sentiment_score": "0.468185",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.155786",
          "ticker_sentiment_score": "-0.021548",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Down More Than 50%, Is DexCom Stock a Bargain Now?",
      "url": "https://www.fool.com/investing/2024/10/02/down-more-than-50-is-dexcom-stock-a-bargain-now/",
      "time_published": "20241002T081100",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market.",
      "banner_image": "https://g.foolcdn.com/editorial/images/792566/investor-calculator-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.162949,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.162878",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.605524",
          "ticker_sentiment_score": "0.209756",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.03257",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace",
      "url": "https://www.zacks.com/stock/news/2327368/the-zacks-analyst-blog-eli-lilly-chevron-abbott-and-bridger-aerospace",
      "time_published": "20240827T063000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/73/488.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.292416,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.305058",
          "ticker_sentiment_score": "0.131484",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAER",
          "relevance_score": "0.206245",
          "ticker_sentiment_score": "-0.028124",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.104002",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.206245",
          "ticker_sentiment_score": "0.200844",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HES",
          "relevance_score": "0.052112",
          "ticker_sentiment_score": "0.273767",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "OSUR Stock Rises Following the Acquisition of Sherlock Biosciences",
      "url": "https://www.zacks.com/stock/news/2388394/osur-stock-rises-following-the-acquisition-of-sherlock-biosciences",
      "time_published": "20241226T160700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.314096,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.155118",
          "ticker_sentiment_score": "0.106113",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.103778",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OSUR",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.286061",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.155118",
          "ticker_sentiment_score": "-0.021488",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped",
      "url": "https://www.zacks.com/stock/news/2397157/pacb-stock-falls-on-preliminary-q4-sales-miss-7-vega-systems-shipped",
      "time_published": "20250115T135700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.270305,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.154785",
          "ticker_sentiment_score": "0.105972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.103554",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PACB",
          "relevance_score": "0.255106",
          "ticker_sentiment_score": "0.161492",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.154785",
          "ticker_sentiment_score": "-0.021458",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March",
      "url": "https://www.fool.com/investing/2024/03/11/dividend-kings-healthcare-stocks-to-buy-in-march/",
      "time_published": "20240311T093500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "These are some of the best-performing stocks in what's arguably society's most important industry.",
      "banner_image": "https://g.foolcdn.com/editorial/images/767296/jnj.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.319223,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.051886",
          "ticker_sentiment_score": "0.015964",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.103554",
          "ticker_sentiment_score": "0.184254",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.20537",
          "ticker_sentiment_score": "0.211033",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.255106",
          "ticker_sentiment_score": "0.149871",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day",
      "url": "https://www.zacks.com/stock/news/2442926/astronics-and-boston-beer-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
      "time_published": "20250410T063700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Chicago, IL - April 10, 2025 - Zacks Equity Research shares Astronics ( ATRO Quick QuoteATRO - ) as the Bull of the Day and The Boston Beer Company ( SAM Quick QuoteSAM - ) as the Bear of the Day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/137.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999594"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.127147,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMRN",
          "relevance_score": "0.164609",
          "ticker_sentiment_score": "0.177106",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UHS",
          "relevance_score": "0.184834",
          "ticker_sentiment_score": "0.218242",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.071934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.020722",
          "ticker_sentiment_score": "-0.089159",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATRO",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.083496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAM",
          "relevance_score": "0.123844",
          "ticker_sentiment_score": "-0.104969",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock",
      "url": "https://www.zacks.com/stock/news/2359250/abts-new-trial-on-advanced-heart-failure-outcomes-set-to-boost-stock",
      "time_published": "20241029T120700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.994953"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.193481,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.054563",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.055519",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMED",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.054563",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "0.095459",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "BDSX Stock Rises After Publication of Study Data for Nodify CDT Test",
      "url": "https://www.zacks.com/stock/news/2393464/bdsx-stock-rises-after-publication-of-study-data-for-nodify-cdt-test",
      "time_published": "20250108T123000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2371.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.2117,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BDSX",
          "relevance_score": "0.252987",
          "ticker_sentiment_score": "0.329971",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.105415",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.102668",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "-0.021342",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 No-Brainer Healthcare Stocks to Buy With $200 Right Now",
      "url": "https://www.fool.com/investing/2025/02/10/3-no-brainer-healthcare-stocks-to-buy-with-200/",
      "time_published": "20250210T092000",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road. If you're more of a cautious investor, you can aim for a well-established and diversified player that pays dividends ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F806867%2Fgettyimages-scientists-in-lab01.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998311"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.255455,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VKTX",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.07791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.153193",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.051111",
          "ticker_sentiment_score": "0.10969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.346365",
          "ticker_sentiment_score": "0.119074",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Medtronic's  ( MDT )  Sphere-360 PFA Study Outcome Favorable",
      "url": "https://www.zacks.com/stock/news/2253903/medtronics-mdt-sphere-360-pfa-study-outcome-favorable",
      "time_published": "20240411T133100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.231256,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.127329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.127329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "0.198608",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "0.039459",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device",
      "url": "https://www.zacks.com/stock/news/2387027/merit-medical-stock-rises-following-fda-nod-for-wrapsody-device",
      "time_published": "20241223T163000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.322268,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "0.104603",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMSI",
          "relevance_score": "0.249873",
          "ticker_sentiment_score": "0.259752",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.101367",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "-0.021172",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Neogen Q1 Earnings Miss Estimates, Margins Crash",
      "url": "https://www.zacks.com/stock/news/2350702/neogen-q1-earnings-miss-estimates-margins-crash",
      "time_published": "20241015T125500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.002405,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.101367",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEOG",
          "relevance_score": "0.389636",
          "ticker_sentiment_score": "0.030024",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AHCO",
          "relevance_score": "0.151539",
          "ticker_sentiment_score": "-0.001287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADUS",
          "relevance_score": "0.201105",
          "ticker_sentiment_score": "0.121042",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardinal Health Stock May Gain With New Texas Distribution Center",
      "url": "https://www.zacks.com/stock/news/2398259/cardinal-health-stock-may-gain-with-new-texas-distribution-center",
      "time_published": "20250116T144600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/3163.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        }
      ],
      "overall_sentiment_score": 0.386057,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.149966",
          "ticker_sentiment_score": "0.106497",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.100308",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.47147",
          "ticker_sentiment_score": "0.577562",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.149966",
          "ticker_sentiment_score": "-0.021021",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio.",
      "url": "https://www.fool.com/investing/2025/04/05/trumps-tariffs-3-things-to-protect-portfolio/",
      "time_published": "20250405T074000",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "The idea of an import tax started weighing on investor sentiment in March, when President Trump laid out his initial plan to target Canada, Mexico, and China. Stocks tumbled, with the S&P 500 ( SNPINDEX: ^GSPC ) and Nasdaq Composite ( NASDAQINDEX: ^IXIC ) both temporarily slipping into correction ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F813729%2Fgettyimages-2203818627-1200x762-95f5f52.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.147721,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.093811",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.067638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.149346",
          "ticker_sentiment_score": "0.081156",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ETSY",
          "relevance_score": "0.339578",
          "ticker_sentiment_score": "0.112003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.067638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.293506",
          "ticker_sentiment_score": "0.112425",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.093811",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PacBio Stock May Gain Following the Collaborated Launch of GutID",
      "url": "https://www.zacks.com/stock/news/2396006/pacbio-stock-may-gain-following-the-collaborated-launch-of-gutid",
      "time_published": "20250113T161100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.309057,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.149346",
          "ticker_sentiment_score": "0.103692",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PACB",
          "relevance_score": "0.198221",
          "ticker_sentiment_score": "0.018791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.149346",
          "ticker_sentiment_score": "-0.02098",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABT Stock Benefits From First Patient Procedures With TAVI System",
      "url": "https://www.zacks.com/stock/news/2375880/abt-stock-benefits-from-first-patient-procedures-with-tavi-system",
      "time_published": "20241127T140100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures. This investigational TAVI system aims to offer best-in-class heart blood flow.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.28372,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.149038",
          "ticker_sentiment_score": "0.055418",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RMD",
          "relevance_score": "0.149038",
          "ticker_sentiment_score": "0.055418",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.099683",
          "ticker_sentiment_score": "0.071386",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.111857",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why Investors Should Retain Abbott  ( ABT )  Stock Now",
      "url": "https://www.zacks.com/stock/news/2243034/heres-why-investors-should-retain-abbott-abt-stock-now",
      "time_published": "20240319T174000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        }
      ],
      "overall_sentiment_score": 0.275075,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.099683",
          "ticker_sentiment_score": "0.186131",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.149038",
          "ticker_sentiment_score": "0.059211",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.149038",
          "ticker_sentiment_score": "0.092145",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.121069",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2025/06/26/want-decades-of-passive-income-5-stocks-to-buy-now/",
      "time_published": "20250626T124500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822512%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998356"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        }
      ],
      "overall_sentiment_score": 0.293386,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WST",
          "relevance_score": "0.099476",
          "ticker_sentiment_score": "0.063682",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.049835",
          "ticker_sentiment_score": "0.033629",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.099476",
          "ticker_sentiment_score": "0.03595",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.159284",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.237888",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.142542",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions",
      "url": "https://www.zacks.com/stock/news/2396783/aray-stock-gains-as-china-approves-latest-radiation-therapy-solutions",
      "time_published": "20250114T171300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.356097,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.148426",
          "ticker_sentiment_score": "0.117248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.148426",
          "ticker_sentiment_score": "0.103313",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.099271",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.29176",
          "ticker_sentiment_score": "0.394348",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?",
      "url": "https://www.zacks.com/stock/news/2430846/abbott-laboratories-gains-127-in-a-year-whats-driving-the-stock",
      "time_published": "20250317T141500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        }
      ],
      "overall_sentiment_score": 0.327069,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.147216",
          "ticker_sentiment_score": "0.048523",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PAHC",
          "relevance_score": "0.195419",
          "ticker_sentiment_score": "0.092871",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.098456",
          "ticker_sentiment_score": "0.229804",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.147216",
          "ticker_sentiment_score": "0.058866",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2386174/reasons-to-hold-west-pharmaceutical-stock-in-your-portfolio-now",
      "time_published": "20241220T130200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        }
      ],
      "overall_sentiment_score": 0.248356,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.049322",
          "ticker_sentiment_score": "-0.178616",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.147216",
          "ticker_sentiment_score": "0.106599",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WST",
          "relevance_score": "0.422268",
          "ticker_sentiment_score": "0.247263",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.098456",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.147216",
          "ticker_sentiment_score": "-0.019464",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub",
      "url": "https://www.zacks.com/stock/news/2401469/gehc-stock-gains-on-the-collaborated-launch-of-care-innovation-hub",
      "time_published": "20250122T162800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/74133.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.374333,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.462953",
          "ticker_sentiment_score": "0.58143",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "0.102695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "-0.02077",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2399636/reasons-to-hold-west-pharmaceutical-stock-in-your-portfolio-now",
      "time_published": "20250120T134200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        }
      ],
      "overall_sentiment_score": 0.2748,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.04882",
          "ticker_sentiment_score": "-0.178544",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.14573",
          "ticker_sentiment_score": "0.105973",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WST",
          "relevance_score": "0.41838",
          "ticker_sentiment_score": "0.245793",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.097457",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.14573",
          "ticker_sentiment_score": "-0.019346",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stock Futures Trade Mixed After Skirting Record Highs In Last Session: GE Aerospace, American Airlines, Union Pacific In Focus - Abbott Laboratories  ( NYSE:ABT ) , American Airlines Gr  ( NASDAQ:AAL ) ",
      "url": "https://www.benzinga.com/general/market-summary/25/01/43155772/us-stock-futures-trade-mixed-after-skirting-record-highs-in-last-session-ge-aerospace-amer",
      "time_published": "20250123T115935",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "U.S. stock futures were mixed on Thursday following Wednesday's rally. Futures of benchmark indices were lower except Dow Jones, which was marginally higher in premarket trade. After being propelled to the brink of a record closing high on Wednesday the S&P 500 index was poised to open lower ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/23/Wall-Street.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999816"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.121801,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.187858",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PLXS",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.105396",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VNCE",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.085286",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.187858",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KNX",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.23523",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNP",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.07683",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.187858",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AAL",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.078943",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "-0.023105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.094056",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq, S&P 500 Futures Rebound Thursday: What's Going On - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39835373/wall-street-gearing-up-for-tech-led-rebound-ahead-of-netflix-earnings-economist-expects-soft-landin",
      "time_published": "20240718T113456",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.'s TSM strong quarterly report lifting sentiment toward tech stocks. The major U.S. index futures were mixed ahead of the trading session.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/wall-street-artificial-ai.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.0,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AA",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "-0.014137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALK",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "-0.014137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.053672",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NOK",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.153904",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DPZ",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "-0.39969",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "SLG",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "-0.014137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.097983",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DMPZF",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "-0.375517",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "-0.073158",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's why Abbott India stock price surged 5% on August 8; details here",
      "url": "https://www.business-standard.com/markets/news/here-s-why-abbott-india-stock-price-surged-5-on-august-8-details-here-124080800556_1.html",
      "time_published": "20240808T070424",
      "authors": [
        "SI Reporter"
      ],
      "summary": "The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).",
      "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/misc/2023-03/21/full/market-stocks-stock-market-trading-stock-market-1679390560-47312620.jpg?im=FeatureCrop,size=(826,465)",
      "source": "Business Standard",
      "category_within_source": "Markets",
      "source_domain": "www.business-standard.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.169937,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.096283",
          "ticker_sentiment_score": "0.045114",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's  ( ABT )  i-STAT TBI Cartridge Receives FDA Approval",
      "url": "https://www.zacks.com/stock/news/2249322/abbotts-abt-i-stat-tbi-cartridge-receives-fda-approval",
      "time_published": "20240402T151800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.13359,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.096283",
          "ticker_sentiment_score": "-0.100976",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.14195",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.033337",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech",
      "url": "https://www.zacks.com/stock/news/2402962/bd-stock-rises-on-biosero-deal-for-ai-powered-robotic-cytometry-tech",
      "time_published": "20250124T144700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.417549,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.1437",
          "ticker_sentiment_score": "0.102641",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.1437",
          "ticker_sentiment_score": "0.138728",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.096091",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.282777",
          "ticker_sentiment_score": "0.381963",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?",
      "url": "https://www.zacks.com/stock/news/2570793/is-it-worth-adding-boston-scientific-stock-to-your-portfolio-now",
      "time_published": "20250710T121800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.996675"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.374558,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.095517",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.18967",
          "ticker_sentiment_score": "0.062814",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.410803",
          "ticker_sentiment_score": "0.527445",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AXNX",
          "relevance_score": "0.047844",
          "ticker_sentiment_score": "0.148755",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.142847",
          "ticker_sentiment_score": "0.02008",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "10 Best Dividend Growth Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/07/21/10-best-dividend-growth-stocks-to-buy-and-hold-for/",
      "time_published": "20240721T143000",
      "authors": [
        "George Budwell"
      ],
      "summary": "Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784033%2Fdividend-bank-roll.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.803643"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.414524,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TGT",
          "relevance_score": "0.142847",
          "ticker_sentiment_score": "0.313895",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.095517",
          "ticker_sentiment_score": "0.088064",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NDSN",
          "relevance_score": "0.142847",
          "ticker_sentiment_score": "0.248651",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "V",
          "relevance_score": "0.142847",
          "ticker_sentiment_score": "0.31512",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PH",
          "relevance_score": "0.095517",
          "ticker_sentiment_score": "0.288706",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NKE",
          "relevance_score": "0.095517",
          "ticker_sentiment_score": "0.264207",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.095517",
          "ticker_sentiment_score": "0.175948",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.142847",
          "ticker_sentiment_score": "0.103087",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.142847",
          "ticker_sentiment_score": "0.189064",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2025/06/11/unstoppable-dividend-stocks-buy-if-sell-off/",
      "time_published": "20250611T090000",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Steady growth and dividend increases over decades can make investors remarkably wealthy.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820816%2Fgetty-dividend-stocks-growing-money-income-cash-5.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.274974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.089123",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "0.230782",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.05508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZTS",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "0.079192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "0.083969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.234911",
          "ticker_sentiment_score": "0.243633",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "-0.034459",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Smartest Dividend Stocks to Buy With $500 Right Now",
      "url": "https://www.fool.com/investing/2024/12/18/the-smartest-dividend-stocks-to-buy-with-500/",
      "time_published": "20241218T101500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801154%2Fgettyimages-135538318.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.955357"
        }
      ],
      "overall_sentiment_score": 0.342913,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TRMNF",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "0.35124",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.108093",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.28008",
          "ticker_sentiment_score": "0.258465",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.140836",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?",
      "url": "https://www.zacks.com/stock/news/2414797/abt-stock-jumps-12-since-q4-earnings-time-to-invest-in-abbott",
      "time_published": "20250212T165400",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "Abbott projects organic sales growth between 7.5% and 8.5% for 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99237"
        }
      ],
      "overall_sentiment_score": 0.310069,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "0.133936",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "0.151034",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "0.151034",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "0.151034",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "TEM Stock Declines Following Preliminary Q4 Sales Miss",
      "url": "https://www.zacks.com/stock/news/2396401/tem-stock-declines-following-preliminary-q4-sales-miss",
      "time_published": "20250114T130900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.306633,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.141448",
          "ticker_sentiment_score": "0.100505",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.094576",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEM",
          "relevance_score": "0.278486",
          "ticker_sentiment_score": "0.230242",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.141448",
          "ticker_sentiment_score": "-0.020307",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Magnificent Dividend Stocks to Buy in October",
      "url": "https://www.fool.com/investing/2024/10/06/3-magnificent-dividend-stocks-to-buy-in-october/",
      "time_published": "20241006T095000",
      "authors": [
        "David Jagielski",
        "Keith Speights",
        "and Prosper Junior Bakiny"
      ],
      "summary": "These dividend stocks are great picks as the fall season gets underway.",
      "banner_image": "https://g.foolcdn.com/editorial/images/792876/retired-woman-investing-laptop-401k-ira.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999922"
        }
      ],
      "overall_sentiment_score": 0.334621,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.364053",
          "ticker_sentiment_score": "0.389014",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.094204",
          "ticker_sentiment_score": "0.067748",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LDNXF",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.147599",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "0.354037",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.232661",
          "ticker_sentiment_score": "0.213443",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Should You Retain Henry Schein Stock in Your Portfolio Right Now?",
      "url": "https://www.zacks.com/stock/news/2565482/should-you-retain-henry-schein-stock-in-your-portfolio-right-now",
      "time_published": "20250707T121700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997335"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.223511,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.093836",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.186378",
          "ticker_sentiment_score": "0.060437",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSIC",
          "relevance_score": "0.520601",
          "ticker_sentiment_score": "0.347819",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.140348",
          "ticker_sentiment_score": "0.021128",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "TMCI Stock May Gain From the Limited Release of the Percuplasty System",
      "url": "https://www.zacks.com/stock/news/2392333/tmci-stock-may-gain-from-the-limited-release-of-the-percuplasty-system",
      "time_published": "20250106T160800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.313369,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TMCI",
          "relevance_score": "0.231773",
          "ticker_sentiment_score": "0.232359",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.140348",
          "ticker_sentiment_score": "0.100074",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.093836",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.140348",
          "ticker_sentiment_score": "-0.020216",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's  ( ABT )  Assert-IQ Cardiac Monitor Receives CE Mark",
      "url": "https://www.zacks.com/stock/news/2246922/abbotts-abt-assert-iq-cardiac-monitor-receives-ce-mark",
      "time_published": "20240327T162500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.237289,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.093836",
          "ticker_sentiment_score": "-0.067865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.186378",
          "ticker_sentiment_score": "0.13933",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.186378",
          "ticker_sentiment_score": "0.032712",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.186378",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain Inogen Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2387688/heres-why-you-should-retain-inogen-stock-in-your-portfolio-now",
      "time_published": "20241224T183000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Expanding product portfolio and high prospects for POC raise optimism for INGN stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.994953"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.30492,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.103535",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.09347",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INGN",
          "relevance_score": "0.402761",
          "ticker_sentiment_score": "0.38187",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "-0.01888",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "-0.08188",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "-0.08188",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device",
      "url": "https://www.zacks.com/stock/news/2389992/inogen-stock-rises-as-fda-clears-simeox-200-airway-clearance-device",
      "time_published": "20241231T142900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2070.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.334514,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.102203",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.093289",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INGN",
          "relevance_score": "0.587962",
          "ticker_sentiment_score": "0.528643",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "-0.020137",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Growth Stocks to Buy Hand Over Fist in August",
      "url": "https://www.fool.com/investing/2024/08/07/dividend-growth-stocks-buy-hand-over-fist-august/",
      "time_published": "20240807T091000",
      "authors": [
        "Justin Pope"
      ],
      "summary": "There are blue-chip bargains paying large and growing dividends in the healthcare space.",
      "banner_image": "https://g.foolcdn.com/editorial/images/785724/money-trees-long-term-investing.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.280693,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.046633",
          "ticker_sentiment_score": "0.067943",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.081485",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.317722",
          "ticker_sentiment_score": "0.354872",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.317722",
          "ticker_sentiment_score": "0.154637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's Why You Should Add Surmodics Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2401876/heres-why-you-should-add-surmodics-stock-to-your-portfolio-now",
      "time_published": "20250123T122500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/89804.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.273407,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.137934",
          "ticker_sentiment_score": "0.041743",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.137934",
          "ticker_sentiment_score": "0.099139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.092213",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRDX",
          "relevance_score": "0.728836",
          "ticker_sentiment_score": "0.386297",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Reckitt Benckiser Group Plc of Class Action Lawsuit and Upcoming Deadlines - RBGLY - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45825037/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-reckitt-ben",
      "time_published": "20250606T212826",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc ( \"Reckitt\" or the \"Company\" ) RBGLY. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ( or ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.061245,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "-0.035092",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "0.106094",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Add Cardinal Health Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2391574/reasons-to-add-cardinal-health-stock-to-your-portfolio-now",
      "time_published": "20250103T142400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999858"
        }
      ],
      "overall_sentiment_score": 0.251381,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "-0.112055",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSIC",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "0.184871",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.137409",
          "ticker_sentiment_score": "-0.019963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.137409",
          "ticker_sentiment_score": "0.101364",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FUJIF",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.133871",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.474321",
          "ticker_sentiment_score": "0.397876",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain BDX Stock in Your Portfolio for Now",
      "url": "https://www.zacks.com/stock/news/2393130/heres-why-you-should-retain-bdx-stock-in-your-portfolio-for-now",
      "time_published": "20250107T165000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        }
      ],
      "overall_sentiment_score": 0.27624,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.136888",
          "ticker_sentiment_score": "0.098739",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.04583",
          "ticker_sentiment_score": "0.131176",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.091509",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.04583",
          "ticker_sentiment_score": "0.130999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.136888",
          "ticker_sentiment_score": "-0.019932",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.091509",
          "ticker_sentiment_score": "0.139007",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cencora Stock May Gain Following the Strategic Acquisition of RCA",
      "url": "https://www.zacks.com/stock/news/2391609/cencora-stock-may-gain-following-the-strategic-acquisition-of-rca",
      "time_published": "20250103T143000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.361843,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.13637",
          "ticker_sentiment_score": "0.102167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.091162",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSSMY",
          "relevance_score": "0.045655",
          "ticker_sentiment_score": "0.193139",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.13637",
          "ticker_sentiment_score": "-0.019891",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.577173",
          "ticker_sentiment_score": "0.554923",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WBA",
          "relevance_score": "0.045655",
          "ticker_sentiment_score": "0.21416",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
      "url": "https://www.zacks.com/stock/news/2389895/heres-why-you-should-retain-revvity-stock-in-your-portfolio-for-now",
      "time_published": "20241231T132700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "RVTY's strong product portfolio raises optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990786"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.451494"
        }
      ],
      "overall_sentiment_score": 0.307864,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.045655",
          "ticker_sentiment_score": "-0.076",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.13637",
          "ticker_sentiment_score": "0.098542",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.091162",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.13637",
          "ticker_sentiment_score": "-0.019891",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVTY",
          "relevance_score": "0.507932",
          "ticker_sentiment_score": "0.405853",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "National Vision Tops Q2 Earnings, Lowers '24 Outlook - National Vision Holdings  ( NASDAQ:EYE ) ",
      "url": "https://www.benzinga.com/news/earnings/24/08/40254280/national-vision-tops-q2-earnings-lowers-24-outlook",
      "time_published": "20240808T153522",
      "authors": [
        "Zacks"
      ],
      "summary": "National Vision Holdings, Inc. EYE delivered an adjusted EPS ( earnings per share ) of 15 cents in the second quarter of 2024 compared with 17 cents in the year-ago period. The figure surpassed the Zacks Consensus Estimate of 6 cents.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/50/1723114757.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        }
      ],
      "overall_sentiment_score": 0.131671,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EYE",
          "relevance_score": "0.471156",
          "ticker_sentiment_score": "0.183952",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.091162",
          "ticker_sentiment_score": "0.053919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.091162",
          "ticker_sentiment_score": "0.063279",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.13637",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.091162",
          "ticker_sentiment_score": "-0.05905",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt Benckiser Group PLC Following $60 Million Baby Formula Verdict and Subsequent Stock Plummet - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/24/03/g37759198/attention-reckitt-benckiser-group-investors-portnoy-law-firm-announces-investigation-into-reckitt-",
      "time_published": "20240315T201101",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 15, 2024 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Reckitt Benckiser Group PLC ( \"Reckitt\" or the \"Company\" ) RBGLY investors that the law firm has initiated an investigation on ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.014814,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.091162",
          "ticker_sentiment_score": "-0.074147",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.268786",
          "ticker_sentiment_score": "-0.075876",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Leadership in Dialysis Services and Products Drives FMS Stock",
      "url": "https://www.zacks.com/stock/news/2384399/leadership-in-dialysis-services-and-products-drives-fms-stock",
      "time_published": "20241217T125700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Fresenius Medical Care leads global dialysis services, driving growth through innovation, restructuring and a strong global footprint in 120+ countries.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.319194,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.090989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.392948",
          "ticker_sentiment_score": "0.385552",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "-0.019859",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAX",
          "relevance_score": "0.045569",
          "ticker_sentiment_score": "0.141954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.100859",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FMS",
          "relevance_score": "0.352432",
          "ticker_sentiment_score": "0.270133",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.045569",
          "ticker_sentiment_score": "0.141954",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "GKOS Stock Gains Following Positive Study Data on iDose Platform",
      "url": "https://www.zacks.com/stock/news/2397144/gkos-stock-gains-following-positive-study-data-on-idose-platform",
      "time_published": "20250115T135100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/25271.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.326808,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GKOS",
          "relevance_score": "0.541576",
          "ticker_sentiment_score": "0.54274",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.135857",
          "ticker_sentiment_score": "0.098347",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.090816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.135857",
          "ticker_sentiment_score": "-0.019849",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Iridium Gearing Up to Report Q3 Earnings: Here's What to Expect - Iridium Comms  ( NASDAQ:IRDM ) , Equifax  ( NYSE:EFX ) ",
      "url": "https://www.benzinga.com/news/earnings/24/10/41315948/iridium-gearing-up-to-report-q3-earnings-heres-what-to-expect",
      "time_published": "20241014T174704",
      "authors": [
        "Zacks"
      ],
      "summary": "Iridium Communications IRDM is slated to release third-quarter 2024 earnings on Oct. 17, before market open. The Zacks Consensus estimate for revenues is pegged at $205.7 million, indicating an increase of 4.1% from the year-ago level.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/ab/81094.jpg?v=885335854",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999756"
        }
      ],
      "overall_sentiment_score": 0.242738,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IRDM",
          "relevance_score": "0.223248",
          "ticker_sentiment_score": "0.193319",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.135094",
          "ticker_sentiment_score": "0.18121",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.090304",
          "ticker_sentiment_score": "0.159066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.135094",
          "ticker_sentiment_score": "0.172765",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "STERIS Q1 Earnings Beat Estimates, Operating Margin Falls - Steris  ( NYSE:STE ) ",
      "url": "https://www.benzinga.com/general/biotech/24/08/40225735/steris-q1-earnings-beat-estimates-operating-margin-falls",
      "time_published": "20240807T185023",
      "authors": [
        "Zacks"
      ],
      "summary": "STERIS plc STE reported first-quarter fiscal 2025 adjusted earnings per share of $2.03, up 10.3% from the year-ago quarter's figure. The figure surpassed the Zacks Consensus Estimate by 2 cents.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/1e/1723034957.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999996"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.1822,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.090304",
          "ticker_sentiment_score": "0.098517",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.135094",
          "ticker_sentiment_score": "0.068041",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.179454",
          "ticker_sentiment_score": "0.124141",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STE",
          "relevance_score": "0.390227",
          "ticker_sentiment_score": "0.272364",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abbott  ( ABT )  Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen",
      "url": "https://www.zacks.com/stock/news/2326206/abbott-abt-gets-fda-approval-for-aspirin-free-heartmate-3-regimen",
      "time_published": "20240823T131200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.223099,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.179121",
          "ticker_sentiment_score": "0.09968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.090134",
          "ticker_sentiment_score": "0.250226",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.179121",
          "ticker_sentiment_score": "0.106826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.134841",
          "ticker_sentiment_score": "0.135251",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.134841",
          "ticker_sentiment_score": "0.052418",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Verano Holdings CIO To Share Insights Into Florida's Cannabis Boom At Benzinga Conference",
      "url": "https://markets.businessinsider.com/news/stocks/verano-holdings-cio-to-share-insights-into-florida-s-cannabis-boom-at-benzinga-conference-1033191268",
      "time_published": "20240325T005523",
      "authors": [
        "Nicol&#225;s Jose Rodriguez"
      ],
      "summary": "Amidst the buzz of potential recreational legalization and federal cannabis rescheduling, comprehending cannabis stock dynamics is vital for investors. Florida's burgeoning market offers a unique chance for those poised to seize emerging opportunities.",
      "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/03/22/dalle_2024-03-22_17.55.09_-_.jpg",
      "source": "Business Insider",
      "category_within_source": "GoogleRSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        }
      ],
      "overall_sentiment_score": 0.357556,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.090134",
          "ticker_sentiment_score": "0.114106",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CEJOF",
          "relevance_score": "0.090134",
          "ticker_sentiment_score": "0.114106",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "BioPorto A/S Appoints President and CEO of BioPorto Inc.",
      "url": "https://www.globenewswire.com/news-release/2024/05/07/2876582/0/en/BioPorto-A-S-Appoints-President-and-CEO-of-BioPorto-Inc.html",
      "time_published": "20240507T111000",
      "authors": [
        "BioPorto A/S"
      ],
      "summary": "May 7, 2024News release ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b9686d8c-3706-4a6c-b22a-ae722c122c21",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.260449,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.045054",
          "ticker_sentiment_score": "0.079326",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.089965",
          "ticker_sentiment_score": "0.083897",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Add MMSI Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2391068/heres-why-you-should-add-mmsi-stock-to-your-portfolio-now",
      "time_published": "20250102T161600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Merit Medical's strong product portfolio raises optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/36600.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.990786"
        }
      ],
      "overall_sentiment_score": 0.318638,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "0.100175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMSI",
          "relevance_score": "0.348103",
          "ticker_sentiment_score": "0.499983",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.089797",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "-0.019716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "-0.059927",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2024/08/30/3-rock-solid-pharma-stocks-to-buy-now-and-hold-for/",
      "time_published": "20240830T104500",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "These three have secure core businesses, plus multiple paths to grow.",
      "banner_image": "https://g.foolcdn.com/editorial/images/788607/doctor-and-nurse-talk-with-investor.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.238076,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.089797",
          "ticker_sentiment_score": "-0.003168",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "0.043756",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.089797",
          "ticker_sentiment_score": "-0.004225",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain Ecolab Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2388858/heres-why-you-should-retain-ecolab-stock-in-your-portfolio-now",
      "time_published": "20241227T145600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ECL continues to gain from its strong segmental performance and improved operating margin.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.320604,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.044885",
          "ticker_sentiment_score": "-0.052467",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.13409",
          "ticker_sentiment_score": "0.097684",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.089629",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.13409",
          "ticker_sentiment_score": "-0.019708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ECL",
          "relevance_score": "0.347492",
          "ticker_sentiment_score": "0.544106",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.044885",
          "ticker_sentiment_score": "-0.126314",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "GEHC Stock Gains on Long-Term Collaboration With Sutter Health",
      "url": "https://www.zacks.com/stock/news/2398891/gehc-stock-gains-on-long-term-collaboration-with-sutter-health",
      "time_published": "20250117T140100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GE HealthCare announces a seven-year strategic collaboration with Sutter Health.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.449232,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.421485",
          "ticker_sentiment_score": "0.437662",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.132368",
          "ticker_sentiment_score": "0.097047",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.088472",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.132368",
          "ticker_sentiment_score": "-0.019571",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "TEM Stock Rises on Launch of AI-Powered Health Concierge App",
      "url": "https://www.zacks.com/stock/news/2402326/tem-stock-rises-on-launch-of-ai-powered-health-concierge-app",
      "time_published": "20250123T160100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.364538,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.129052",
          "ticker_sentiment_score": "0.093495",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.152232",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.129052",
          "ticker_sentiment_score": "0.13351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.086245",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEM",
          "relevance_score": "0.254751",
          "ticker_sentiment_score": "0.353937",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Is Your Smartphone The Future Of Heart Disease Detection? This Finnish Startup Thinks So",
      "url": "https://www.benzinga.com/news/24/04/38085175/is-your-smartphone-the-future-of-heart-disease-detection-this-finnish-startup-thinks-so",
      "time_published": "20240404T084743",
      "authors": [
        "Benzinga Neuro"
      ],
      "summary": "CardioSignal, a Finnish startup, has developed a system that uses smartphone motion sensors to detect heart disease. This innovation is a significant breakthrough in the health tech industry.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Monitoring-Of-Patients-Heart-In-Intensiv_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.385272,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SSNLF",
          "relevance_score": "0.086245",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.086245",
          "ticker_sentiment_score": "0.208412",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Can AbbVie Regain Its Status As a Top Dividend Growth Stock?",
      "url": "https://www.fool.com/investing/2024/09/16/can-abbvie-regain-its-status-as-a-top-dividend-gro/",
      "time_published": "20240916T110000",
      "authors": [
        "George Budwell"
      ],
      "summary": "The dividend growth powerhouse is turning the corner.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790803%2Fu-turn.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972476"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.312508,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.409171",
          "ticker_sentiment_score": "0.390142",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.085629",
          "ticker_sentiment_score": "0.129735",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2417456/hims-hers-stock-jumps-1569-in-three-months-whats-next",
      "time_published": "20250218T152000",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.47017,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.370908",
          "ticker_sentiment_score": "0.406136",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.085476",
          "ticker_sentiment_score": "0.293469",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.085476",
          "ticker_sentiment_score": "0.293469",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Nasdaq, S&P 500 To Start New Week In The Green: What's Driving Sentiment - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/40008162/us-stocks-look-to-extend-gains-ahead-of-key-tech-earnings-fomc-meeting-analyst-says-this-could-serv",
      "time_published": "20240729T114326",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "Index futures trading indicates cautious optimism as traders anticipate a busy week, with a slew of earnings reports, the two-day Federal Open Market Committee meeting starting Tuesday, and Friday's non-farm payrolls report.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/Icahn-Enterprises-L-P.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.986714"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        }
      ],
      "overall_sentiment_score": 0.076552,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "-0.020376",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LSCC",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.097466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDNDF",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RMBS",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.097466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SANM",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.097466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.211069",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FFIV",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.097466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCD",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "-0.306488",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "-0.020376",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TLRY",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.097466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPLA",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.095623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.127456",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ON",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "-0.182795",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?",
      "url": "https://www.zacks.com/stock/news/2456252/tariffs-cast-a-shadow-on-abbotts-2025-view-time-to-sell-abt-stock",
      "time_published": "20250425T190000",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        }
      ],
      "overall_sentiment_score": 0.304024,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.126561",
          "ticker_sentiment_score": "0.204788",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.126561",
          "ticker_sentiment_score": "0.204788",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.084572",
          "ticker_sentiment_score": "0.053969",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott  ( ABT )  Receives FDA's Approval for the TriClip TEER System",
      "url": "https://www.zacks.com/stock/news/2251212/abbott-abt-receives-fdas-approval-for-the-triclip-teer-system",
      "time_published": "20240405T135200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.224271,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.084572",
          "ticker_sentiment_score": "0.096913",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.126561",
          "ticker_sentiment_score": "0.049657",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.126561",
          "ticker_sentiment_score": "0.049657",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.168197",
          "ticker_sentiment_score": "0.039405",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks",
      "url": "https://www.zacks.com/research-daily/2251046/top-analyst-reports-for-t-mobile-us-abbott-laboratories-palo-alto-networks",
      "time_published": "20240405T205500",
      "authors": [
        "Sheraz Mian"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default182.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.353542,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TMUS",
          "relevance_score": "0.084423",
          "ticker_sentiment_score": "0.258565",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.084423",
          "ticker_sentiment_score": "0.393699",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PANW",
          "relevance_score": "0.084423",
          "ticker_sentiment_score": "0.069222",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "My Top 5 Stocks to Buy in Early 2025",
      "url": "https://www.fool.com/investing/2025/01/23/my-top-5-stocks-to-buy-in-early-2025/",
      "time_published": "20250123T091500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F804658%2Fhappy-person-at-laptop-success-winning-fists-up-victory-yes.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.329713,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.125679",
          "ticker_sentiment_score": "0.144355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRMNF",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "0.37055",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.08398",
          "ticker_sentiment_score": "0.145698",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.08398",
          "ticker_sentiment_score": "0.296731",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "0.09011",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.167032",
          "ticker_sentiment_score": "0.119928",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OPKO Health  ( OPK )  Q2 Earnings Top Estimates, Gross Margin Down",
      "url": "https://www.zacks.com/stock/news/2319449/opko-health-opk-q2-earnings-top-estimates-gross-margin-down",
      "time_published": "20240808T161400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/62145.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988915"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.004812,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "-0.112386",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.08398",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPK",
          "relevance_score": "0.506917",
          "ticker_sentiment_score": "0.016334",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.167032",
          "ticker_sentiment_score": "0.024842",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.167032",
          "ticker_sentiment_score": "0.023457",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "0.011773",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Scott+Scott Attorneys at Law LLP Reminds Investors of Its Current Investigation Into Reckitt Benckiser Group PLC  ( OTC: RBGLY )  - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44766874/scott-scott-attorneys-at-law-llp-reminds-investors-of-its-current-investigation-into-reckitt-benck",
      "time_published": "20250411T155800",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 11, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( \"Scott+Scott\" ) , a shareholder and consumer rights litigation firm, is investigating whether Reckitt Benckiser Group PLC ( \"Reckitt\" or the \"Company\" ) RBGLY or certain of its officers and directors issued ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": -0.017059,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TOP",
          "relevance_score": "0.083833",
          "ticker_sentiment_score": "0.069097",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.083833",
          "ticker_sentiment_score": "-0.136505",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.083833",
          "ticker_sentiment_score": "-0.127256",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Verano Holdings CIO To Share Insights Into Florida's Cannabis Boom At Conference - Verano Holdings  ( OTC:VRNOF ) ",
      "url": "https://www.benzinga.com/markets/cannabis/24/03/37901231/verano-holdings-cio-to-share-insights-into-floridas-cannabis-boom-at-benzinga-conference",
      "time_published": "20240325T003301",
      "authors": [
        "Nicol\u00e1s Jose Rodriguez"
      ],
      "summary": "Amidst the buzz of potential recreational legalization and federal cannabis rescheduling, comprehending cannabis stock dynamics is vital for investors. Florida's burgeoning market offers a unique chance for those poised to seize emerging opportunities. At Verano Holdings Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/22/dalle_2024-03-22_17.55.09_-_.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.992549"
        }
      ],
      "overall_sentiment_score": 0.362342,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.083251",
          "ticker_sentiment_score": "0.112514",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CEJOF",
          "relevance_score": "0.083251",
          "ticker_sentiment_score": "0.112514",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock",
      "url": "https://www.zacks.com/stock/news/2492210/cardiovascular-tailwind-boosts-bsx-heres-how-to-play-the-stock",
      "time_published": "20250610T125300",
      "authors": [
        "Sridatri Sarkar"
      ],
      "summary": "Boston Scientific rides strong cardiovascular momentum, with booming EP and WATCHMAN sales despite macro headwinds. What is the investment outlook?",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/667.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99992"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.421505,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.082677",
          "ticker_sentiment_score": "0.228742",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.123738",
          "ticker_sentiment_score": "0.25715",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.500159",
          "ticker_sentiment_score": "0.578283",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AXNX",
          "relevance_score": "0.041394",
          "ticker_sentiment_score": "0.244386",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2332325/hims-hers-stock-plunges-321-in-three-months-whats-next",
      "time_published": "20240905T160300",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.331018,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.320453",
          "ticker_sentiment_score": "0.210001",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.082251",
          "ticker_sentiment_score": "0.028275",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.082251",
          "ticker_sentiment_score": "0.028275",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses; August 4, 2025 Deadline to file Lead Plaintiff Motion - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g46130007/reckitt-benckiser-group-plc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-a",
      "time_published": "20250626T222743",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.09189,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.082111",
          "ticker_sentiment_score": "-0.092926",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.319933",
          "ticker_sentiment_score": "0.041329",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings",
      "url": "https://www.zacks.com/stock/news/2449219/heres-how-quest-diagnostics-is-placed-ahead-of-q1-earnings",
      "time_published": "20250415T132800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/99342.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.307613,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "III",
          "relevance_score": "0.041039",
          "ticker_sentiment_score": "0.160288",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VEEV",
          "relevance_score": "0.08197",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.08197",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.08197",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.528728",
          "ticker_sentiment_score": "0.524213",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ELV",
          "relevance_score": "0.041039",
          "ticker_sentiment_score": "0.186313",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Avanos  ( AVNS )  Q2 Earnings Top Estimates, Gross Margin Contracts",
      "url": "https://www.zacks.com/stock/news/2314560/avanos-avns-q2-earnings-top-estimates-gross-margin-contracts",
      "time_published": "20240801T165500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999606"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.126693,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.080188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVNS",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.068369",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.024095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.022751",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?",
      "url": "https://www.zacks.com/stock/news/2473056/hims-hers-stock-declines-31-in-3-months-is-it-a-buy-now",
      "time_published": "20250516T142500",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        }
      ],
      "overall_sentiment_score": 0.345356,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.080055",
          "ticker_sentiment_score": "0.131382",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.080055",
          "ticker_sentiment_score": "0.131382",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.419575",
          "ticker_sentiment_score": "0.305184",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.040078",
          "ticker_sentiment_score": "0.11668",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?",
      "url": "https://www.zacks.com/stock/news/2369800/hims-hers-stock-gains-311-since-q3-earnings-whats-next",
      "time_published": "20241113T152800",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.455547,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.380591",
          "ticker_sentiment_score": "0.396013",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.07913",
          "ticker_sentiment_score": "0.263239",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.07913",
          "ticker_sentiment_score": "0.263239",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain Stryker Stock in Your Portfolio for Now",
      "url": "https://www.zacks.com/stock/news/2384385/heres-why-you-should-retain-stryker-stock-in-your-portfolio-for-now",
      "time_published": "20241217T124200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/1670.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.316915,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.117678",
          "ticker_sentiment_score": "0.095394",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.078611",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.570165",
          "ticker_sentiment_score": "0.450663",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.117678",
          "ticker_sentiment_score": "-0.017303",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Integer Holdings  ( ITGR )  Q2 Earnings Top Estimates, Margins Up",
      "url": "https://www.zacks.com/stock/news/2310286/integer-holdings-itgr-q2-earnings-top-estimates-margins-up",
      "time_published": "20240726T165400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999819"
        }
      ],
      "overall_sentiment_score": 0.138446,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.078611",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.156461",
          "ticker_sentiment_score": "0.022464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITGR",
          "relevance_score": "0.510302",
          "ticker_sentiment_score": "0.210259",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.156461",
          "ticker_sentiment_score": "0.022464",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "RECKITT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45875537/reckitt-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-against",
      "time_published": "20250611T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Reckitt Benckiser Group plc ( \"Reckitt\" or the \"Company\" ) RBGLY in the United States District Court for ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.002433,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.078354",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.078354",
          "ticker_sentiment_score": "-0.134842",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.078354",
          "ticker_sentiment_score": "0.030593",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain OPKO Health Stock in Your Portfolio",
      "url": "https://www.zacks.com/stock/news/2394202/heres-why-you-should-retain-opko-health-stock-in-your-portfolio",
      "time_published": "20250109T125300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.223582,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.117104",
          "ticker_sentiment_score": "0.091829",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.078226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPK",
          "relevance_score": "0.341437",
          "ticker_sentiment_score": "0.344137",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.03916",
          "ticker_sentiment_score": "0.111481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LH",
          "relevance_score": "0.03916",
          "ticker_sentiment_score": "0.111481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.117104",
          "ticker_sentiment_score": "-0.018443",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Surges 69.2% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2406873/hims-hers-stock-surges-692-in-three-months-whats-next",
      "time_published": "20250130T160100",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.447465,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.375439",
          "ticker_sentiment_score": "0.403162",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.077972",
          "ticker_sentiment_score": "0.239164",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.077972",
          "ticker_sentiment_score": "0.239164",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Reasons to Add McKesson Stock to Your Portfolio Right Now",
      "url": "https://www.zacks.com/stock/news/2385061/reasons-to-add-mckesson-stock-to-your-portfolio-right-now",
      "time_published": "20241218T123500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "MCK's strategic collaborations and strength in Biologics raise optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999336"
        }
      ],
      "overall_sentiment_score": 0.277697,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.116725",
          "ticker_sentiment_score": "0.093959",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSGR",
          "relevance_score": "0.039033",
          "ticker_sentiment_score": "-0.020473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.077972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCK",
          "relevance_score": "0.537109",
          "ticker_sentiment_score": "0.387374",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.039033",
          "ticker_sentiment_score": "0.113695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.116725",
          "ticker_sentiment_score": "-0.018408",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Neurosurgery Market Size to Reach USD 6.8 Billion by 2034, Growing at 4.5% CAGR with Technological Advancements and Rising Focus on Personalized Medicine - Analysis by TMR",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44277307/neurosurgery-market-size-to-reach-usd-6-8-billion-by-2034-growing-at-4-5-cagr-with-technological-a",
      "time_published": "20250312T140231",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. -, March 12, 2025 ( GLOBE NEWSWIRE ) -- Advancements in robotic-assisted surgery and neuroimaging are driving innovation in brain and spine procedures. The Global Neurosurgery Industry was valued at US$ 4.2 billion in 2023.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/4b5d1e3f-7cec-42a8-8399-9b8f5e26f945/neurosurgery-market-outlook-2034.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.340392,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.025901",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.171272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.171272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LIVN",
          "relevance_score": "0.025901",
          "ticker_sentiment_score": "0.084556",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRUMF",
          "relevance_score": "0.025901",
          "ticker_sentiment_score": "0.084556",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IART",
          "relevance_score": "0.025901",
          "ticker_sentiment_score": "0.084556",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NMTC",
          "relevance_score": "0.025901",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.11308",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.114812",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ",
      "url": "https://www.benzinga.com/partner/biotech/24/12/42290788/driving-innovation-in-diabetes-management-glucotrack-begins-enrollment-for-human-clinical-trials-",
      "time_published": "20241203T140046",
      "authors": [
        "Joshenomoto@benzinga.com"
      ],
      "summary": "In the rapidly evolving medical technology sector, diabetes management specialist Glucotrack Inc. GCTK aims to disrupt the present care framework for the benefit of patients. Thanks to its Continuous Blood Glucose Monitor ( CBGM ) , millions of people affected by the disease may be able to access ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/03/Screenshot-2024-12-03-at-7-43-04PM.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.232893,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "-0.001022",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GCTK",
          "relevance_score": "0.335772",
          "ticker_sentiment_score": "0.330682",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "-0.001022",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it",
      "url": "https://www.zacks.com/stock/news/2449864/hims-hers-stock-gains-58-in-3-months-heres-how-to-play-it",
      "time_published": "20250416T124300",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.28915,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.369319",
          "ticker_sentiment_score": "0.198754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076602",
          "ticker_sentiment_score": "0.130325",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.076602",
          "ticker_sentiment_score": "0.130325",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain PacBio Stock in Your Portfolio for Now",
      "url": "https://www.zacks.com/stock/news/2401474/heres-why-you-should-retain-pacbio-stock-in-your-portfolio-for-now",
      "time_published": "20250122T163000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "PACB continues to deliver growth from its unique technologies amid business seasonality concerns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.287163,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.114318",
          "ticker_sentiment_score": "0.094314",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TXG",
          "relevance_score": "0.038223",
          "ticker_sentiment_score": "0.141152",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PACB",
          "relevance_score": "0.226301",
          "ticker_sentiment_score": "0.224972",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.114318",
          "ticker_sentiment_score": "-0.01709",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/12/12/1-magnificent-sp-500-dividend-stock-down-14-to-buy/",
      "time_published": "20241212T110000",
      "authors": [
        "Bradley Guichard"
      ],
      "summary": "This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the market made history every five days this year.",
      "banner_image": "https://media.ycharts.com/charts/04690dae5cdf0318f153ec25dd40dcfc.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.214907,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.70826",
          "ticker_sentiment_score": "0.380907",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.22722",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Should You Bet on HOLX Stock This Breast Cancer Awareness Month?",
      "url": "https://www.zacks.com/stock/news/2348255/should-you-bet-on-holx-stock-this-breast-cancer-awareness-month",
      "time_published": "20241009T134600",
      "authors": [
        "Moumi Mondal"
      ],
      "summary": "Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.21192,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HOLX",
          "relevance_score": "0.368227",
          "ticker_sentiment_score": "0.30533",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "-0.008164",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "-0.008164",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "TransMedics Stock Plunges 57.5% in Three Months: What's Next?",
      "url": "https://www.zacks.com/stock/news/2383547/transmedics-stock-plunges-575-in-three-months-whats-next",
      "time_published": "20241213T171700",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.254218,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "-0.017215",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMDX",
          "relevance_score": "0.58401",
          "ticker_sentiment_score": "0.407278",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076236",
          "ticker_sentiment_score": "-0.01538",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "-0.017215",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Meta, Palantir, Abbott Laboratories, SandRidge and CompX",
      "url": "https://www.zacks.com/stock/news/2534199/the-zacks-analyst-blog-highlights-meta-palantir-abbott-laboratories-sandridge-and-compx",
      "time_published": "20250623T093700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "META, PLTR and ABT lead this week's Zacks blog as AI growth, strong pipelines and solid earnings drive investor interest.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/23/489.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.333552,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.261517",
          "ticker_sentiment_score": "0.321537",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.075995",
          "ticker_sentiment_score": "0.025222",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.075995",
          "ticker_sentiment_score": "0.025222",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NMDP Strengthens Executive Leadership Team",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43243855/nmdp-strengthens-executive-leadership-team",
      "time_published": "20250127T175315",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "MINNEAPOLIS, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- NMDPSM, a global nonprofit leader in cell therapy, announced today executive leadership news - including introducing Alexander Rosenstein as general counsel and chief compliance officer and adding strategic responsibilities under Erica Jensen, ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.402571,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.042351",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Hold Avanos Medical Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2401900/reasons-to-hold-avanos-medical-stock-in-your-portfolio-now",
      "time_published": "20250123T124800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AVNS' strong product line and focus on R&D raise optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.279409,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.110632",
          "ticker_sentiment_score": "0.03882",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CURN",
          "relevance_score": "0.036983",
          "ticker_sentiment_score": "0.035606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.110632",
          "ticker_sentiment_score": "0.089879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.073886",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVNS",
          "relevance_score": "0.183337",
          "ticker_sentiment_score": "0.292882",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FOREX:AUD",
          "relevance_score": "0.036983",
          "ticker_sentiment_score": "0.035606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:UYU",
          "relevance_score": "0.036983",
          "ticker_sentiment_score": "0.035606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:JPY",
          "relevance_score": "0.036983",
          "ticker_sentiment_score": "0.035606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:MXN",
          "relevance_score": "0.036983",
          "ticker_sentiment_score": "0.035606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.036983",
          "ticker_sentiment_score": "0.035606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.073886",
          "ticker_sentiment_score": "0.037397",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Key Trends in Infant Clinical Nutrition Industry Propel Toward a US$ 49.47 billion Valuation: Fact.MR Study",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41374199/key-trends-in-infant-clinical-nutrition-industry-propel-toward-a-us-49-47-billion-valuation-fact-m",
      "time_published": "20241017T074500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville Pike, Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- A newly published study by Fact.MR, a market research and competitive intelligence provider, mentions that revenue from the demand for infant clinical nutrition is approximated to reach a valuation of US$ 27.55 billion in 2024.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/6ef6d48e-62ba-41fb-ad37-98968f5bc7b6/infant-clinical-nutrition-market-outlook-1.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.303498,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "INGR",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "0.089157",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.073659",
          "ticker_sentiment_score": "0.144303",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "0.089157",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAX",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "0.089157",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.073659",
          "ticker_sentiment_score": "0.079734",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "0.089157",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "0.089157",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stock Likely To Open Lower As US-China Tariff War Continues: 'Valuations Are Now Looking More Compelling,' Says Expert - Abbott Laboratories  ( NYSE:ABT ) , ASML Holding  ( NASDAQ:ASML ) ",
      "url": "https://www.benzinga.com/25/04/44833169/us-stock-futures-tumble-after-trump-imposes-245-tariff-on-china-valuations-are-now-looking-more-compelling-says-e",
      "time_published": "20250416T094741",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "U.S. stock futures declined on Wednesday following a muted day of trading on Tuesday. Futures of major benchmark indices were lower in premarket.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/16/Closeup-Of-Wall-St--Street-Sign-And-Larg.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998962"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999939"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.014428,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LRHC",
          "relevance_score": "0.110124",
          "ticker_sentiment_score": "0.080938",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "0.064454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "0.050695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "0.050695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "0.078579",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PGR",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "-0.025473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.036812",
          "ticker_sentiment_score": "0.083275",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.110124",
          "ticker_sentiment_score": "0.008084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.073546",
          "ticker_sentiment_score": "-0.025792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ICAD",
          "relevance_score": "0.110124",
          "ticker_sentiment_score": "0.008084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.036812",
          "ticker_sentiment_score": "0.11309",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Retain GE HealthCare Stock in Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2385060/reasons-to-retain-ge-healthcare-stock-in-your-portfolio-now",
      "time_published": "20241218T123600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997335"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.323033,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.417419",
          "ticker_sentiment_score": "0.43559",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.109289",
          "ticker_sentiment_score": "0.092787",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.072987",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LNTH",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.074513",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.032088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.109289",
          "ticker_sentiment_score": "-0.016786",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "TMDX Stock Plunges 49.2% in Three Months: What's Behind the Downfall?",
      "url": "https://www.zacks.com/stock/news/2402324/tmdx-stock-plunges-492-in-three-months-whats-behind-the-downfall",
      "time_published": "20250123T160300",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "TransMedics is navigating macroeconomic challenges amid its focus on meaningful progress across each of its growth initiatives.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.019503,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.10863",
          "ticker_sentiment_score": "0.069263",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMDX",
          "relevance_score": "0.637426",
          "ticker_sentiment_score": "0.003715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.072545",
          "ticker_sentiment_score": "0.062399",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.10863",
          "ticker_sentiment_score": "0.069263",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why you Should Add Nevro Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2402307/heres-why-you-should-add-nevro-stock-to-your-portfolio-now",
      "time_published": "20250123T155800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.240408,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RMD",
          "relevance_score": "0.10863",
          "ticker_sentiment_score": "0.120006",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.10863",
          "ticker_sentiment_score": "0.122201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVRO",
          "relevance_score": "0.317983",
          "ticker_sentiment_score": "0.215043",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.072545",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Reasons to Add GE HealthCare Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2399286/reasons-to-add-ge-healthcare-stock-to-your-portfolio-now",
      "time_published": "20250117T183400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997335"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.331264,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.415128",
          "ticker_sentiment_score": "0.441107",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.10863",
          "ticker_sentiment_score": "0.0915",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.072545",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LNTH",
          "relevance_score": "0.03631",
          "ticker_sentiment_score": "0.074448",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.03631",
          "ticker_sentiment_score": "0.032065",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.10863",
          "ticker_sentiment_score": "-0.01674",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer's top 10 things to watch in the stock market Wednesday",
      "url": "https://www.cnbc.com/2025/01/22/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday.html",
      "time_published": "20250122T141337",
      "authors": [],
      "summary": "Wall Street was tracking for a higher open on strong earnings after the S&P 500 rose Tuesday for the fifth straight session.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.986714"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.9996"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.205649,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.06954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.12296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "-0.056493",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "-0.037423",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "-0.097445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.140357",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.389985",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GEV",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.189086",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?",
      "url": "https://www.zacks.com/stock/news/2429842/hims-hers-stock-gains-86-in-three-months-how-to-play-it",
      "time_published": "20250313T162400",
      "authors": [
        "Debanjana Dey"
      ],
      "summary": "HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.342348,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HIMS",
          "relevance_score": "0.348592",
          "ticker_sentiment_score": "0.276716",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.072",
          "ticker_sentiment_score": "0.124881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.072",
          "ticker_sentiment_score": "0.124881",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zacks Initiates Coverage of NVE Corp With Neutral Recommendation",
      "url": "https://www.zacks.com/stock/news/2280418/zacks-initiates-coverage-of-nve-corp-with-neutral-recommendation",
      "time_published": "20240529T113400",
      "authors": [
        "Urbashi Dutta"
      ],
      "summary": "Discover why Zacks rates NVE Corp (NVEC) as \"Neutral,\" being the first on Wall Street to initiate coverage on the stock. Explore how NVE Corp's growth prospects in the semiconductor industry remain promising, with strong dividend yield and solid cash position amid labor market challenges.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/2653.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.303108,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVEC",
          "relevance_score": "0.628066",
          "ticker_sentiment_score": "0.464785",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "0.086604",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teleflex Tops Q2 Earnings Estimates, Raises 2024 Outlook - Teleflex  ( NYSE:TFX ) ",
      "url": "https://www.benzinga.com/general/biotech/24/08/40131223/teleflex-tops-q2-earnings-estimates-raises-2024-outlook",
      "time_published": "20240802T173630",
      "authors": [
        "Zacks"
      ],
      "summary": "Teleflex Incorporated TFX posted adjusted earnings per share from continuing operations of $3.42 in the second quarter of 2024, up 0.3% from the year-ago quarter's figure. The metric topped the Zacks Consensus Estimate by 2.7%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/40/1722586620.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.17651,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.069798",
          "ticker_sentiment_score": "0.053182",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.069798",
          "ticker_sentiment_score": "0.062223",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.069798",
          "ticker_sentiment_score": "0.093383",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TFX",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.21278",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain DexCom Stock in Your Portfolio for Now",
      "url": "https://www.zacks.com/stock/news/2395595/heres-why-you-should-retain-dexcom-stock-in-your-portfolio-for-now",
      "time_published": "20250113T132300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "DXCM continues to raise optimism among investors owing to its strong product portfolio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.339098,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.103183",
          "ticker_sentiment_score": "0.091086",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.068896",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.588539",
          "ticker_sentiment_score": "0.513168",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.103183",
          "ticker_sentiment_score": "-0.017558",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Seizing Opportunities in Medical Foods Market to Grow at 7.5% CAGR, Reaching USD 44 Billion by 2031- Report by Transparency Market Research Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40136611/seizing-opportunities-in-medical-foods-market-to-grow-at-7-5-cagr-reaching-usd-44-billion-by-2031-",
      "time_published": "20240802T163937",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research ( TMR ) , the global Medical Foods Market ( \uc758\ub8cc\uc2dd\ud488\uc2dc\uc7a5 ) is estimated to reach US$ 44.0 Bn by 2031 at a noticeable CAGR of 7.5% ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.217298,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.058398",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MGAAF",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.066986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.067632",
          "ticker_sentiment_score": "0.120011",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.066986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRGM",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.066986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.101296",
          "ticker_sentiment_score": "0.057761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.067632",
          "ticker_sentiment_score": "0.084872",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Diamond Hill Mutual Funds for Consistent Returns",
      "url": "https://www.zacks.com/stock/news/2289577/3-diamond-hill-mutual-funds-for-consistent-returns",
      "time_published": "20240618T105700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Invests in Diamond Hill mutual funds such as DHLTX, DHLSX and DHLAX for disciplined investment strategies.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/554.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999897"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.360987,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.050095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.050095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.050095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RRR",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.045083",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.050095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WCC",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.045083",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AIG",
          "relevance_score": "0.13459",
          "ticker_sentiment_score": "0.059538",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45715635/aravax-appoints-louise-peacock-as-chief-regulatory-and-quality-officer-as-it-prepares-for-phase-3-",
      "time_published": "20250602T080000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 ( GLOBE NEWSWIRE ) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.145048,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NSRGF",
          "relevance_score": "0.134214",
          "ticker_sentiment_score": "0.031154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.067347",
          "ticker_sentiment_score": "0.026073",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Health Care Select Sector SPDR Fund  ( XLV )  Is Moving - SPDR Select Sector Fund - Health Care  ( ARCA:XLV ) , Pfizer  ( NYSE:PFE ) , UnitedHealth Group  ( NYSE:UNH ) ",
      "url": "https://www.benzinga.com/news/25/04/44672212/why-health-care-select-sector-spdr-fund-xlv-is-moving",
      "time_published": "20250407T182127",
      "authors": [
        "Henry Khederian"
      ],
      "summary": "Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major sectors. With stocks plunging, steady income is key.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/07/doctor-2568481.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.06834,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.132368",
          "ticker_sentiment_score": "0.213989",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.00201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.00201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.270194",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.132368",
          "ticker_sentiment_score": "0.213989",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.270194",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "DexCom  ( DXCM ) , Abbott to Launch First FDA Cleared OTC CGMs",
      "url": "https://www.zacks.com/stock/news/2297344/dexcom-dxcm-abbott-to-launch-first-fda-cleared-otc-cgms",
      "time_published": "20240705T155400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.928139"
        }
      ],
      "overall_sentiment_score": 0.260446,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.066047",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.09893",
          "ticker_sentiment_score": "0.096392",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.351467",
          "ticker_sentiment_score": "0.250791",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ECL",
          "relevance_score": "0.09893",
          "ticker_sentiment_score": "0.076187",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings",
      "url": "https://www.zacks.com/stock/news/2449666/robust-specialty-diagnostics-segment-likely-to-aid-tmos-q1-earnings",
      "time_published": "20250416T113200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's first-quarter 2025 performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default202.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.215474,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VEEV",
          "relevance_score": "0.065957",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.065957",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.065957",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.259382",
          "ticker_sentiment_score": "0.244998",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pacemaker Devices Market Size to Reach USD 6.9 Billion by 2034, Driven by Minimally Invasive Techniques and Personalized Medicine | Transparency Market Research Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/09/g40856519/pacemaker-devices-market-size-to-reach-usd-6-9-billion-by-2034-driven-by-minimally-invasive-techni",
      "time_published": "20240913T151357",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- The global pacemaker devices market ( \uc2ec\uc7a5\ubc15\ub3d9\uae30 \uc7a5\uce58 \uc2dc\uc7a5 ) is estimated to surge at a CAGR of 3.8% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/fb2838b8-05ab-488b-80d2-737a1c2b815c/pacemaker-devices-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.431268,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.032961",
          "ticker_sentiment_score": "0.050574",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.065866",
          "ticker_sentiment_score": "0.197897",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.065866",
          "ticker_sentiment_score": "0.197897",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.098659",
          "ticker_sentiment_score": "0.053052",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.098659",
          "ticker_sentiment_score": "0.110089",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Down More Than 50% From Its High, Is DexCom Stock a Buy?",
      "url": "https://www.fool.com/investing/2024/10/09/down-more-than-50-from-high-dexcom-stock-buy/",
      "time_published": "20241009T101500",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Is DexCom's business in trouble, or could this be a great buying opportunity for investors?",
      "banner_image": "https://g.foolcdn.com/editorial/images/793107/person-checking-their-blood-sugar-levels-on-a-device.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999365"
        }
      ],
      "overall_sentiment_score": 0.126712,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.541766",
          "ticker_sentiment_score": "0.154086",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.065685",
          "ticker_sentiment_score": "0.215297",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "DexCom, Abbott to Launch First FDA Cleared OTC CGMs - Abbott Laboratories  ( NYSE:ABT ) , DaVita  ( NYSE:DVA ) ",
      "url": "https://www.benzinga.com/news/earnings/24/07/39649922/dexcom-abbott-to-launch-first-fda-cleared-otc-cgms",
      "time_published": "20240705T185811",
      "authors": [
        "Zacks"
      ],
      "summary": "DexCom Inc. DXCM and Abbott Laboratories ABT are likely to launch their first over-the-counter ( OTC ) continuous glucose monitors ( CGMs ) in the coming months of 2024.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/05/louis-reed-pwckf7l4-no-unsplash.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.96136"
        }
      ],
      "overall_sentiment_score": 0.269527,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.065685",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.098389",
          "ticker_sentiment_score": "0.084566",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.349665",
          "ticker_sentiment_score": "0.254546",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ECL",
          "relevance_score": "0.098389",
          "ticker_sentiment_score": "0.085628",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "At-home Testing Kits Market to be Worth USD 12.3 billion by 2034, Growing a CAGR 5.9% - Exclusive Report by Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41247090/at-home-testing-kits-market-to-be-worth-usd-12-3-billion-by-2034-growing-a-cagr-5-9-exclusive-repo",
      "time_published": "20241009T112000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- The global at-home testing kits market ( \uc7ac\ud0dd \ud14c\uc2a4\ud2b8 \ud0a4\ud2b8 \uc2dc\uc7a5 ) is estimated to ascend at a CAGR of 5.9% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/b71c9b0d-45cb-40b4-aef3-f436b4c53e18/at-home-testing-kits-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.373238,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.032825",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.065595",
          "ticker_sentiment_score": "0.161566",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OSUR",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.166496",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.055124",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Diamond Hill Mutual Funds for Higher Returns",
      "url": "https://www.zacks.com/stock/news/2261957/3-diamond-hill-mutual-funds-for-higher-returns",
      "time_published": "20240425T122100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Invests in Diamond Hill mutual funds like DHLSX, DHLTX and DHLAX for diversified investment opportunities across various asset classes.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/591.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.288551,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.050043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.050043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.050043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RRR",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.045037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.050043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WCC",
          "relevance_score": "0.065327",
          "ticker_sentiment_score": "0.045037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AIG",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.05856",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?",
      "url": "https://www.zacks.com/stock/news/2400636/dxcms-preliminary-results-show-strong-growth-how-to-play-the-stock",
      "time_published": "20250121T155000",
      "authors": [
        "Harshit Gupta"
      ],
      "summary": "DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if it's a buy or hold for your portfolio!",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.345595,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PODD",
          "relevance_score": "0.032602",
          "ticker_sentiment_score": "0.142728",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.06515",
          "ticker_sentiment_score": "0.209521",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.06515",
          "ticker_sentiment_score": "0.150265",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.65281",
          "ticker_sentiment_score": "0.493201",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "3 Things You Need to Know if You Buy AbbVie Stock Today",
      "url": "https://www.fool.com/investing/2024/09/09/3-things-you-need-to-know-if-you-buy-abbvie-stock/",
      "time_published": "20240909T160500",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "This dynamic big pharma is undergoing a few key changes.",
      "banner_image": "https://g.foolcdn.com/editorial/images/789927/doctor-and-businessman-working-on-digital-tablet-in-the-office.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.246889,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.193207",
          "ticker_sentiment_score": "0.149755",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.064973",
          "ticker_sentiment_score": "0.042028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.064973",
          "ticker_sentiment_score": "0.059427",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Cheap Dividend Growth Stocks to Buy Right Now",
      "url": "https://www.fool.com/investing/2025/06/04/3-cheap-dividend-growth-stocks-to-buy-right-now/",
      "time_published": "20250604T095000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effects of inflation.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820086%2Fa-couple-shaking-hands-with-an-advisor.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.752319"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.290094,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.285107",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.064104",
          "ticker_sentiment_score": "0.121118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.252332",
          "ticker_sentiment_score": "0.179826",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.394099",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Europe Molecular Diagnostics Market Size & Share to Surpass USD 17.3 billion by 2034 | Analysis by Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/09/g40944113/europe-molecular-diagnostics-market-size-share-to-surpass-usd-17-3-billion-by-2034-analysis-by-tra",
      "time_published": "20240919T164934",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- The Europe molecular diagnostics market is estimated to flourish at a CAGR of 10.2% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/1275d4a5-ef98-478c-97ff-9d57c607aed4/molecular-diagnostics-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.381384,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "0.231762",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "A",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "0.166617",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.318053",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GRFS",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.158971",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "0.212384",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ORYZF",
          "relevance_score": "0.031992",
          "ticker_sentiment_score": "0.158971",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.095771",
          "ticker_sentiment_score": "0.082276",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "BD  ( BDX )  Q3 Earnings Surpass Estimates, Margins Expand",
      "url": "https://www.zacks.com/stock/news/2314564/bd-bdx-q3-earnings-surpass-estimates-margins-expand",
      "time_published": "20240801T165700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.134097,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EW",
          "relevance_score": "0.031612",
          "ticker_sentiment_score": "0.165224",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.063174",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.125953",
          "ticker_sentiment_score": "0.021057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.125953",
          "ticker_sentiment_score": "0.019883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.125953",
          "ticker_sentiment_score": "0.115689",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Medtronic Stock a Buy?",
      "url": "https://www.fool.com/investing/2024/09/01/is-medtronic-stock-a-buy/",
      "time_published": "20240901T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It might not be the most exciting business, but it has other things going its way.",
      "banner_image": "https://g.foolcdn.com/editorial/images/788711/diabetes-patient-adjusting-device.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988915"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.255659,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.523784",
          "ticker_sentiment_score": "0.29039",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.063091",
          "ticker_sentiment_score": "0.136098",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Analyst Reports for SAP, Abbott Laboratories & Citigroup",
      "url": "https://www.zacks.com/research-daily/2307996/top-analyst-reports-for-sap-abbott-laboratories-citigroup",
      "time_published": "20240724T161400",
      "authors": [
        "Sheraz Mian"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.316384,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TISI",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.25078",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.040361",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?",
      "url": "https://www.fool.com/investing/2025/03/10/this-top-dividend-stock-just-entered-the-weight/",
      "time_published": "20250310T115700",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales.",
      "banner_image": "https://g.foolcdn.com/editorial/images/810254/pharmacist-talking-to-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.25668,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "0.074144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.654016",
          "ticker_sentiment_score": "0.377813",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "0.225566",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Investing $60,000 in These 3 Funds Could Generate Annual Income of Over $6,500",
      "url": "https://www.fool.com/investing/2025/04/13/investing-60000-in-these-3-funds-could-generate-an/",
      "time_published": "20250413T084900",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Income investors could pay attention to the price fluctuations of the assets they own. But they don't have to. What really matters for them is that the dividends and distributions keep flowing steadily -- and the higher the yield, the better.Where can you find great candidates to achieve these ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/814488/hands-behind-head.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.17892,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.137504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.137504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.031112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLFPF",
          "relevance_score": "0.124486",
          "ticker_sentiment_score": "0.235125",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MORN",
          "relevance_score": "0.124486",
          "ticker_sentiment_score": "0.043346",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.031112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.137504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.031112",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Neurology Devices Market is Expected to Reach USD 22,335.5 Million by 2035, Growing at 6.7% CAGR | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44216025/neurology-devices-market-is-expected-to-reach-usd-22-335-5-million-by-2035-growing-at-6-7-cagr-fac",
      "time_published": "20250310T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, March 10, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global neurology devices market is estimated to reach a valuation of USD 11,678 million in 2025 and is expected to grow at a CAGR of 6.7% during the forecast ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/b515a33e-a3b6-4fab-8264-fa93fc32b0a8/neurology-devices-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.245889,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NPCE",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NHNKF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.062271",
          "ticker_sentiment_score": "0.067009",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.062271",
          "ticker_sentiment_score": "0.067009",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EKTAY",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCRPF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.062271",
          "ticker_sentiment_score": "0.067009",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIVN",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRUMF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRSYF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IART",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEN",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.092761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.062271",
          "ticker_sentiment_score": "0.067009",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years",
      "url": "https://www.fool.com/investing/2024/11/08/1-stock-to-buy-near-its-52-week-low-and-hold-for/",
      "time_published": "20241108T151500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "This medical device company is down but not out.",
      "banner_image": "https://media.ycharts.com/charts/fbbb3077b2f24261ca34385e48193feb.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.156355,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.56296",
          "ticker_sentiment_score": "0.29265",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.022071",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Does Workday Have a Major Revenue Problem?",
      "url": "https://www.fool.com/investing/2024/09/12/does-workday-have-a-major-revenue-problem/",
      "time_published": "20240912T140800",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "Its top-line growth is slowing. However, there are some positive factors that could mitigate that.",
      "banner_image": "https://g.foolcdn.com/editorial/images/789376/a-group-of-people-gathered-around-a-table-in-an-office.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.995973"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.300135,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SHAK",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.212189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.212189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CCZ",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.212189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix",
      "url": "https://www.cnbc.com/2025/04/11/jim-cramers-week-ahead-earnings-from-goldman-sachs-netflix.html",
      "time_published": "20250411T225659",
      "authors": [],
      "summary": "CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        }
      ],
      "overall_sentiment_score": 0.102159,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.092248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.061315",
          "ticker_sentiment_score": "-0.089256",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068475",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.061315",
          "ticker_sentiment_score": "0.189097",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.061315",
          "ticker_sentiment_score": "-0.093149",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.061315",
          "ticker_sentiment_score": "0.104012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.118753",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.007024",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "-0.026897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.188978",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "-0.026897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.061315",
          "ticker_sentiment_score": "0.189097",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock",
      "url": "https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/",
      "time_published": "20241012T183100",
      "authors": [
        "Adam Spatacco"
      ],
      "summary": "BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.110608,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALT",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "-0.030155",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "-0.053275",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIOA",
          "relevance_score": "0.68145",
          "ticker_sentiment_score": "0.176071",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "0.053065",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "-0.036",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott Wins FDA Approval For Two Over-The-Counter Diabetes Trackers",
      "url": "https://www.forbes.com/sites/brucejapsen/2024/06/10/abbott-wins-fda-approval-for-two-over-the-counter-diabetes-trackers/",
      "time_published": "20240610T162109",
      "authors": [
        "Bruce Japsen"
      ],
      "summary": "Abbott Laboratories Monday said the U.S. Food and Drug Administration has cleared for sale two new over-the-counter continuous glucose monitoring systems, devices that could bring more access to millions of people with diabetes.",
      "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6525ab3937f6fb687889a34b/0x0.jpg?format=jpg&crop=2498,1406,x0,y125,safe&height=900&width=1600&fit=bounds",
      "source": "Forbes",
      "category_within_source": "n/a",
      "source_domain": "www.forbes.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.193842,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.060848",
          "ticker_sentiment_score": "0.043",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees",
      "url": "https://www.fool.com/investing/2025/01/14/3-high-yielding-dividend-stocks-that-could-be-idea/",
      "time_published": "20250114T101500",
      "authors": [
        "David Jagielski"
      ],
      "summary": "If you're a retiree looking for dependable and reliable dividend income, there are many quality stocks out there that can be suitable options for your portfolio. The stocks I've listed below pay above-average yields, grow their dividends on a regular basis, and aren't volatile investments.",
      "banner_image": "https://g.foolcdn.com/editorial/images/803651/senior-couple-looking-at-a-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.436332,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.405963",
          "ticker_sentiment_score": "0.491821",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.060694",
          "ticker_sentiment_score": "0.161035",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.457566",
          "ticker_sentiment_score": "0.528621",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.578296",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines",
      "url": "https://www.zacks.com/stock/news/2394452/angiodynamics-stock-up-on-q2-earnings-beat-gross-margin-declines",
      "time_published": "20250109T144800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/62145.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.092552,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BSX",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.118108",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.060541",
          "ticker_sentiment_score": "0.065",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.060541",
          "ticker_sentiment_score": "0.065",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stocks Likely To Open Higher Ahead Of Festive Weekend: 'Current Equity Levels Offer An Attractive Entry Opportunity' - Abbott Laboratories  ( NYSE:ABT ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",
      "url": "https://www.benzinga.com/government/regulations/25/04/44859233/us-stocks-likely-to-open-higher-ahead-of-festive-weekend-current-equity-levels-offer-an-at",
      "time_published": "20250417T101512",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "U.S. stock futures rose on Thursday ahead of the long weekend, with Good Friday falling on April 18 and Easter Sunday on April 20. Futures of major benchmark indices were higher in premarket. Federal Reserve Chairman Jerome Powell dismissed the possibility of a \"Fed put\" in the near term while ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/17/Wall-Street.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999975"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997874"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.121352,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.070998",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "-0.16083",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WDS",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.291211",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.029951",
          "ticker_sentiment_score": "0.221489",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BP",
          "relevance_score": "0.089685",
          "ticker_sentiment_score": "0.195448",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KOS",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.188032",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "-0.022039",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.121002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.318293",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.029951",
          "ticker_sentiment_score": "0.176221",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMD",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "-0.216062",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "RIO",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRV",
          "relevance_score": "0.05986",
          "ticker_sentiment_score": "0.318293",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNPRF",
          "relevance_score": "0.029951",
          "ticker_sentiment_score": "0.280227",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.17824",
          "ticker_sentiment_score": "0.03756",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Heart Failure Monitoring Systems Market Growth to Reach US$ 24,612.2 Million at a CAGR of 5.7% by 2034 | Fact.MR",
      "url": "https://www.benzinga.com/pressreleases/24/09/g40934283/heart-failure-monitoring-systems-market-growth-to-reach-us-24-612-2-million-at-a-cagr-of-5-7-by-20",
      "time_published": "20240919T100000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global heart failure monitoring systems market is estimated to reach a valuation of US$ 14,079.6 million in 2024 and is expected to grow at a CAGR of 5.7% during ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/c968a57a-0435-4f6e-bade-03aac87495ef/heart-failure-monitoring-systems-market.jpg",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.362841,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.059711",
          "ticker_sentiment_score": "0.016026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.089462",
          "ticker_sentiment_score": "0.031098",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.089462",
          "ticker_sentiment_score": "0.08166",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GE",
          "relevance_score": "0.119088",
          "ticker_sentiment_score": "0.018556",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.029876",
          "ticker_sentiment_score": "0.105544",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHG",
          "relevance_score": "0.059711",
          "ticker_sentiment_score": "0.016026",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend Stocks to Buy in May and Hold Forever",
      "url": "https://www.fool.com/investing/2025/05/10/2-high-yield-dividend-stocks-to-buy-in-may-and-hol/",
      "time_published": "20250510T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.Businesses that are solid enough to perform well over extended periods, while consistently raising ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F817503%2Felderly-person-sitting-on-a-bed.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.986714"
        }
      ],
      "overall_sentiment_score": 0.296452,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.499254",
          "ticker_sentiment_score": "0.472311",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.059636",
          "ticker_sentiment_score": "0.008014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.235252",
          "ticker_sentiment_score": "0.299975",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NVE Corp Gains After Posting Y/Y Earnings Rise in Q4, Eyes FY26 Growth",
      "url": "https://www.zacks.com/stock/news/2467113/nve-corp-gains-after-posting-yy-earnings-rise-in-q4-eyes-fy26-growth",
      "time_published": "20250512T172000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "NVEC's Q4 results reflect revenue growth and margin gains, fueled by R&D investments and strong demand for advanced magnetic sensor products.",
      "banner_image": "https://staticx-tuner.zacks.com/images/charts/13/1747065340.png",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        }
      ],
      "overall_sentiment_score": 0.235267,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVEC",
          "relevance_score": "0.290952",
          "ticker_sentiment_score": "0.244757",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.059488",
          "ticker_sentiment_score": "0.192024",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Reasons to Buy AbbVie Stock on the Dip",
      "url": "https://www.fool.com/investing/2024/05/05/3-reasons-to-buy-abbvie-stock-on-the-dip/",
      "time_published": "20240505T174400",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "A little patience with the drugmaker should pay off.",
      "banner_image": "https://g.foolcdn.com/editorial/images/774891/patient-taking-medicine.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.168056,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.542261",
          "ticker_sentiment_score": "0.293827",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "0.143438",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Much You'd Have If You Invested $1000 in Agilent Technologies a Decade Ago",
      "url": "https://www.zacks.com/stock/news/2514647/heres-how-much-youd-have-if-you-invested-1000-in-agilent-technologies-a-decade-ago",
      "time_published": "20250619T123004",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default334.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.216105,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.232996",
          "ticker_sentiment_score": "0.211755",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VECO",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SHMZF",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRKR",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HPQ",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.063089",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WAT",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Incredible Dividend Growth Stocks to Buy Now",
      "url": "https://www.fool.com/investing/2025/05/21/2-incredible-dividend-growth-stocks-to-buy-now/",
      "time_published": "20250521T104500",
      "authors": [
        "George Budwell"
      ],
      "summary": "Dividend growth stocks have long been reliable engines of wealth creation. Historically, companies with 10-year annualized dividend growth rates above 6% have consistently outperformed the S&P 500.The reason is simple. Sustained dividend growth typically signals strong underlying business ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F818901%2Fdividends.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.550044,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "0.460406",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058615",
          "ticker_sentiment_score": "0.240035",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes - Glucotrack Wants To Make It Easier - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ",
      "url": "https://www.benzinga.com/partner/health-care/24/08/40459450/continuous-blood-glucose-monitoring-can-materially-improve-the-quality-of-life-for-people-wit",
      "time_published": "20240820T120658",
      "authors": [
        "Meg Flippin"
      ],
      "summary": "You can't wing it when it comes to diabetes. Everything you eat and drink, the amount of physical activity you engage in and the medicines you take must be monitored closely. Keeping your blood glucose level within its target range is vital in preventing other medical issues.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.073867,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.058615",
          "ticker_sentiment_score": "-0.038007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GCTK",
          "relevance_score": "0.203094",
          "ticker_sentiment_score": "0.048642",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058615",
          "ticker_sentiment_score": "-0.007",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About",
      "url": "https://www.fool.com/investing/2025/04/03/3-high-yielding-dividend-stocks-that-retirees-can/",
      "time_published": "20250403T130000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "\"Buy and hold\" is a simple strategy for investors, but it can be a hard one to stick to in actual practice. That's because many people want to pick stocks and trade them, and feel like they need to actively intervene to generate significant gains.",
      "banner_image": "https://g.foolcdn.com/editorial/images/812980/seniors-walking-together.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.256423,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KMB",
          "relevance_score": "0.174167",
          "ticker_sentiment_score": "0.191595",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.230782",
          "ticker_sentiment_score": "0.172434",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058472",
          "ticker_sentiment_score": "0.023982",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.230782",
          "ticker_sentiment_score": "0.305921",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Where Will DexCom Be in 5 Years?",
      "url": "https://www.fool.com/investing/2024/10/18/where-will-dexcom-be-in-5-years/",
      "time_published": "20241018T120000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Recent developments might have scared away some investors, but patience could pay off.",
      "banner_image": "https://media.ycharts.com/charts/b59f065b39b7f3526c9cc44312ecdb4c.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.243012,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.658507",
          "ticker_sentiment_score": "0.41184",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05833",
          "ticker_sentiment_score": "0.099072",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This Is Great News for Medtronic, but Is It Time to Buy the Stock?",
      "url": "https://www.fool.com/investing/2024/08/26/great-news-for-medtronic-investors-time-to-buy/",
      "time_published": "20240826T130000",
      "authors": [
        "Dan Victor"
      ],
      "summary": "This MedTech leader is back on track with profitable growth.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788089%2Fgettyimages-2150701511-1200x800-5b2df79.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.993856"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.400165,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.657331",
          "ticker_sentiment_score": "0.541866",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.058188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Diabetes Monitoring Apps Don't Deliver Meaningful Benefits, Report Says",
      "url": "https://www.forbes.com/sites/brucejapsen/2024/03/21/report-questions-value-of-diabetes-monitoring-apps/",
      "time_published": "20240321T150000",
      "authors": [
        "Bruce Japsen"
      ],
      "summary": "Digital diabetes management tools \"fail to deliver meaningful benefits to patients\" while at the same time increasing the cost of healthcare to consumers, health insurers and taxpayers, a new report finds.",
      "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fb261cf7042485436c59aa/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
      "source": "Forbes",
      "category_within_source": "n/a",
      "source_domain": "www.forbes.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.245252,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRIO",
          "relevance_score": "0.058047",
          "ticker_sentiment_score": "0.023977",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058047",
          "ticker_sentiment_score": "0.023977",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.058047",
          "ticker_sentiment_score": "0.029054",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 High-Yielding Healthcare Stocks to Buy With $1,000 in July",
      "url": "https://www.fool.com/investing/2024/07/01/3-high-yielding-healthcare-stocks-to-buy-with-1000/",
      "time_published": "20240701T144800",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "These reliable dividend payers are no-brainer buys right now.",
      "banner_image": "https://g.foolcdn.com/editorial/images/782176/individual-investors-at-home-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999365"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.225924,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.388018",
          "ticker_sentiment_score": "0.244885",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.33628",
          "ticker_sentiment_score": "0.399523",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.10097",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "My Top 10 Stocks to Buy for 2025",
      "url": "https://www.fool.com/investing/2024/12/21/my-top-10-stocks-to-buy-for-2025/",
      "time_published": "20241221T090500",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan for the year ahead.It's been a solid year for many, with all three indexes heading for ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801386%2Fgettyimages-1070239362.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.294166,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.057698",
          "ticker_sentiment_score": "0.101011",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRMNF",
          "relevance_score": "0.028868",
          "ticker_sentiment_score": "0.271297",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.057698",
          "ticker_sentiment_score": "0.189079",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.057698",
          "ticker_sentiment_score": "0.125112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRWD",
          "relevance_score": "0.115094",
          "ticker_sentiment_score": "0.172189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ETSY",
          "relevance_score": "0.199977",
          "ticker_sentiment_score": "0.029445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.057698",
          "ticker_sentiment_score": "0.239009",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.115094",
          "ticker_sentiment_score": "0.231631",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.171892",
          "ticker_sentiment_score": "0.119767",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.115094",
          "ticker_sentiment_score": "0.101426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.057698",
          "ticker_sentiment_score": "0.025011",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yield Dividend Stocks That Still Look Like Bargains",
      "url": "https://www.fool.com/investing/2024/07/14/3-high-yield-dividend-stocks-that-still-look-like/",
      "time_published": "20240714T082700",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "The prices of these reliable dividend payers haven't kept pace with the frothy stock market.",
      "banner_image": "https://g.foolcdn.com/editorial/images/783254/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.208126,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADC",
          "relevance_score": "0.27838",
          "ticker_sentiment_score": "0.266088",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CURN",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "-0.012004",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.382088",
          "ticker_sentiment_score": "0.3892",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.098933",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.169279",
          "ticker_sentiment_score": "0.298133",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Down 40% in 1 Day, Is DexCom Stock Still a Buy?",
      "url": "https://www.fool.com/investing/2024/08/06/down-40-in-1-day-is-dexcom-stock-still-a-buy/",
      "time_published": "20240806T110000",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "Competition and new growth headwinds could derail the stock even further.",
      "banner_image": "https://g.foolcdn.com/editorial/images/785365/two-investors-look-at-figures.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.996718"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.063306,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.477704",
          "ticker_sentiment_score": "0.031623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "0.049",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "0.049",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Digital PCR and Real-Time PCR Market Size Worth USD 17.54 billion by 2031 at 9.1% CAGR | The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45493282/digital-pcr-and-real-time-pcr-market-size-worth-usd-17-54-billion-by-2031-at-9-1-cagr-the-insight-",
      "time_published": "20250519T133333",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 19, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global digital PCR and real-time PCR market is witnessing substantial growth with the surging incidence of genetic and infectious diseases and rising investments in gene ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.271131,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.042015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.101989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.101989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.028288",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.118143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.101989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.110138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.028288",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "My Favorite Dividend King to Buy in November",
      "url": "https://www.fool.com/investing/2024/11/09/abbvie/",
      "time_published": "20241109T104800",
      "authors": [
        "Keith Speights"
      ],
      "summary": "This Dividend King truly wears the crown.",
      "banner_image": "https://g.foolcdn.com/editorial/images/796634/king-chess-piece-held-by-woman.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.335795,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.564693",
          "ticker_sentiment_score": "0.458944",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is DexCom a Millionaire Maker?",
      "url": "https://www.fool.com/investing/2024/09/25/is-dexcom-a-millionaire-maker/",
      "time_published": "20240925T120700",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "It isn't the most likely candidate to make someone a millionaire, but it's theoretically possible.",
      "banner_image": "https://g.foolcdn.com/editorial/images/790548/doctors-with-investors.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972756"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.247732,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.277118",
          "ticker_sentiment_score": "0.128403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.14695",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Rock-Solid Dividend Stocks That Are Ideal for Retirees",
      "url": "https://www.fool.com/investing/2024/05/10/3-rock-solid-dividend-stocks-ideal-for-retirees/",
      "time_published": "20240510T133000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "These are low-risk stocks with high yields.",
      "banner_image": "https://g.foolcdn.com/editorial/images/775891/couple-using-a-computer.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.254137,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERE",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "-0.03902",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "0.133645",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.124934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "T",
          "relevance_score": "0.277118",
          "ticker_sentiment_score": "0.102301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.05271",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer",
      "url": "https://www.fool.com/investing/2024/09/01/2-high-yield-dividend-stocks-to-buy-in-september-a/",
      "time_published": "20240901T095300",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "A drugmaker and a telecom business have what it takes to safely boost your passive income stream.",
      "banner_image": "https://g.foolcdn.com/editorial/images/789010/investors-evaluating-a-stock-purchase-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.206401,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "T",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.160048",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.328819",
          "ticker_sentiment_score": "0.231537",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.058914",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Does This Move Make Medtronic Stock a Buy?",
      "url": "https://www.fool.com/investing/2025/05/31/does-this-move-make-medtronic-stock-a-buy/",
      "time_published": "20250531T114500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Over the past few years, Medtronic ( NYSE: MDT ) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F819805%2Fpatient-self-administering-a-shot.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.407297,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.056011",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.76767",
          "ticker_sentiment_score": "0.587022",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.056011",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.056011",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2024/11/26/2-high-yield-dividend-stocks-to-buy-now-for-a-life/",
      "time_published": "20241126T100300",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the ...",
      "banner_image": "https://media.ycharts.com/charts/34d49543d4741856f5330321da34b958.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.220953,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BHVN",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.098877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.273399",
          "ticker_sentiment_score": "0.08876",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.102879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.37552",
          "ticker_sentiment_score": "0.427768",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs",
      "url": "https://www.fool.com/investing/2024/10/31/5-dividend-stocks-to-double-up-on-right-now/",
      "time_published": "20241031T093000",
      "authors": [
        "Selena Maranjian"
      ],
      "summary": "It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795426%2Fgetty-hiking-outdoors-beard.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999975"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.247253,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MO",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.033122",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "-0.02202",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "-0.02202",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.11123",
          "ticker_sentiment_score": "0.209389",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.064112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "O",
          "relevance_score": "0.11123",
          "ticker_sentiment_score": "0.060634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Beat the Nasdaq With This Cash-Gushing Dividend Stock",
      "url": "https://www.fool.com/investing/2024/10/23/beat-the-nasdaq-with-this-cash-gushing-dividend-st/",
      "time_published": "20241023T105000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "The company is performing well despite recently losing its biggest growth driver.",
      "banner_image": "https://media.ycharts.com/charts/1e4214ac7ed64e44b91332f6a4fbd401.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.209965,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.091987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.091987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.558244",
          "ticker_sentiment_score": "0.251438",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.116997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.11123",
          "ticker_sentiment_score": "0.064919",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
      "url": "https://www.fool.com/investing/2024/04/09/3-dividend-growth-stocks-with-yields-above-3-that/",
      "time_published": "20240409T082100",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Income-seeking investors can look forward to steady payout raises from these pharma stocks.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772112%2Finvestor-stock-charts-laptop-getty.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.207428,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.057886",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.083778",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "-0.058885",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWAV",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.027025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.220308",
          "ticker_sentiment_score": "0.217001",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.06886",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Pharmaceutical Stocks to Buy Hand Over Fist in March",
      "url": "https://www.fool.com/investing/2024/03/11/3-pharmaceutical-stocks-to-buy-hand-over-fist-in/",
      "time_published": "20240311T132800",
      "authors": [
        "Justin Pope"
      ],
      "summary": "There are some great companies at attractive prices in the lucrative pharmaceutical space.",
      "banner_image": "https://g.foolcdn.com/editorial/images/767295/drug-development-pharmaceutical-pharma-research-researchers-doctors-1.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.234754,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.219809",
          "ticker_sentiment_score": "0.063941",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055621",
          "ticker_sentiment_score": "0.035129",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DNA",
          "relevance_score": "0.272788",
          "ticker_sentiment_score": "0.151968",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.219809",
          "ticker_sentiment_score": "0.196",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Excellent Dividend Stocks to Buy on the Dip",
      "url": "https://www.fool.com/investing/2024/12/23/2-excellent-dividend-stocks-to-buy-on-the-dip/",
      "time_published": "20241223T093200",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their ...",
      "banner_image": "https://media.ycharts.com/charts/4bcb02efb3ae79099f939b6b71ea724e.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.26662,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.512596",
          "ticker_sentiment_score": "0.31906",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055364",
          "ticker_sentiment_score": "0.085",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.373112",
          "ticker_sentiment_score": "0.395561",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.055364",
          "ticker_sentiment_score": "0.077088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.055364",
          "ticker_sentiment_score": "0.21904",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.",
      "url": "https://www.fool.com/investing/2024/04/09/forget-viking-therapeutics-heres-1-weight-loss-sto/",
      "time_published": "20240409T104500",
      "authors": [
        "Adam Spatacco"
      ],
      "summary": "Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771899%2Fgettyimages-1429005115.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.212999,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALT",
          "relevance_score": "0.594257",
          "ticker_sentiment_score": "0.31462",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.110209",
          "ticker_sentiment_score": "0.254587",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055236",
          "ticker_sentiment_score": "0.099032",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.218325",
          "ticker_sentiment_score": "0.06582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.055236",
          "ticker_sentiment_score": "-0.047873",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Reasons to Buy Medtronic Stock Like There's No Tomorrow",
      "url": "https://www.fool.com/investing/2025/01/28/3-reasons-to-buy-medtronic-stock-like-no-tomorrow/",
      "time_published": "20250128T144500",
      "authors": [
        "Dan Victor"
      ],
      "summary": "This medtech giant is leveraging the power of artificial intelligence for a strong growth outlook.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F805187%2Fmedtronic-bullish-stock-price-outlook-2025.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.492022,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.147864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.147864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.147864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.510588",
          "ticker_sentiment_score": "0.571713",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.147864",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Neurorehabilitation Devices Market Size to Reach US$ 7.09 Billion by 2031, Driven by Technological Advancements and Rising Neurological Disorders",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43268472/neurorehabilitation-devices-market-size-to-reach-us-7-09-billion-by-2031-driven-by-technological-a",
      "time_published": "20250128T143406",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- According to a comprehensive report from The Insight Partners, \"Neurorehabilitation Devices Market Size and Forecast ( 2021 - 2031 ) , Global and Regional Share, Trend, and Growth Opportunity Analysis Report \".",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/9b945e59-33c0-4f1a-a9db-48c982da0236/image1.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.253161,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EKSO",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DNPUF",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.197901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SSUMF",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.197901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MAAL",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.197901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WLDS",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.065831",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNSHF",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income",
      "url": "https://www.fool.com/investing/2024/08/17/3-high-yielding-dividend-growth-stocks-that-retire/",
      "time_published": "20240817T140000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.",
      "banner_image": "https://g.foolcdn.com/editorial/images/786770/a-person-counting-money-in-their-living-room.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999967"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.356372,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PLD",
          "relevance_score": "0.320279",
          "ticker_sentiment_score": "0.520726",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CERE",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.119432",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.417995",
          "ticker_sentiment_score": "0.444782",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.033885",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.369946",
          "ticker_sentiment_score": "0.222933",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2025/03/07/2-dividend-stocks-to-buy-for-a-lifetime-of-passive/",
      "time_published": "20250307T100300",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.",
      "banner_image": "https://g.foolcdn.com/editorial/images/809353/physician-giving-medicine-to-elderly-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.2653,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.506613",
          "ticker_sentiment_score": "0.37115",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.462395",
          "ticker_sentiment_score": "0.324747",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.114801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Got $200? 2 Healthcare Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2025/02/26/got-200-2-healthcare-stocks-to-buy-and-hold-foreve/",
      "time_published": "20250226T093200",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns.",
      "banner_image": "https://media.ycharts.com/charts/97e6e50f60cb0732ccf5e46ac333c9d8.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.372198,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.415413",
          "ticker_sentiment_score": "0.466122",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054483",
          "ticker_sentiment_score": "0.251942",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.215415",
          "ticker_sentiment_score": "0.210136",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Jim Cramer's top 10 things to watch in the stock market Thursday",
      "url": "https://www.cnbc.com/2024/08/22/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html",
      "time_published": "20240822T130623",
      "authors": [],
      "summary": "Citi backs Nvidia ahead of earnings, while James Gorman is in charge of Disney's succession planning.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998682"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.17351,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.162073",
          "ticker_sentiment_score": "0.128639",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.049002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.070025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.214937",
          "ticker_sentiment_score": "0.075724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TJX",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.070025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.020059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.005555",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.16055",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.117781",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DELL",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.020059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "URBN",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.110261",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.",
      "url": "https://www.fool.com/investing/2024/08/05/worried-about-a-market-correction-2-high-yield-div/",
      "time_published": "20240805T095600",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.",
      "banner_image": "https://g.foolcdn.com/editorial/images/785854/smart-investor-looking-at-stock-charts-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.050877,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.266828",
          "ticker_sentiment_score": "0.068603",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.054981",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.266828",
          "ticker_sentiment_score": "0.237324",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?",
      "url": "https://www.fool.com/investing/2024/10/06/billionaires-are-loading-up-on-this-high-yield-div/",
      "time_published": "20241006T083100",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Declining earnings haven't scared billionaire investors away from this stock.",
      "banner_image": "https://g.foolcdn.com/editorial/images/792959/investor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.247688,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.585687",
          "ticker_sentiment_score": "0.37233",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054236",
          "ticker_sentiment_score": "0.200856",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BGNE",
          "relevance_score": "0.054236",
          "ticker_sentiment_score": "-0.055095",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2025/07/05/want-decades-of-passive-income-3-stocks-to-buy-now/",
      "time_published": "20250705T094100",
      "authors": [
        "Keith Speights"
      ],
      "summary": "There's a strong parallel between investing for passive income and planting an apple tree. Both require some work up front. But if all goes well, you can reap the fruits of those labors ( literally, in the case of the apple tree ) for years afterward.Of course, there are some potential pitfalls.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F823590%2Fpassive-income.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.321757,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENB",
          "relevance_score": "0.365294",
          "ticker_sentiment_score": "0.350273",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.412861",
          "ticker_sentiment_score": "0.431858",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054114",
          "ticker_sentiment_score": "0.081766",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "O",
          "relevance_score": "0.265666",
          "ticker_sentiment_score": "0.29213",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer",
      "url": "https://markets.businessinsider.com/news/stocks/tricares-announces-the-appointment-of-ahmed-elmouelhi-as-president-chief-executive-officer-1033191681",
      "time_published": "20240325T060000",
      "authors": [
        "markets.businessinsider.com"
      ],
      "summary": "Paris, France and Munich, Germany, March 25, 2024 - TRiCares SAS ( \"TRiCares\" ) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer ( CEO ) .",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b7926093-fc48-4e23-bec8-3dc7cbed4110/image2.jpeg",
      "source": "Business Insider",
      "category_within_source": "RSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.325206,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.127",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATRC",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.127",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.127",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks You Can Safely Hold Through a Recession",
      "url": "https://www.fool.com/investing/2024/09/02/2-dividend-stocks-you-can-safely-hold-through-a/",
      "time_published": "20240902T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These stocks can help you sleep peacefully at night, even in bad times.",
      "banner_image": "https://g.foolcdn.com/editorial/images/788898/doctor-with-patient-talking.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.210419,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.264515",
          "ticker_sentiment_score": "0.155202",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05387",
          "ticker_sentiment_score": "0.072757",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "If You Invested $1000 in AbbVie a Decade Ago, This is How Much It'd Be Worth Now",
      "url": "https://www.zacks.com/stock/news/2291993/if-you-invested-1000-in-abbvie-a-decade-ago-this-is-how-much-itd-be-worth-now",
      "time_published": "20240624T123002",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default164.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.180042,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.720339",
          "ticker_sentiment_score": "0.308289",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05387",
          "ticker_sentiment_score": "-0.025004",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Growth Stocks to Buy and Hold for a Decade",
      "url": "https://www.fool.com/investing/2025/05/02/2-growth-stocks-to-buy-and-hold-for-a-decade/",
      "time_published": "20250502T081600",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid.",
      "banner_image": "https://media.ycharts.com/charts/6cd81df73bedee4e7a8dc102841aea0d.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.972756"
        }
      ],
      "overall_sentiment_score": 0.299935,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MELI",
          "relevance_score": "0.455978",
          "ticker_sentiment_score": "0.266688",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.410338",
          "ticker_sentiment_score": "0.446274",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.053749",
          "ticker_sentiment_score": "0.1036",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bull Market Buys: 2 Growth Stocks to Own for the Long Haul",
      "url": "https://www.fool.com/investing/2024/06/03/bull-market-buys-2-growth-stocks-to-own-for-the/",
      "time_published": "20240603T114500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Innovation is paying off for both of these medical device specialists.",
      "banner_image": "https://g.foolcdn.com/editorial/images/778453/physicians-in-an-operating-room.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.149762,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MFCSF",
          "relevance_score": "0.05339",
          "ticker_sentiment_score": "0.009998",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05339",
          "ticker_sentiment_score": "0.082705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.407844",
          "ticker_sentiment_score": "0.128562",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "0.195038",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is AbbVie Stock a Buy?",
      "url": "https://www.fool.com/investing/2025/04/20/is-abbvie-stock-a-buy/",
      "time_published": "20250420T121500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "The pharmaceutical giant has been a roller coaster over the past several months.",
      "banner_image": "https://media.ycharts.com/charts/2318a3cb70f1b8b9bf80349e81121021.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.069931,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SPGI",
          "relevance_score": "0.052918",
          "ticker_sentiment_score": "-0.057939",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.71174",
          "ticker_sentiment_score": "0.194376",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052918",
          "ticker_sentiment_score": "0.053728",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200",
      "url": "https://www.fool.com/investing/2024/08/18/2-unstoppable-healthcare-stocks-to-buy-right-now/",
      "time_published": "20240818T144500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These companies' growth paths should only be briefly interrupted by headwinds.",
      "banner_image": "https://media.ycharts.com/charts/a2321f70eae9ea118150d0a6bc3e2c59.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.264664,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.49219",
          "ticker_sentiment_score": "0.368067",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GRWC",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.270837",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.075066",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?",
      "url": "https://www.fool.com/investing/2024/07/22/abbvie-could-soar-24-according-to-a-wall-street-an/",
      "time_published": "20240722T144100",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "The big pharma company's top drug is losing ground, but its dividend keeps rising.",
      "banner_image": "https://media.ycharts.com/charts/3dfbc2d588b6bc329a81fadb412211f4.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.103354,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.063998",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BGNE",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "-0.048034",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "-0.048034",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.357049",
          "ticker_sentiment_score": "0.193114",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVNC",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "-0.058001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ",
      "url": "https://www.benzinga.com/partner/health-care/24/10/41162090/expanding-continuous-glucose-monitoring-options-how-glucotrack-is-helping-usher-in-the-next-g",
      "time_published": "20241003T120306",
      "authors": [
        "Joshenomoto@benzinga.com"
      ],
      "summary": "Introduced in the late 1990s, continuous glucose monitoring ( CGM ) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring ( BGM ) methodologies - which involve patients using a lancet to prick their fingers and apply a drop of blood to a test strip - represented the norm.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/03/Screenshot-2024-10-03-at-5-30-47PM.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.1396,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GCTK",
          "relevance_score": "0.307603",
          "ticker_sentiment_score": "0.116885",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.130596",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.078783",
          "ticker_sentiment_score": "0.107187",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.078783",
          "ticker_sentiment_score": "-0.003077",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DexCom Is Great. Here's Why You Shouldn't Buy It.",
      "url": "https://www.fool.com/investing/2024/09/25/dexcom-is-great-heres-why-you-shouldnt-buy-it/",
      "time_published": "20240925T134500",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "Two key uncertainties make the prospect of buying it today riskier than is desirable.",
      "banner_image": "https://media.ycharts.com/charts/a45f74f7ab0caee33f8f304d48e56e8f.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988915"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.197055,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.307603",
          "ticker_sentiment_score": "0.175968",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.077999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "-0.013009",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200",
      "url": "https://www.fool.com/investing/2024/09/14/2-unstoppable-healthcare-stocks-to-buy-right-now-f/",
      "time_published": "20240914T093000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "No need to break the bank to get in on these excellent companies.",
      "banner_image": "https://media.ycharts.com/charts/afbb325916a5bf3ec0bf2c08d120daf7.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.276063,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.079634",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTRCF",
          "relevance_score": "0.104911",
          "ticker_sentiment_score": "0.231754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.402135",
          "ticker_sentiment_score": "0.23158",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.356008",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker Testing Gains Momentum",
      "url": "https://www.prnewswire.com/news-releases/japan-in-vitro-diagnostics-market-analysis-report-2024-2030-strategic-partnerships-drive-innovations-tumor-marker-testing-gains-momentum-302085636.html",
      "time_published": "20240312T023000",
      "authors": [
        "Research and Markets"
      ],
      "summary": "Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker ... PR ...",
      "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.204707,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.226323",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ONTTF",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.117906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.117906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.226323",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.117906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.117906",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.",
      "url": "https://www.fool.com/investing/2025/03/12/worried-about-a-market-meltdown-2-dividend-stocks/",
      "time_published": "20250312T111000",
      "authors": [
        "Bradley Guichard"
      ],
      "summary": "I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.The new administration wasted no time implementing many policies, including sweeping layoffs of federal employees and tariffs and tariff threats.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F810419%2Fvici.png&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.206122,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.17991",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VICI",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.164697",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CZR",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.095991",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.256719",
          "ticker_sentiment_score": "0.175644",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.155",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer",
      "url": "https://www.benzinga.com/pressreleases/24/09/g40874218/abata-therapeutics-appoints-joanne-beck-ph-d-as-chief-technical-officer",
      "time_published": "20240916T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "WATERTOWN, Mass., Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.273548,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ATXS",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "-0.022833",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "-0.022833",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.115902",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.115902",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors - Elanco Animal Health  ( NYSE:ELAN ) ",
      "url": "https://www.benzinga.com/pressreleases/24/04/n38018168/elanco-appoints-two-animal-health-industry-executives-kathy-turner-and-craig-wallace-to-its-board-",
      "time_published": "20240401T103000",
      "authors": [
        "PRNewswire"
      ],
      "summary": "New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated ELAN today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors ( ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.217498,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IDXX",
          "relevance_score": "0.051886",
          "ticker_sentiment_score": "0.065606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CEVA",
          "relevance_score": "0.051886",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051886",
          "ticker_sentiment_score": "0.065606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ELAN",
          "relevance_score": "0.129237",
          "ticker_sentiment_score": "0.268143",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TRUP",
          "relevance_score": "0.051886",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Transformative Growth Expected In The Global Medical Equipment Market: Market Size To Reach $1,077 Billion By 2028 As Per The Business Research Company's Medical Equipment Global Market Report 2024",
      "url": "https://www.benzinga.com/pressreleases/24/04/g38072444/transformative-growth-expected-in-the-global-medical-equipment-market-market-size-to-reach-1-077-b",
      "time_published": "20240403T153000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Medical Equipment Global Market Report 2024, the medical equipment market has witnessed robust growth in recent years, with the market size expected to reach $775.42 billion in 2024, reflecting a compound annual ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.338179,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.299729",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.126428",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.126428",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.126428",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Better Dividend Stock: AbbVie or Johnson & Johnson?",
      "url": "https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/",
      "time_published": "20240428T082000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "One thing is for sure: Dividend seekers can't go wrong with either.",
      "banner_image": "https://media.ycharts.com/charts/606ca6d7bad2ded63e4e23f32d1c43b2.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.215112,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.596349",
          "ticker_sentiment_score": "0.286691",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051221",
          "ticker_sentiment_score": "0.025897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.479385",
          "ticker_sentiment_score": "0.29997",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend ETFs to Buy to Generate Passive Income",
      "url": "https://www.fool.com/investing/2025/02/23/2-high-yield-dividend-etfs-to-buy-to-generate-pass/",
      "time_published": "20250223T120000",
      "authors": [
        "Neha Chamaria"
      ],
      "summary": "With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income.",
      "banner_image": "https://media.ycharts.com/charts/47f5b420ec09df618169e8653a7e76f4.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.315329,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.051111",
          "ticker_sentiment_score": "0.232927",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "0.222142",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051111",
          "ticker_sentiment_score": "0.253579",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.25142",
          "ticker_sentiment_score": "0.109944",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "0.137198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.253458",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2024/12/15/want-decades-passive-income-stocks-buy-and-hold/",
      "time_published": "20241215T103500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.",
      "banner_image": "https://g.foolcdn.com/editorial/images/800052/forever-investing.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.243192,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.391158",
          "ticker_sentiment_score": "0.122827",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "-0.028898",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.250902",
          "ticker_sentiment_score": "0.311697",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.29887",
          "ticker_sentiment_score": "0.34943",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/09/05/got-1000-healthcare-stocks-buy-and-hold-forever/",
      "time_published": "20240905T085000",
      "authors": [
        "Justin Pope"
      ],
      "summary": "There is something for everybody in America's $4.5 trillion healthcare market.",
      "banner_image": "https://g.foolcdn.com/editorial/images/787539/healthcare-nurse.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.988915"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.379156,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.345674",
          "ticker_sentiment_score": "0.374821",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.214468",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.152178",
          "ticker_sentiment_score": "0.199721",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.345674",
          "ticker_sentiment_score": "0.381327",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CVRx Announces Key Senior Leadership Team Hires",
      "url": "https://www.globenewswire.com/news-release/2024/05/16/2883291/0/en/CVRx-Announces-Key-Senior-Leadership-Team-Hires.html",
      "time_published": "20240516T113000",
      "authors": [
        "CVRx",
        "Inc."
      ],
      "summary": "MINNEAPOLIS, May 16, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( \"CVRx\" ) , a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP ( Ed ) has been appointed as Chief Medical Officer, ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/04c4feba-7841-4ac8-8ca5-6c03be383a0e",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.241974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.055976",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVRX",
          "relevance_score": "0.477606",
          "ticker_sentiment_score": "0.309363",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.086006",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors",
      "url": "https://www.prnewswire.com/news-releases/elanco-appoints-two-animal-health-industry-executives-kathy-turner-and-craig-wallace-to-its-board-of-directors-302104172.html",
      "time_published": "20240401T103000",
      "authors": [
        "Elanco Animal Health"
      ],
      "summary": "New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee",
      "banner_image": "https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.199018,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IDXX",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.065521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CEVA",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.065521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ELAN",
          "relevance_score": "0.226536",
          "ticker_sentiment_score": "0.315243",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TRUP",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Syphilis Immunoassay Diagnostics Market Expands with Innovations in Screening and Detection Techniques, Projected to Reach USD 978.5 Million by 2034 | Transparency Market Research",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42953478/syphilis-immunoassay-diagnostics-market-expands-with-innovations-in-screening-and-detection-techni",
      "time_published": "20250113T170124",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. -, Jan. 13, 2025 ( GLOBE NEWSWIRE ) -- The global syphilis immunoassay diagnostics market ( \u6885\u6bd2\u514d\u75ab\u6e2c\u5b9a\u8a3a\u65ad\u5e02\u5834 ) was valued at US$ 548.5 million in 2023. It is projected to grow at a robust CAGR of 5.5% during the forecast period from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/88014c02-7d39-42bd-9ca1-e68a5dccc1ae/syphilis-immunoassay-diagnostics-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.301163,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BIO",
          "relevance_score": "0.050572",
          "ticker_sentiment_score": "0.110332",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.050572",
          "ticker_sentiment_score": "0.055529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050572",
          "ticker_sentiment_score": "0.324689",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.150906",
          "ticker_sentiment_score": "0.096125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.050572",
          "ticker_sentiment_score": "0.278559",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is AbbVie Stock a Buy?",
      "url": "https://www.fool.com/investing/2025/01/24/is-abbvie-stock-a-buy/",
      "time_published": "20250124T104800",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F803391%2Fabbvie-long-term-sales-projection.png&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.389474,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.624423",
          "ticker_sentiment_score": "0.601047",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050465",
          "ticker_sentiment_score": "0.122299",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Retain Edward Lifesciences  ( EW )  for Now",
      "url": "https://www.zacks.com/stock/news/2278839/heres-why-you-should-retain-edward-lifesciences-ew-for-now",
      "time_published": "20240524T145700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999483"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        }
      ],
      "overall_sentiment_score": 0.241167,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.199859",
          "ticker_sentiment_score": "0.065974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EHC",
          "relevance_score": "0.199859",
          "ticker_sentiment_score": "0.112734",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.387374",
          "ticker_sentiment_score": "0.358704",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050465",
          "ticker_sentiment_score": "0.146287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.050465",
          "ticker_sentiment_score": "0.146287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RMD",
          "relevance_score": "0.199859",
          "ticker_sentiment_score": "0.077141",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.050465",
          "ticker_sentiment_score": "0.146287",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Growth Stocks to Buy in the Tariff-Fueled Market Correction",
      "url": "https://www.fool.com/investing/2025/04/10/2-growth-stocks-to-buy-in-the-tariff-fueled-market/",
      "time_published": "20250410T141500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy. Unless a company's investment thesis has changed because of recent developments, market downturns aren't a good enough reason for most investors to sell.For those who can ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/814137/person-sitting-at-a-desk-looking-at-two-monitors.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.138482,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.149966",
          "ticker_sentiment_score": "0.110262",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.263792",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.016905",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Vegan Food Market to Excel USD 40.53 Billion by 2031 | SkyQuest",
      "url": "https://www.benzinga.com/pressreleases/24/07/g39748127/vegan-food-market-to-excel-usd-40-53-billion-by-2031-skyquest",
      "time_published": "20240712T123355",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Westford, USA, July 12, 2024 ( GLOBE NEWSWIRE ) -- Global Vegan Food Market size was valued at around USD 16.5 Billion in 2022 and is poised to grow from USD Billion 18.23 in 2023 to USD 40.53 Billion by 2031, at a CAGR of 10.5% over the forecast period ( 2024-2031 ) .",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.313946,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CAG",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GIS",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BC",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is AbbVie a Millionaire Maker?",
      "url": "https://www.fool.com/investing/2024/04/14/is-abbvie-a-millionaire-maker/",
      "time_published": "20240414T052300",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "Everything is going according to plan, and more growth is on the way.",
      "banner_image": "https://g.foolcdn.com/editorial/images/771959/two-investors-consider-a-stock-with-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.324719,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.414875",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "0.174265",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill",
      "url": "https://www.fool.com/investing/2025/07/11/what-good-dividend-stock-healthcare-stocks-buy/",
      "time_published": "20250711T075500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "A steady dose of quality companies will keep your portfolio growing big and strong.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F824227%2Fstacking-blocks-up-arrows.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.357602,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.060822",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.338913",
          "ticker_sentiment_score": "0.369126",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.157193",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.338913",
          "ticker_sentiment_score": "0.462861",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.133026",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adobe Stock Slips 20% in a Week: Should You Brace for a Tough 2025?",
      "url": "https://www.zacks.com/stock/news/2385862/adobe-stock-slips-20-in-a-week-should-you-brace-for-a-tough-2025",
      "time_published": "20241219T162300",
      "authors": [
        "Aniruddha Ganguly"
      ],
      "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele amid increasing competition and stretched valuation.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        }
      ],
      "overall_sentiment_score": 0.284965,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.121928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.194833",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.055468",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "-0.016966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.081987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "-0.016966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.081987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.081987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.765945",
          "ticker_sentiment_score": "0.399433",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.081987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HUBS",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.194833",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.149038",
          "ticker_sentiment_score": "0.0706",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?",
      "url": "https://www.fool.com/investing/2024/08/08/these-stocks-just-dropped-by-40-and-15-should-you/",
      "time_published": "20240808T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It might be a great time to buy low.",
      "banner_image": "https://g.foolcdn.com/editorial/images/785566/dexcom-g6-full-family.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.972756"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.206535,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.338251",
          "ticker_sentiment_score": "0.094051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049835",
          "ticker_sentiment_score": "0.027685",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PINS",
          "relevance_score": "0.338251",
          "ticker_sentiment_score": "0.351101",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement",
      "url": "https://www.globenewswire.com/news-release/2025/05/21/3086209/0/en/Senseonics-Holdings-Inc-Announces-Closing-of-Public-Offering-Including-Exercise-in-Full-of-the-Underwriters-Option-to-Purchase-Additional-Shares-and-Closing-of-Private-Placement.html",
      "time_published": "20250521T210600",
      "authors": [
        "Senseonics Holdings",
        "Inc."
      ],
      "summary": "GERMANTOWN, Md., May 21, 2025 ( GLOBE NEWSWIRE ) -- Senseonics Holdings, Inc. ( NYSE American: SENS ) , a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring ( CGM ) systems for people with diabetes, today announced the ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/78f68bac-fb37-47d9-af74-1c8b3b06cfde",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.993856"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.105165,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BR",
          "relevance_score": "0.049629",
          "ticker_sentiment_score": "0.060403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049629",
          "ticker_sentiment_score": "0.172141",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.099066",
          "ticker_sentiment_score": "0.056042",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
      "url": "https://www.fool.com/investing/2024/12/03/3-high-yield-dividend-growth-stocks-to-buy-in-dece/",
      "time_published": "20241203T092400",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 ( SNPINDEX: ^GSPC ) index rose a whopping 57.1% higher.During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.",
      "banner_image": "https://g.foolcdn.com/editorial/images/799277/board-room-chart-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.275012,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.156113",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.196212",
          "ticker_sentiment_score": "0.173649",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.196212",
          "ticker_sentiment_score": "0.163973",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.149845",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIPC",
          "relevance_score": "0.380736",
          "ticker_sentiment_score": "0.427828",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Stock Market Shows Bearish Action: Weekly Review",
      "url": "https://www.investors.com/news/stock-market-taiwan-semiconductor-asml-netflix-united-airlines-weekly-review/",
      "time_published": "20240419T165100",
      "authors": [
        "IBD STAFF",
        "Investor's Business Daily"
      ],
      "summary": "Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.041784,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "-0.148103",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.098862",
          "ticker_sentiment_score": "-0.034689",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBKR",
          "relevance_score": "0.098862",
          "ticker_sentiment_score": "0.102009",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.108439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.108439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.071953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLB",
          "relevance_score": "0.123399",
          "ticker_sentiment_score": "0.018007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BK",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.108439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.105983",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.108869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.004134",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KBH",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.102972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.071953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "-0.127853",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "-0.076438",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.107278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.101928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.095435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.088742",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BA",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.0156",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade",
      "url": "https://www.fool.com/investing/2024/03/30/3-reliable-dividend-growth-stocks-with-yields-abov/",
      "time_published": "20240330T091900",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "These advantaged businesses have what it takes to keep raising their payouts.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770568%2Fgroup-of-investors-looking-at-charts.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.967321"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        }
      ],
      "overall_sentiment_score": 0.238472,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "-0.045412",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049221",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.049573",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWAV",
          "relevance_score": "0.049221",
          "ticker_sentiment_score": "0.133067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Beaten-Down Growth Stocks You Might Regret Not Buying",
      "url": "https://www.fool.com/investing/2024/10/05/2-beaten-down-growth-stocks-you-might-regret-not/",
      "time_published": "20241005T104500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Their headwinds won't last forever.",
      "banner_image": "https://media.ycharts.com/charts/b9217d04221e3a9bb6fa601f58f6a4ca.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.972756"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.980716"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.275476,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ROKU",
          "relevance_score": "0.420705",
          "ticker_sentiment_score": "0.371902",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.241924",
          "ticker_sentiment_score": "0.340688",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.04912",
          "ticker_sentiment_score": "0.113088",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade",
      "url": "https://www.fool.com/investing/2025/01/04/3-high-yield-dividend-stocks-to-buy-now-and-hold-a/",
      "time_published": "20250104T101900",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.There isn't much that you can do to stop the march of inflation, but ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/802604/individual-investor-three-stock-charts-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.100465,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.287762",
          "ticker_sentiment_score": "0.168234",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049019",
          "ticker_sentiment_score": "0.076228",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.194242",
          "ticker_sentiment_score": "0.03334",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.287762",
          "ticker_sentiment_score": "0.056246",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Laboratory Robotics Market Set to Grow at 6.6% CAGR, Reaching US$ 548.6 Million by 2034 Amid Increasing Adoption in Pharma and Biotech | Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44438773/laboratory-robotics-market-set-to-grow-at-6-6-cagr-reaching-us-548-6-million-by-2034-amid-increasi",
      "time_published": "20250321T151432",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research, Inc. -, March 21, 2025 ( GLOBE NEWSWIRE ) -- Automation is revolutionizing scientific research and diagnostics, driving steady growth in the Laboratory Robotics Market Size.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/670b71fd-70c8-4e4b-a32f-ef2c17209976/laboratory-robotics-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.295129,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.024496",
          "ticker_sentiment_score": "0.048239",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.024496",
          "ticker_sentiment_score": "0.050056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.048969",
          "ticker_sentiment_score": "0.135015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMAWF",
          "relevance_score": "0.024496",
          "ticker_sentiment_score": "0.048239",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.048969",
          "ticker_sentiment_score": "0.072246",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.024496",
          "ticker_sentiment_score": "0.048239",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.073396",
          "ticker_sentiment_score": "0.150584",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever",
      "url": "https://www.fool.com/investing/2025/01/21/3-unstoppable-dividend-growth-stocks-yielding-more/",
      "time_published": "20250121T091700",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.In 2023, ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/804374/investor-with-stock-chart-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.236502,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.15898",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.048621",
          "ticker_sentiment_score": "0.084124",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.215993",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.097062",
          "ticker_sentiment_score": "0.222534",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.145145",
          "ticker_sentiment_score": "0.133649",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans",
      "url": "https://www.zacks.com/stock/news/2405888/syk-stock-down-despite-q4-earnings-beat-and-spine-biz-divestment-plans",
      "time_published": "20250129T160600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/33/84583.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999981"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.275654,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEN",
          "relevance_score": "0.072802",
          "ticker_sentiment_score": "0.085576",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.072802",
          "ticker_sentiment_score": "0.051307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.048572",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.51639",
          "ticker_sentiment_score": "0.263313",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NARI",
          "relevance_score": "0.072802",
          "ticker_sentiment_score": "0.082737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WM",
          "relevance_score": "0.024297",
          "ticker_sentiment_score": "0.246086",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adobe Declines 30% in a Year: Buy, Sell or Hold the Stock in 2025?",
      "url": "https://www.zacks.com/stock/news/2403071/adobe-declines-30-in-a-year-buy-sell-or-hold-the-stock-in-2025",
      "time_published": "20250124T161200",
      "authors": [
        "Aniruddha Ganguly"
      ],
      "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele amid increasing competition and stretched valuation.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.891286"
        }
      ],
      "overall_sentiment_score": 0.244537,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.19231",
          "ticker_sentiment_score": "0.15715",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.21281",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.055318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "-0.016942",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.081947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "-0.016942",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.081947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.081947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.638641",
          "ticker_sentiment_score": "0.404911",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.081947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HUBS",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.21281",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.144853",
          "ticker_sentiment_score": "0.069435",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Wearable Patch Market to Expand at a High 7.9% CAGR through 2031 | SkyQuest Technology",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42158479/wearable-patch-market-to-expand-at-a-high-7-9-cagr-through-2031-skyquest-technology",
      "time_published": "20241125T101001",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Westford, USA, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the wearable patch market size will attain a value of USD 17.09 billion by 2031, with a CAGR of 7.9% over the forecast period ( 2024-2031 ) .",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.333709,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRTC",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHG",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.057301",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Prediction: These 2 Stocks Will Beat the Market in the Next Decade",
      "url": "https://www.fool.com/investing/2025/05/27/prediction-these-2-stocks-will-beat-the-market-in/",
      "time_published": "20250527T074600",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly ( NYSE: LLY ) and DexCom ( NASDAQ: DXCM ) .Eli ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F819382%2Fpatient-self-administering-a-shot.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        }
      ],
      "overall_sentiment_score": 0.250301,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.45634",
          "ticker_sentiment_score": "0.355973",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.048425",
          "ticker_sentiment_score": "0.13656",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.415318",
          "ticker_sentiment_score": "0.254694",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.048425",
          "ticker_sentiment_score": "0.016956",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - Assertio Holdings  ( NASDAQ:ASRT ) ",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42529180/assertio-holdings-inc-appoints-mark-reisenauer-to-its-board-of-directors",
      "time_published": "20241217T133000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "LAKE FOREST, Ill., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Assertio Holdings, Inc. ( \"Assertio\" or the \"Company\" ) ASRT, a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.199934,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASRT",
          "relevance_score": "0.454714",
          "ticker_sentiment_score": "0.170333",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.04823",
          "ticker_sentiment_score": "0.031833",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.04823",
          "ticker_sentiment_score": "0.031833",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Breath Analyzer Market Size Projected to Surge $3.68 Billion Growth by 2030, With CAGR of 15.19% | The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45192739/breath-analyzer-market-size-projected-to-surge-3-68-billion-growth-by-2030-with-cagr-of-15-19-the-",
      "time_published": "20250505T124725",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 05, 2025 ( GLOBE NEWSWIRE ) -- As per a new, comprehensive report from The Insight Partners, the breath analyzer market is experiencing significant growth owing to the growing trend of alcohol consumption and the surging cases of alcohol-impaired driving accidents.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.185574,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.048133",
          "ticker_sentiment_score": "0.047352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLOZF",
          "relevance_score": "0.048133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGWPF",
          "relevance_score": "0.048133",
          "ticker_sentiment_score": "0.047352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LCTC",
          "relevance_score": "0.048133",
          "ticker_sentiment_score": "0.047352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HON",
          "relevance_score": "0.048133",
          "ticker_sentiment_score": "0.047352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.048133",
          "ticker_sentiment_score": "0.047352",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Continuous Glucose Monitoring Devices Market Size expected to reach US$ 32.97 billion by 2031, Increasing Demand for Effective Diabetes Management Propels Growth",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45694139/continuous-glucose-monitoring-devices-market-size-expected-to-reach-us-32-97-billion-by-2031-incre",
      "time_published": "20250530T133516",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 30, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global continuous glucose monitoring devices market is observing significant growth owing to the increasing demand for effective diabetes management and the growing use of OTC ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.795202"
        }
      ],
      "overall_sentiment_score": 0.273191,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "YPHDF",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "-0.075079",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "-0.075079",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.095707",
          "ticker_sentiment_score": "0.022468",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.190043",
          "ticker_sentiment_score": "0.175685",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "-0.075079",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement",
      "url": "https://www.globenewswire.com/news-release/2025/05/16/3082805/0/en/Senseonics-Announces-Pricing-of-50-Million-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html",
      "time_published": "20250516T031200",
      "authors": [
        "Inc.",
        "Senseonics Holdings"
      ],
      "summary": "GERMANTOWN, Md., May 15, 2025 ( GLOBE NEWSWIRE ) -- Senseonics Holdings, Inc. ( NYSE American: SENS ) , a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring ( CGM ) systems for people with diabetes, today announced the ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/78f68bac-fb37-47d9-af74-1c8b3b06cfde",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998311"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.112832,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BR",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "0.097882",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "0.178697",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.090176",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher",
      "url": "https://www.fool.com/investing/2024/08/30/2-monster-stocks-you-can-buy-right-now-before-they/",
      "time_published": "20240830T134500",
      "authors": [
        "Rachel Warren"
      ],
      "summary": "These businesses can stand the test of time in a diversified portfolio.",
      "banner_image": "https://g.foolcdn.com/editorial/images/788639/getty-happy-victory-profits-winning-success-gains-pleased.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.244036,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CAVA",
          "relevance_score": "0.142005",
          "ticker_sentiment_score": "0.135819",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.366736",
          "ticker_sentiment_score": "0.145436",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.047559",
          "ticker_sentiment_score": "0.073038",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 No-Brainer Dividend Stocks to Buy With $250 in 2025",
      "url": "https://www.fool.com/investing/2025/01/06/2-no-brainer-dividend-stocks-to-buy-with-250-in-20/",
      "time_published": "20250106T091700",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields. The other basic option available to dividend investors is to buy stocks with really high yields.",
      "banner_image": "https://g.foolcdn.com/editorial/images/802887/individual-investors-at-home-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999956"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.188554,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EXR",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.164874",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.405651",
          "ticker_sentiment_score": "0.316273",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.107689",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom",
      "url": "https://www.cnbc.com/2025/04/30/healthy-returns-trumps-pharma-tariffs-fuel-new-us-investments.html",
      "time_published": "20250430T201224",
      "authors": [],
      "summary": "Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.143533,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRMND",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.086979",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLDAF",
          "relevance_score": "0.09347",
          "ticker_sentiment_score": "0.019752",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.09347",
          "ticker_sentiment_score": "0.12762",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "-0.086801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Spectacular High-Yield Dividend Stocks to Buy in November",
      "url": "https://www.fool.com/investing/2024/11/10/spectacular-high-yield-dividend-stocks-to-buy-in/",
      "time_published": "20241110T143000",
      "authors": [
        "David Jagielski",
        "and Prosper Junior Bakiny",
        "Keith Speights"
      ],
      "summary": "High yields aren't a warning indicator with these three stocks.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797003/scientists-in-a-lab-monitor-microscope.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.293865,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.361407",
          "ticker_sentiment_score": "0.434985",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.178476",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.402761",
          "ticker_sentiment_score": "0.326656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.230892",
          "ticker_sentiment_score": "0.281124",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - Cogent Biosciences  ( NASDAQ:COGT ) ",
      "url": "https://www.benzinga.com/pressreleases/24/05/g38995156/cogent-biosciences-appoints-cole-pinnow-as-chief-commercial-officer",
      "time_published": "20240523T210500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.997405"
        }
      ],
      "overall_sentiment_score": 0.268344,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COGT",
          "relevance_score": "0.274834",
          "ticker_sentiment_score": "0.157429",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.139534",
          "ticker_sentiment_score": "0.029139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.022939",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Q&A: This New CEO Has Big Ideas For A Small Biotech",
      "url": "https://www.investors.com/news/technology/catalyst-pharmaceuticals-biotech-stock-richard-daly-qa/",
      "time_published": "20240510T133000",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "Catalyst Pharmaceuticals CEO Richard Daly: Big Plans For The Small Biotech Stock Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/TECH1_daly_051024.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.337516,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.046363",
          "ticker_sentiment_score": "0.244453",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CPRX",
          "relevance_score": "0.069495",
          "ticker_sentiment_score": "0.088537",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.279129",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.023191",
          "ticker_sentiment_score": "0.223411",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.069495",
          "ticker_sentiment_score": "0.236529",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TAK",
          "relevance_score": "0.046363",
          "ticker_sentiment_score": "0.067621",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 No-Brainer Stocks to Buy in July",
      "url": "https://www.fool.com/investing/2025/07/07/3-no-brainer-stocks-to-buy-in-july/",
      "time_published": "20250707T104000",
      "authors": [
        "Keith Speights",
        "David Jagielski",
        "and Prosper Junior Bakiny"
      ],
      "summary": "Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.Three Motley Fool contributors think they've found no-brainer stocks to buy this month. Here's why they picked healthcare stocks AbbVie ( NYSE: ABBV ) , Eli Lilly ( NYSE: LLY ) ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F823995%2Fscientist-wearing-goggles-in-lab.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.220794,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.106897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.436009",
          "ticker_sentiment_score": "0.334879",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.321312",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.262403",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "-0.216274",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Bio-Rad  ( BIO )  Hurt by Softness in BioPharma and Competition",
      "url": "https://www.zacks.com/stock/news/2256187/bio-rad-bio-hurt-by-softness-in-biopharma-and-competition",
      "time_published": "20240416T145600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.993781"
        }
      ],
      "overall_sentiment_score": 0.130647,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.045482",
          "ticker_sentiment_score": "0.065784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.224487",
          "ticker_sentiment_score": "0.034281",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.090816",
          "ticker_sentiment_score": "0.06947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.045482",
          "ticker_sentiment_score": "0.065784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.045482",
          "ticker_sentiment_score": "0.065784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.135857",
          "ticker_sentiment_score": "-0.069883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.135857",
          "ticker_sentiment_score": "0.051422",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVA",
          "relevance_score": "0.18046",
          "ticker_sentiment_score": "0.041398",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement - Senseonics Holdings  ( AMEX:SENS ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45554030/senseonics-holdings-inc-announces-closing-of-public-offering-including-exercise-in-full-of-the-und",
      "time_published": "20250521T210626",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 ( GLOBE NEWSWIRE ) -- Senseonics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998947"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.103206,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BR",
          "relevance_score": "0.04531",
          "ticker_sentiment_score": "0.05688",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.04531",
          "ticker_sentiment_score": "0.171044",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.090474",
          "ticker_sentiment_score": "0.052799",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement - Senseonics Holdings  ( AMEX:SENS ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45459778/senseonics-announces-pricing-of-50-million-public-offering-of-common-stock-and-concurrent-private-",
      "time_published": "20250516T031242",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "GERMANTOWN, Md., May 15, 2025 ( GLOBE NEWSWIRE ) -- Senseonics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999763"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.126828,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BR",
          "relevance_score": "0.044718",
          "ticker_sentiment_score": "0.092322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.044718",
          "ticker_sentiment_score": "0.170858",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.089295",
          "ticker_sentiment_score": "0.085835",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bio-Rad  ( BIO )  Suffers due to BioPharma Softness, Stiff Competition",
      "url": "https://www.zacks.com/stock/news/2239177/bio-rad-bio-suffers-due-to-biopharma-softness-stiff-competition",
      "time_published": "20240312T122700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997335"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.140344,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.063671",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.094646",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.089129",
          "ticker_sentiment_score": "0.067141",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.030972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.063671",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.063671",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.104173",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.16695",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/09/14/3-stocks-to-buy-and-hold-forever/",
      "time_published": "20240914T113000",
      "authors": [
        "Keith Speights",
        "David Jagielski",
        "and Prosper Junior Bakiny"
      ],
      "summary": "These stocks are built for the long run.",
      "banner_image": "https://g.foolcdn.com/editorial/images/790595/hands-behind-head-young-man.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.302576,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.420783",
          "ticker_sentiment_score": "0.432652",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.218423",
          "ticker_sentiment_score": "0.259411",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.260652",
          "ticker_sentiment_score": "0.074855",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.044222",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2025/04/26/4-surefire-dividend-stocks-to-buy-in-the-sell-off/",
      "time_published": "20250426T220500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.",
      "banner_image": "https://g.foolcdn.com/editorial/images/815642/gettyimages-2161678259.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        }
      ],
      "overall_sentiment_score": 0.306651,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZTS",
          "relevance_score": "0.381625",
          "ticker_sentiment_score": "0.280911",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.21803",
          "ticker_sentiment_score": "0.270672",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.098191",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.176375",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.236682",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "0.19269",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Electroceuticals/Bioelectric Medicine Market is Expected to Reach $33.6 billion | MarketsandMarkets\u2122",
      "url": "https://www.benzinga.com/pressreleases/24/04/g38045112/electroceuticalsbioelectric-medicine-market-is-expected-to-reach-33-6-billion-marketsandmarkets",
      "time_published": "20240402T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Chicago, April 02, 2024 ( GLOBE NEWSWIRE ) -- Electroceuticals/Bioelectric Medicine market in terms of revenue was estimated to be worth $23.9 billion in 2024 and is poised to reach $33.6 billion by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a latest report published by ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.221399,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NPCE",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ECOR",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVRO",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STIM",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHEOF",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIVN",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCRPF",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXNX",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sarcopenia Treatment Market to Experience 4.2% CAGR, Reaching US$ 4.63 Billion by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/24/11/g41803914/sarcopenia-treatment-market-to-experience-4-2-cagr-reaching-us-4-63-billion-by-2034-fact-mr-report",
      "time_published": "20241107T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- The world population has crossed 8 billion, with a significant number of elderly people suffering from sarcopenia. As per a new study by Fact.MR, the global sarcopenia treatment market is estimated at US$ 3.07 billion in 2024 and is projected to ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/dffe8a91-4256-447a-9e0b-0df6773f886f/sarcopenia-treatment-market.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.330212,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.051706",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.051706",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLN",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.051706",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.051706",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.051706",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock",
      "url": "https://www.cnbc.com/2024/09/05/healthy-returns-eli-lilly-could-become-the-first-1-trillion-healthcare-stock.html",
      "time_published": "20240905T184706",
      "authors": [],
      "summary": "Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.22981,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "0.124722",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "0.124722",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.087027",
          "ticker_sentiment_score": "-0.038955",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "0.119764",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Scott+Scott Attorneys at Law LLP Reminds Investors of Its Securities Class Action Against Reckitt Benckiser Group PLC  ( OTC: RBGLY )  - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/07/g46348112/scott-scott-attorneys-at-law-llp-reminds-investors-of-its-securities-class-action-against-reckitt-",
      "time_published": "20250710T155800",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, July 10, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( \"Scott+Scott\" ) , an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.069916,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TOP",
          "relevance_score": "0.042723",
          "ticker_sentiment_score": "0.065682",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.042723",
          "ticker_sentiment_score": "-0.130184",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.085324",
          "ticker_sentiment_score": "0.016617",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Reckitt Benckiser Group PLC  ( OTC: RBGLY )  - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/07/g46278651/scott-scott-attorneys-at-law-llp-files-securities-class-action-against-reckitt-benckiser-group-plc",
      "time_published": "20250707T155500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, July 07, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( \"Scott+Scott\" ) , an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.069916,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TOP",
          "relevance_score": "0.042723",
          "ticker_sentiment_score": "0.065682",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.042723",
          "ticker_sentiment_score": "-0.130184",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.085324",
          "ticker_sentiment_score": "0.016617",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Amarin Board of Directors Announces CEO Transition",
      "url": "https://www.globenewswire.com/news-release/2024/06/04/2892939/18362/en/Amarin-Board-of-Directors-Announces-CEO-Transition.html",
      "time_published": "20240604T113000",
      "authors": [
        "Amarin Corporation plc"
      ],
      "summary": "-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/00eeab93-e634-4279-86b3-7973c2a21623",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.857896"
        }
      ],
      "overall_sentiment_score": 0.115734,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AMRN",
          "relevance_score": "0.686097",
          "ticker_sentiment_score": "0.175368",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.042271",
          "ticker_sentiment_score": "0.0139",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
      "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
      "time_published": "20240401T083000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
      "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.24052,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.042048",
          "ticker_sentiment_score": "0.180009",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.125679",
          "ticker_sentiment_score": "0.255601",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.248259",
          "ticker_sentiment_score": "0.115038",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.207928",
          "ticker_sentiment_score": "0.28535",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.167032",
          "ticker_sentiment_score": "0.306284",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167032",
          "ticker_sentiment_score": "0.286408",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.207928",
          "ticker_sentiment_score": "0.134207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.207928",
          "ticker_sentiment_score": "0.100054",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
      "url": "https://www.fool.com/investing/2024/04/27/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
      "time_published": "20240427T111500",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "You'll get dividends and more with these great stocks.",
      "banner_image": "https://g.foolcdn.com/editorial/images/774374/light-bulbs-with-dollar-sign-person-looking-up.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998962"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.273184,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.396888",
          "ticker_sentiment_score": "0.293766",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.360171",
          "ticker_sentiment_score": "0.156442",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.041466",
          "ticker_sentiment_score": "0.176676",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FCAP",
          "relevance_score": "0.041466",
          "ticker_sentiment_score": "0.086608",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.284106",
          "ticker_sentiment_score": "0.173062",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Tryptamine API Market is Set to Reach $2.25 Billion with 11.5% CAGR by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/24/11/g41771015/tryptamine-api-market-is-set-to-reach-2-25-billion-with-11-5-cagr-by-2034-fact-mr-report",
      "time_published": "20241106T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report by Fact.MR, the global tryptamine API market is projected to be worth US$ 757.2 million in 2024 and thereafter advance at 11.5% CAGR from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/18fb0e6e-db43-4c11-b7bd-6fd62b559f8c/tryptamine-api-market.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.155293,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "APG",
          "relevance_score": "0.164188",
          "ticker_sentiment_score": "-0.009626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.041323",
          "ticker_sentiment_score": "-0.069904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.041323",
          "ticker_sentiment_score": "-0.069904",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adobe Expands Portfolio for Advertisers: Buy or Hold the Stock?",
      "url": "https://www.zacks.com/stock/news/2419591/adobe-expands-portfolio-for-advertisers-buy-or-hold-the-stock",
      "time_published": "20250221T145800",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele amid increasing competition and stretched valuation.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.891286"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.238772,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.250261",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.16304",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.079524",
          "ticker_sentiment_score": "0.112275",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNOW",
          "relevance_score": "0.079524",
          "ticker_sentiment_score": "0.033457",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TTD",
          "relevance_score": "0.079524",
          "ticker_sentiment_score": "0.033457",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.053731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.053731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.079524",
          "ticker_sentiment_score": "0.150373",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.053731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.053731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.681884",
          "ticker_sentiment_score": "0.347572",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.053731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HUBS",
          "relevance_score": "0.039811",
          "ticker_sentiment_score": "0.250261",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Healthcare Stocks to Buy at a Discount",
      "url": "https://www.fool.com/investing/2024/07/14/2-healthcare-stocks-to-buy-at-a-discount/",
      "time_published": "20240714T140000",
      "authors": [
        "Rachel Warren"
      ],
      "summary": "Beaten-down stocks can sometimes present an opportunity.",
      "banner_image": "https://g.foolcdn.com/editorial/images/783034/investing-woman-wall-street-suit-stocks-finance.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        }
      ],
      "overall_sentiment_score": 0.260259,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.038969",
          "ticker_sentiment_score": "0.119066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.038969",
          "ticker_sentiment_score": "0.178542",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TDOC",
          "relevance_score": "0.077845",
          "ticker_sentiment_score": "0.101704",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.038969",
          "ticker_sentiment_score": "0.119066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.267664",
          "ticker_sentiment_score": "0.23861",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "STD Testing Market Projected to Reach $14.11 billion by 2030 - Exclusive Report by 360iResearch",
      "url": "https://www.prnewswire.com/news-releases/std-testing-market-projected-to-reach-14-11-billion-by-2030---exclusive-report-by-360iresearch-302114358.html",
      "time_published": "20240413T033300",
      "authors": [
        "360iResearch"
      ],
      "summary": "PUNE, India, April 12, 2024 /PRNewswire/ -- The report titled \"STD Testing Market by Type ( Blood Tests, Lumbar Puncture, Swab Tests ) , Product Type ( Instruments, Reagents & Kits ) , Test Settings, Indication, End-user - Global Forecast 2024-2030\" is now available on 360iResearch.com's ...",
      "banner_image": "https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.376763,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TRMNF",
          "relevance_score": "0.038843",
          "ticker_sentiment_score": "0.170574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.038843",
          "ticker_sentiment_score": "0.104464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.038843",
          "ticker_sentiment_score": "0.104464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.038843",
          "ticker_sentiment_score": "0.104464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.038843",
          "ticker_sentiment_score": "0.104464",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Molecular Diagnostics Market to Reach USD 37.00 Billion by 2031 | SkyQuest",
      "url": "https://www.benzinga.com/pressreleases/24/07/g39708532/molecular-diagnostics-market-to-reach-usd-37-00-billion-by-2031-skyquest",
      "time_published": "20240710T130000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Westford, USA, July 10, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Molecular Diagnostics Market will attain a value of USD 37.00 Billion by 2031, with a CAGR of 11.4% during the forecast period ( 2024-2031 ) .",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.251137,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GRFS",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Home Healthcare Market size is set to grow by USD 312.33 million from 2023-2027, Quality of home healthcare ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/home-healthcare-market-size-is-set-to-grow-by-usd-312-33-million-from-2023-2027--quality-of-home-healthcare-increasing-patient-satisfaction-boost-the-market-technavio-302155780.html",
      "time_published": "20240527T210000",
      "authors": [],
      "summary": "Home Healthcare Market size is set to grow by USD 312.33 million from 2023-2027, Quality of home healthcare ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.297595,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OMRNF",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RMD",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAX",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVCRQ",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.038345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.232694",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Rheumatology Therapeutics Market Size is Anticipated to Surpass Revenue of USD 65.1 Billion by 2034 at a Grow CAGR of 2.6% | Transparency Market Research Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40382614/rheumatology-therapeutics-market-size-is-anticipated-to-surpass-revenue-of-usd-65-1-billion-by-203",
      "time_published": "20240814T213000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc.-, Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global rheumatology therapeutics market ( \u30ea\u30a6\u30de\u30c1\u6cbb\u7642\u85ac\u5e02\u5834 ) was worth US$ 48.8 Billion in 2023 and is expected to reach US$ ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/a8fed192-c91a-4fb3-9f0b-9237251567b2/rheumatology-therapeutics-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.138353,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.051692",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMAWF",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.113597",
          "ticker_sentiment_score": "0.06894",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.03798",
          "ticker_sentiment_score": "0.135565",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Polyneuropathy Treatment Market is Projected to Grow at a 4.9% CAGR, Reaching US$ 3.31 Billion by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42839593/polyneuropathy-treatment-market-is-projected-to-grow-at-a-4-9-cagr-reaching-us-3-31-billion-by-203",
      "time_published": "20250107T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD , Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 billion in 2024 and further expand at a CAGR of 4.9% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/25077c2c-0686-4a6c-bb6a-755c24c235f7/polyneuropathy-treatment-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.327163,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVRO",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMRNF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Point of Care Diagnostics Market is Expected to Reach $77.8 billion | MarketsandMarkets\u2122",
      "url": "https://www.benzinga.com/pressreleases/24/03/g37889705/point-of-care-diagnostics-market-is-expected-to-reach-77-8-billion-marketsandmarkets",
      "time_published": "20240322T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Chicago, March 22, 2024 ( GLOBE NEWSWIRE ) -- Point of Care Diagnostics market in terms of revenue was estimated to be worth $49.7 billion in 2023 and is poised to reach $77.8 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028 according to a latest report published by ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.285736,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRIB",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EKDHF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QDEL",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott launches its first over-the-counter continuous glucose monitor in the U.S.",
      "url": "https://www.cnbc.com/2024/09/05/-abbott-launches-its-first-over-the-counter-continuous-glucose-monitor-in-the-us.html",
      "time_published": "20240905T130001",
      "authors": [],
      "summary": "Abbott Laboratories announced Lingo, its first over-the-counter continuous glucose monitor, is available in the U.S.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.167094,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NKE",
          "relevance_score": "0.037563",
          "ticker_sentiment_score": "-0.194728",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.037563",
          "ticker_sentiment_score": "0.17488",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.037563",
          "ticker_sentiment_score": "0.106946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ULTA",
          "relevance_score": "0.037563",
          "ticker_sentiment_score": "0.357201",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.037563",
          "ticker_sentiment_score": "0.03335",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
      "time_published": "20240322T161800",
      "authors": [],
      "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.244345,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BAYZF",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLCO",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "-0.020684",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.037387",
          "ticker_sentiment_score": "0.099883",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biodegradable Stents Market Size is on Track for Significant Expansion to USD 809.2 Million by 2034 with 7.8% CAGR | Analysis by Transparency Market Research",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40345867/biodegradable-stents-market-size-is-on-track-for-significant-expansion-to-usd-809-2-million-by-203",
      "time_published": "20240813T163415",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global biodegradable stents market ( Markt f\u00fcr biologisch abbaubare Stents was worth US$ 351.6 Mn in 2023 and is expected ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/99d436ec-207d-4cd9-92a9-27ea1f8a77fb/biodegradable-stents-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.334683,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.037155",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.037155",
          "ticker_sentiment_score": "0.056337",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.111144",
          "ticker_sentiment_score": "0.066252",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.037155",
          "ticker_sentiment_score": "0.056337",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRUMF",
          "relevance_score": "0.037155",
          "ticker_sentiment_score": "0.056337",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Protein Hydrolysate Ingredient Market is Projected to Reach US$ 6.15 Billion, Growing at a CAGR of 5.7% by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42964604/protein-hydrolysate-ingredient-market-is-projected-to-reach-us-6-15-billion-growing-at-a-cagr-of-5",
      "time_published": "20250114T003000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD , Jan. 13, 2025 ( GLOBE NEWSWIRE ) -- The global protein hydrolysate ingredient market is projected to reach US$ 6.15 billion by the end of 2034, up from US$ 3.53 billion in 2024, according to a new industry analysis compiled by Fact.MR.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/57a107ff-4fd7-4541-98b0-2b25503d272b/coccidioidomycosis-drugs-market-1-.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.359226,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BNTGF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "-0.09112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INGR",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "-0.09112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "-0.09112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVKIF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "-0.09112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADM",
          "relevance_score": "0.073773",
          "ticker_sentiment_score": "-0.095767",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KRYAY",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "-0.09112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLAPF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "-0.09112",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunoassay Market to Surpass Market Valuation of USD 54.27 Billion by 2031 | SkyQuest Technology",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41514552/immunoassay-market-to-surpass-market-valuation-of-usd-54-27-billion-by-2031-skyquest-technology",
      "time_published": "20241024T120000",
      "authors": [],
      "summary": "Westford, USA, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Immunoassay Market will reach a value of USD 54.27 Billion by 2031, with a CAGR of 5.59% during the forecast period ( 2024-2031 ) .",
      "banner_image": null,
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.194543,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ENZ",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TECH",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SZIHF",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QDEL",
          "relevance_score": "0.036926",
          "ticker_sentiment_score": "0.017056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TOSCF",
          "relevance_score": "0.073773",
          "ticker_sentiment_score": "0.018113",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, Reckitt, and Tempus and Encourages Investors to Contact the Firm - Reckitt Benckiser Group  ( OTC:RBGLY ) , PepGen  ( NASDAQ:PEPG ) ",
      "url": "https://www.benzinga.com/pressreleases/25/07/g46382284/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-vesti",
      "time_published": "20250712T191200",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, July 12, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation VSTS, PepGen, Inc. PEPG, Reckitt Benckiser Group plc RBGLY, and ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        }
      ],
      "overall_sentiment_score": -0.104141,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "-0.128781",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VSTS",
          "relevance_score": "0.322608",
          "ticker_sentiment_score": "-0.048088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.073659",
          "ticker_sentiment_score": "-0.082794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFTBF",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "-0.048589",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEPG",
          "relevance_score": "0.182782",
          "ticker_sentiment_score": "-0.079056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEM",
          "relevance_score": "0.110293",
          "ticker_sentiment_score": "0.026174",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.036869",
          "ticker_sentiment_score": "0.026571",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Chlamydia Infection Diagnostics and Therapeutics Market Size is Estimated to Reach 2.3 Billion, Expanding at a CAGR of 6.9 % by 2034 | TMR Research",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40372339/chlamydia-infection-diagnostics-and-therapeutics-market-size-is-estimated-to-reach-2-3-billion-exp",
      "time_published": "20240814T155201",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global chlamydia infection diagnostics and therapeutics market ( \ud074\ub77c\ubbf8\ub514\uc544 \uac10\uc5fc \uc9c4\ub2e8 \ubc0f \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) was worth US$ 1.1 Billion in 2023 ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/6c7fcd4a-22c9-442c-94f6-e613cdddc87f/chlamydia-infection-diagnostics-and-therapeutics-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.147152,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "0.051403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMAWF",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.109455",
          "ticker_sentiment_score": "0.045263",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "-0.028254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSOI",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "0.189473",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BNXYF",
          "relevance_score": "0.036587",
          "ticker_sentiment_score": "0.189473",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Peripheral Stent Implant Market is Projected to Climb to US$ 7.76 Billion by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41570484/peripheral-stent-implant-market-is-projected-to-climb-to-us-7-76-billion-by-2034-fact-mr-report",
      "time_published": "20241028T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- The global peripheral stent implant market is set to be valued at US$ 4.11 billion in 2024 and is projected to expand at 6.6% CAGR from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/c296590b-a5fe-4c76-8e3a-7c3910061684/peripheral-stent-implant-market.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.261751,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRUMF",
          "relevance_score": "0.072987",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.206091",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCRPF",
          "relevance_score": "0.036532",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Analyst Predicts Bitcoin High In Weeks, $90K By Year-End; TSMC Nears $1 Trillion Valuation After 8% Premarket Surge - Top Headlines Today While US Slept",
      "url": "https://www.benzinga.com/markets/cryptocurrency/24/10/41382444/analyst-predicts-bitcoin-high-in-weeks-90k-by-year-end-tsmc-nears-1-trillion-valuation-aft",
      "time_published": "20241017T140916",
      "authors": [
        "Akanksha Bakshi"
      ],
      "summary": "ESMA Pushes For Stronger Crypto Regulations Under MiCA Framework Crypto Advocate Reacts To Elizabeth Warren's 'Return On Investment' Allegations Against John Deaton, Outlines ROI He Expects From GOP Candidate Bitcoin Defies Election Jitters, Analyst Sees King Crypto Scaling $70K Milestone Again ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/Soccer--Bitcoin.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.124857,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WIT",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.029991",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXPE",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.215881",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OPTGF",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.17618",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TCTZF",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.232828",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "-0.236822",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SSNLF",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.130509",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.439347",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.136545",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.320095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TDG",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.168272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ADIL",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.22969",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WKSP",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "-0.01087",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAVE",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "-0.496092",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.049572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AA",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BABA",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.249701",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DEA",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.168272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "-0.187983",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.099709",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAH",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.168272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.439347",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NOK",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "-0.365491",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "TME",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.232828",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PSX",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.286902",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.108466",
          "ticker_sentiment_score": "0.11775",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:ETH",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.146588",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:NANO",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.187071",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRYPTO:SHIB",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.113275",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:DOGE",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.171497",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now",
      "url": "https://www.fool.com/investing/2024/10/05/2-top-dividend-stocks-yielding-3-or-more-to-buy/",
      "time_published": "20241005T101500",
      "authors": [
        "Rachel Warren"
      ],
      "summary": "These companies can lend growth and dividend returns to a long-term investor's portfolio.",
      "banner_image": "https://g.foolcdn.com/editorial/images/792527/investing-woman-wall-street-suit-stocks-finance-1.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999186"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.181548,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.143415",
          "ticker_sentiment_score": "0.089662",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "0.030721",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ICNB",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "-0.024285",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "0.084206",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KHC",
          "relevance_score": "0.380802",
          "ticker_sentiment_score": "0.195899",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pharmerging Market Size Projected to Surpass USD 7.1 Billion by 2034 at an 11.6% CAGR| Report by Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41385094/pharmerging-market-size-projected-to-surpass-usd-7-1-billion-by-2034-at-an-11-6-cagr-report-by-tra",
      "time_published": "20241017T153646",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- The pharmerging market accounted for US$ 2.1 billion in 2023. It is expected to advance at a CAGR of 11.6% from 2024 to 2034 and reach US$ 7.1 billion by the end of 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/189205ba-f1ce-492f-a96b-5f9f034f881e/pharmerging-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.263889,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.035821",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.035821",
          "ticker_sentiment_score": "0.106278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.035821",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.107175",
          "ticker_sentiment_score": "0.018849",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHG",
          "relevance_score": "0.035821",
          "ticker_sentiment_score": "0.079128",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Americans are savings less these days. Here's why and what that means | Business",
      "url": "https://www.cnn.com/2024/04/14/economy/stocks-week-ahead-americans-savings-less-economy-spending/index.html",
      "time_published": "20240414T113000",
      "authors": [
        "Bryan Mena"
      ],
      "summary": "Americans are saving less these days. Here's why and what that means ...",
      "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1387286445.jpg?c=16x9&q=w_800,c_fill",
      "source": "CNN",
      "category_within_source": "Markets",
      "source_domain": "www.cnn.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.079323,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALK",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.034531",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.034531",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTRS",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BK",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.079111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.055057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.034531",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XINXF",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.107016",
          "ticker_sentiment_score": "-0.024274",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.034531",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCO",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.086648",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "0.217581",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.035768",
          "ticker_sentiment_score": "-0.079111",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Laboratory Consumables Market Size Poised for Growth with Surpassing USD 301.2 Billion by 2031 at a 5.1% CAGR: Transparency Market Research",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40510671/laboratory-consumables-market-size-poised-for-growth-with-surpassing-usd-301-2-billion-by-2031-at-",
      "time_published": "20240822T152005",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global laboratory consumables market ( \uc2e4\ud5d8\uc2e4 \uc18c\ubaa8\ud488 \uc2dc\uc7a5 ) was worth US$ 191.2 Billion in 2022 and is expected to reach US$ 301.2 ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7eec8c9b-40ba-43bd-b830-1186c07a2820/laboratory-consumables-market-.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.225286,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "-0.035718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "0.048332",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "-0.035718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EKDHF",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "-0.035718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLW",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "-0.035718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTOIF",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "0.103297",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "-0.035718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.106699",
          "ticker_sentiment_score": "0.065222",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.035661",
          "ticker_sentiment_score": "-0.035718",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardiac Troponin Market Size to be Worth USD 11.5 billion by 2034, Growing at CAGR of 8.9% | Exclusive Report by Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/07/g39791778/cardiac-troponin-market-size-to-be-worth-usd-11-5-billion-by-2034-growing-at-cagr-of-8-9-exclusive",
      "time_published": "20240716T124000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. - , July 16, 2024 ( GLOBE NEWSWIRE ) -- The global cardiac troponin market ( Markt f\u00fcr kardiales Troponin ) stood at US$ 4.5 billion in 2023, and the global market is projected to reach US$ 11.5 billion in 2034.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.26065,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.035555",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.106384",
          "ticker_sentiment_score": "0.067411",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.035555",
          "ticker_sentiment_score": "0.299995",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Gastroparesis Treatment Market Size Estimated to Rise at a CAGR of 4.6%, Projected to Reach US$ 10.3 Billion by 2034: Transparency Market Research Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/07/g39862578/gastroparesis-treatment-market-size-estimated-to-rise-at-a-cagr-of-4-6-projected-to-reach-us-10-3-",
      "time_published": "20240719T153426",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , July 19, 2024 ( GLOBE NEWSWIRE ) -- The global gastroparesis treatment market ( \uc704\ub9c8\ube44 \uce58\ub8cc \uc2dc\uc7a5 ) stood at US$ 6.3 billion in 2023, and the global market is projected to reach US$ 10.3 billion in 2034.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.165074,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.035138",
          "ticker_sentiment_score": "0.051084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.035138",
          "ticker_sentiment_score": "0.139175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035138",
          "ticker_sentiment_score": "0.083455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.035138",
          "ticker_sentiment_score": "-0.234127",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ETER",
          "relevance_score": "0.035138",
          "ticker_sentiment_score": "0.139175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.105141",
          "ticker_sentiment_score": "0.06817",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TAK",
          "relevance_score": "0.035138",
          "ticker_sentiment_score": "-0.234127",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/antibiotics-market-size-is-set-to-grow-by-usd-16-63-billion-from-2024-2028--rising-prevalence-of-infectious-diseases-boost-the-market-technavio-302166383.html",
      "time_published": "20240607T211500",
      "authors": [],
      "summary": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.069745,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APNHF",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MAYNF",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TAK",
          "relevance_score": "0.035086",
          "ticker_sentiment_score": "0.01328",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cancer Diagnostics Market Size is Expected to Reach USD 178.26 Billion by 2033, Growing at a CAGR of 5.91%: Straits Research",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43432677/cancer-diagnostics-market-size-is-expected-to-reach-usd-178-26-billion-by-2033-growing-at-a-cagr-o",
      "time_published": "20250203T132500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, United States, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Cancer diagnostics is the process of identifying biomarkers, proteins, and other indicators that assist in identifying a cancerous tumor.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.151791,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "-0.071182",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "-0.067692",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "-0.071182",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.070002",
          "ticker_sentiment_score": "-0.06789",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "-0.067692",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "InnovationRx: Tarsus Pharmaceuticals Takes Aim At Disease-Causing Bugs",
      "url": "https://www.forbes.com/sites/alexknapp/2024/06/12/innovationrx-tarsus-pharmaceuticals-takes-aim-at-disease-causing-bugs/",
      "time_published": "20240612T223347",
      "authors": [
        "Alex Knapp"
      ],
      "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. round 25 million Americans are affected by the eye disease Demodex blepharitis, which is caused by small mites that make their way into the eyelid.",
      "banner_image": "https://imageio.forbes.com/specials-images/imageserve/666a1df6f0243545f49d23a5/0x0.jpg?format=jpg&crop=2830,1465,x120,y45,safe&height=900&width=1600&fit=bounds",
      "source": "Forbes",
      "category_within_source": "n/a",
      "source_domain": "www.forbes.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.00971,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TARS",
          "relevance_score": "0.034984",
          "ticker_sentiment_score": "-0.124735",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.034984",
          "ticker_sentiment_score": "0.092372",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.0699",
          "ticker_sentiment_score": "0.014426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.034984",
          "ticker_sentiment_score": "0.037431",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Companion Diagnostics Market Size to Hit USD 9.3 Billion Revenue by 2028 with 9% CAGR: Report by Transparency Market Research",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40465060/companion-diagnostics-market-size-to-hit-usd-9-3-billion-revenue-by-2028-with-9-cagr-report-by-tra",
      "time_published": "20240820T143821",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- The global companion diagnostics market ( \ub3d9\ubc18\uc9c4\ub2e8 \uc2dc\uc7a5 ) was worth US$ 5.2 Bn in 2020 and is expected to reach US$ 9.3 Billion by the year 2028 at a sizzling CAGR of 9.0% between 2020 and 2028.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/02b80288-636d-4be6-9b2a-a6cd6b677392/companion-diagnostics-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.038428,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.03478",
          "ticker_sentiment_score": "0.035786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.03478",
          "ticker_sentiment_score": "0.035786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.03478",
          "ticker_sentiment_score": "0.051003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03478",
          "ticker_sentiment_score": "0.035786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.03478",
          "ticker_sentiment_score": "0.035786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.03478",
          "ticker_sentiment_score": "0.035786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.104078",
          "ticker_sentiment_score": "0.051455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.104078",
          "ticker_sentiment_score": "0.070137",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Laboratory Information Management System (LIMS) Market size is set to grow by USD 1.62 billion from 2024-2028 ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/laboratory-information-management-system-lims-market-size-is-set-to-grow-by-usd-1-62-billion-from-2024-2028--increase-in-recent-developments-in-lims-to-boost-the-market-growth-technavio-302185306.html",
      "time_published": "20240628T211100",
      "authors": [],
      "summary": "Laboratory Information Management System ( LIMS ) Market size is set to grow by USD 1.62 billion from 2024-2028 ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.353411,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DTST",
          "relevance_score": "0.03473",
          "ticker_sentiment_score": "0.172407",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03473",
          "ticker_sentiment_score": "0.096832",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTTHF",
          "relevance_score": "0.03473",
          "ticker_sentiment_score": "0.147604",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.03473",
          "ticker_sentiment_score": "0.096832",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SHMZF",
          "relevance_score": "0.03473",
          "ticker_sentiment_score": "0.096832",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.069394",
          "ticker_sentiment_score": "0.133849",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/dry-eye-syndrome-drugs-market-size-is-set-to-grow-by-usd-2-13-billion-from-2024-2028--growing-geriatric-population-boost-the-market-technavio-302178705.html",
      "time_published": "20240621T215500",
      "authors": [],
      "summary": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.145318,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNPHF",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BHC",
          "relevance_score": "0.03458",
          "ticker_sentiment_score": "0.021037",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Rapid Medical Diagnostic Kits Market to Surpass $26 Billion with 4% CAGR by 2034 | Fact.MR Analysis",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41376663/rapid-medical-diagnostic-kits-market-to-surpass-26-billion-with-4-cagr-by-2034-fact-mr-analysis",
      "time_published": "20241017T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- Fact.MR, a market research and competitive intelligence provider, reveals in its updated research report that the global rapid medical diagnostic kit market is approximated at a size of US$ 17.6 billion in 2024 and is forecasted to increase to ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/71926703-cfde-4fde-85d1-dc027551f7e3/rapid-medical-diagnostic-kit-market.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.358256,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRIB",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZTS",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.03448",
          "ticker_sentiment_score": "0.091218",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer",
      "url": "https://www.globenewswire.com/news-release/2024/05/23/2887700/0/en/Cogent-Biosciences-Appoints-Cole-Pinnow-as-Chief-Commercial-Officer.html",
      "time_published": "20240523T210500",
      "authors": [
        "Inc.",
        "Cogent Biosciences"
      ],
      "summary": "WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.992549"
        }
      ],
      "overall_sentiment_score": 0.181146,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COGT",
          "relevance_score": "0.137083",
          "ticker_sentiment_score": "0.099114",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.103035",
          "ticker_sentiment_score": "0.025341",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03443",
          "ticker_sentiment_score": "0.022348",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Patient Monitoring Devices Market is Expected to Reach $71.1 billion | MarketsandMarkets\u2122",
      "url": "https://www.benzinga.com/pressreleases/24/05/g38640933/patient-monitoring-devices-market-is-expected-to-reach-71-1-billion-marketsandmarkets",
      "time_published": "20240506T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Chicago, May 06, 2024 ( GLOBE NEWSWIRE ) -- Patient Monitoring Devices market in terms of revenue was estimated to be worth $48.5 billion in 2024 and is poised to reach $71.1 billion by 2029, growing at a CAGR of 8.0% from 2024 to 2029 according to a latest report published by MarketsandMarkets\u2122.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.387942,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OMRNF",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NHNKF",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGWPF",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAX",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GNGBY",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.027212",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Blood Screening Market Growth at USD 6.33 Billion by 2031 | SkyQuest Technology",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41250900/blood-screening-market-growth-at-usd-6-33-billion-by-2031-skyquest-technology",
      "time_published": "20241009T133248",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Westford, USA, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- Global Blood Screening Market size was valued at USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period ( 2024-2031 ) . Blood screening is the process of screening donated blood.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.210588,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTRA",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GRFS",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "-0.002005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.001881",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/india-baby-care-products-market-size-to-grow-by-usd-15-69-billion-from-2022-to-2027--market-is-fragmented-due-to-the-presence-of-prominent-companies-like-abbott-laboratories-artsana-spa-bio-veda-action-research-co-and-many-mor-302090314.html",
      "time_published": "20240318T011200",
      "authors": [],
      "summary": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.260822,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KMB",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MHCRF",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PIGEF",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UL",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHG",
          "relevance_score": "0.033751",
          "ticker_sentiment_score": "0.064873",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Protein Hydrolysate Ingredient Market Projects to reach US$ 6.15 billion Valuation by 2034",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42547858/protein-hydrolysate-ingredient-market-projects-to-reach-us-6-15-billion-valuation-by-2034",
      "time_published": "20241218T092118",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville Pike, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- The global protein hydrolysate ingredient market is projected to reach US$ 6.15 billion by the end of 2034, up from US$ 3.53 billion in 2024, according to a new industry analysis compiled by Fact.MR.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7810d6b8-06ef-4a0b-aa5c-b548b18434a4/protein-hydrolysate-ingredient-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.369245,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BNTGF",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.056419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INGR",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.056419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.056419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVKIF",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.056419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADM",
          "relevance_score": "0.067064",
          "ticker_sentiment_score": "-0.060106",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KRYAY",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.056419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLAPF",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.056419",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "In-vitro Colorectal Cancer Screening Tests Market to Reach Over US$ 2.5 Bn by 2034, Driven by a 7.1% CAGR | Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42436794/in-vitro-colorectal-cancer-screening-tests-market-to-reach-over-us-2-5-bn-by-2034-driven-by-a-7-1-",
      "time_published": "20241211T135057",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. - , Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- The global in-vitro colorectal cancer screening tests market ( march\u00e9 des tests de d\u00e9pistage du cancer colorectal in vitro ) was valued at US$ 1.2 billion in 2023 and is projected to expand at a CAGR ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/0702a22b-1756-445a-b042-05d16db393ee/in-vitro-colorectal-cancer-screening-tests-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.08347,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.033515",
          "ticker_sentiment_score": "0.052606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.06697",
          "ticker_sentiment_score": "0.095203",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.033515",
          "ticker_sentiment_score": "-0.016956",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.033515",
          "ticker_sentiment_score": "-0.104935",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.100308",
          "ticker_sentiment_score": "-0.030611",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.033515",
          "ticker_sentiment_score": "-0.155165",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Polymerase Chain Reaction Market to Reach $16 Billion by 2034 at 10% CAGR - Fact.MR Analysis",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40156065/polymerase-chain-reaction-market-to-reach-16-billion-by-2034-at-10-cagr-fact-mr-analysis",
      "time_published": "20240805T103000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- As per this updated industry report by Fact.MR, a market research and competitive intelligence provider, the global polymerase chain reaction market size is expected to attain a valuation of US$ 6.2 billion in 2024.",
      "banner_image": "https://ml.globenewswire.com/media/f482b854-04d1-4f4e-9237-f7c7c6823e10/small/factmr-logo-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.318234,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.091702",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "0.079129",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LAB",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.033236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Global In Vitro Toxicology Testing Market Size is projected to reach USD 28.19 billion by 2031, growing at a CAGR of 10.8%: Straits Research",
      "url": "https://www.benzinga.com/pressreleases/24/03/g37656766/global-in-vitro-toxicology-testing-market-size-is-projected-to-reach-usd-28-19-billion-by-2031-gro",
      "time_published": "20240313T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- In Vitro toxicology testing is used to determine the toxicity of a substance on non-living cells or tissues. It is a crucial component of preclinical safety evaluation in the pharmaceutical, chemical, and regulatory industries.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.152705,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTLT",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRL",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LH",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ERFSF",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.03319",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Baby Food and Infant Formula Market size is set to grow by USD 39.99 billion from 2024-2028, New product launches boost the market, Technavio - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/baby-food-and-infant-formula-market-size-is-set-to-grow-by-usd-39-99-billion-from-2024-2028--new-product-launches-boost-the-market-technavio-302195127.html",
      "time_published": "20240712T212500",
      "authors": [],
      "summary": "Baby Food and Infant Formula Market size is set to grow by USD 39.99 billion from 2024-2028, New product launches boost the market, Technavio PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.188625,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CPB",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AUDYF",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KHC",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PZCUY",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.075806",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Blood Collection Market size worth $ 14.76 Billion, Globally, by 2031 at 5.10% CAGR - Report By Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/04/g38294071/blood-collection-market-size-worth-14-76-billion-globally-by-2031-at-5-10-cagr-report-by-verified-",
      "time_published": "20240417T143000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Jersey City, New Jersey, April 17, 2024 ( GLOBE NEWSWIRE ) -- The Global Blood Collection Market is projected to grow at a CAGR of 5.10% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.284943,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRUMF",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.171113",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.033144",
          "ticker_sentiment_score": "0.098403",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nutraceutical Market Surges to USD 453.78 Billion by 2031, Propelled by 2.10% CAGR - Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40368964/nutraceutical-market-surges-to-usd-453-78-billion-by-2031-propelled-by-2-10-cagr-verified-market-r",
      "time_published": "20240814T141500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- The Global Nutraceutical Market Size is projected to grow at a CAGR of 2.10% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/0b99d04e-f3e3-4dda-ba7b-2871bab340ea/nutraceutical-market-size-and-forecast-768x432.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.303121,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.109966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLF",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.109966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.109966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.109966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAIN",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.109966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.17109",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Brain Implants Market Growth Driven by Increasing Neurological Disorders and Aging Population, Says The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44396621/brain-implants-market-growth-driven-by-increasing-neurological-disorders-and-aging-population-says",
      "time_published": "20250319T125656",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, March 19, 2025 ( GLOBE NEWSWIRE ) -- According to a comprehensive report from The Insight Partners, \"Brain Implants Market Size and Forecasts ( 2020 - 2030 ) , Global and Regional Share, Trends, and Growth Opportunity Analysis Report\", The Brain Implants Market is expected to reach ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/95b8f75f-2cec-41eb-aca4-71568989fa70/image1.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.149746,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NPCE",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "-0.054387",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "-0.054387",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "-0.054387",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "-0.054387",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.066047",
          "ticker_sentiment_score": "0.015067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNSHF",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "-0.054387",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSOI",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "0.141611",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Traws Pharma Announces Management Updates",
      "url": "https://www.globenewswire.com/news-release/2025/03/28/3051648/0/en/Traws-Pharma-Announces-Management-Updates.html",
      "time_published": "20250328T203000",
      "authors": [
        "Inc.",
        "Traws Pharma"
      ],
      "summary": "NEWTOWN, Pa., March 28, 2025 ( GLOBE NEWSWIRE ) -- Traws Pharma, Inc. ( NASDAQ: TRAW ) ( \"Traws Pharma\", \"Traws\" or \"the Company\" ) , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/1eb1780a-724e-4555-ab4d-455e27d18544",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.682689"
        }
      ],
      "overall_sentiment_score": 0.1211,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.032916",
          "ticker_sentiment_score": "0.066703",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.065775",
          "ticker_sentiment_score": "-0.019015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SVYSF",
          "relevance_score": "0.032916",
          "ticker_sentiment_score": "0.066703",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRAW",
          "relevance_score": "0.163465",
          "ticker_sentiment_score": "0.128807",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IKNA",
          "relevance_score": "0.065775",
          "ticker_sentiment_score": "-0.019015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLPG",
          "relevance_score": "0.032916",
          "ticker_sentiment_score": "0.024205",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.032916",
          "ticker_sentiment_score": "0.066703",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:GBP",
          "relevance_score": "0.032916",
          "ticker_sentiment_score": "0.066703",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Technetium-99m Market Poised for Growth, Projected to Reach Over US$ 8.6 Billion by 2034 | Transparency Market Research",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42233486/technetium-99m-market-poised-for-growth-projected-to-reach-over-us-8-6-billion-by-2034-transparenc",
      "time_published": "20241128T143000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research, Inc., Nov. 28, 2024 ( GLOBE NEWSWIRE ) -- The Technetium-99m market ( March\u00e9 du techn\u00e9tium-99m ) is experiencing significant growth due to its essential role in medical diagnostics, particularly in imaging for chronic and non-communicable ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/253373be-47e5-45be-ba61-484216b48bce/technetium-99m-market-outlook.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.32904,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.032338",
          "ticker_sentiment_score": "0.05231",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.032338",
          "ticker_sentiment_score": "0.19629",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SBGSF",
          "relevance_score": "0.032338",
          "ticker_sentiment_score": "0.19629",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HTHIF",
          "relevance_score": "0.032338",
          "ticker_sentiment_score": "0.19629",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.096801",
          "ticker_sentiment_score": "0.074238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GE",
          "relevance_score": "0.032338",
          "ticker_sentiment_score": "0.19629",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Enteral Nutrition Market Size is expected to reach US$ 17.33 Billion by 2031, with CAGR of 7.3% | The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45318877/enteral-nutrition-market-size-is-expected-to-reach-us-17-33-billion-by-2031-with-cagr-of-7-3-the-i",
      "time_published": "20250509T140532",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 09, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the enteral nutrition market is witnessing significant growth owing to the rising prevalence of chronic diseases and the aging population across the world.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.25712,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.032251",
          "ticker_sentiment_score": "-0.049455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.032251",
          "ticker_sentiment_score": "-0.049455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NAOV",
          "relevance_score": "0.064449",
          "ticker_sentiment_score": "0.195371",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.032251",
          "ticker_sentiment_score": "-0.049455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.032251",
          "ticker_sentiment_score": "-0.049455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.032251",
          "ticker_sentiment_score": "-0.049455",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Digital PCR Market: $10.0B to $14.8B Growth Forecast  ( 2024-2029 )  | MarketsandMarkets\u2122",
      "url": "https://www.benzinga.com/pressreleases/24/07/g39836891/digital-pcr-market-10-0b-to-14-8b-growth-forecast-2024-2029-marketsandmarkets",
      "time_published": "20240718T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Chicago, July 18, 2024 ( GLOBE NEWSWIRE ) -- The \"Digital PCR Market Size, Share & Trends by Offering ( Product ( Reagents & Consumables, Instrument ) , Software, Services ) , Application ( Clinical ( infectious, Oncology ) , Research, Forensic, Environmental ) - Global Forecast to 2029\" report ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.245629,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ENZ",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.064362",
          "ticker_sentiment_score": "0.089099",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LAB",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.064362",
          "ticker_sentiment_score": "0.115153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QDEL",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.046874",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/hospital-infection-therapeutics-market-size-is-set-to-grow-by-usd-3-46-billion-from-2024-2028--increase-in-incidence-and-prevalence-of-respiratory-disorders-boost-the-market-technavio-302177964.html",
      "time_published": "20240621T210500",
      "authors": [],
      "summary": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.097863,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BAYZF",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACHL",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.032207",
          "ticker_sentiment_score": "0.010439",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline",
      "url": "https://www.globenewswire.com/news-release/2024/10/16/2963976/0/en/Achieve-Life-Sciences-Promotes-Jaime-Xinos-to-Chief-Commercial-Officer-to-Advance-Commercial-Readiness-of-Cytisinicline.html",
      "time_published": "20241016T120000",
      "authors": [
        "Achieve Life Sciences"
      ],
      "summary": "SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Achieve Life Sciences, Inc. ( Nasdaq: ACHV ) , a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, is pleased to ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/121ccb0d-c3bc-44d5-a431-ee2834c93a79",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.171519,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACHV",
          "relevance_score": "0.158519",
          "ticker_sentiment_score": "0.22166",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.031907",
          "ticker_sentiment_score": "0.055974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.031907",
          "ticker_sentiment_score": "0.055974",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These kinds of businesses are driving a surge in US corporate bankruptcies | Business",
      "url": "https://www.cnn.com/2024/07/14/business/stocks-week-ahead-businesses-failing-bankruptcies/index.html",
      "time_published": "20240714T113000",
      "authors": [
        "Bryan Mena"
      ],
      "summary": "These kinds of businesses are driving a surge in US corporate bankruptcies ...",
      "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1360507858-copy.jpg?c=16x9&q=w_800,c_fill",
      "source": "CNN",
      "category_within_source": "Economy",
      "source_domain": "www.cnn.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.049798,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BLK",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LVS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FITB",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.051963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "-0.115298",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INFY",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTRS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NOK",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAL",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AN",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MAN",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTAS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These kinds of businesses are driving a surge in US corporate bankruptcies | Business",
      "url": "https://amp.cnn.com/cnn/2024/07/14/business/stocks-week-ahead-businesses-failing-bankruptcies",
      "time_published": "20240714T113000",
      "authors": [
        "Bryan Mena"
      ],
      "summary": "These kinds of businesses are driving a surge in US corporate bankruptcies ...",
      "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1360507858-copy.jpg?c=16x9&q=w_800,c_fill",
      "source": "CNN",
      "category_within_source": "Markets",
      "source_domain": "amp.cnn.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.049798,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BLK",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LVS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FITB",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.051963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "-0.115298",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INFY",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTRS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMI",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "-0.051234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NOK",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAL",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AN",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MAN",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTAS",
          "relevance_score": "0.031822",
          "ticker_sentiment_score": "0.066358",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Meal Replacement Market Surges to USD 16.62 Billion by 2031, Propelled by 4.40% CAGR - Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40191275/meal-replacement-market-surges-to-usd-16-62-billion-by-2031-propelled-by-4-40-cagr-verified-market",
      "time_published": "20240806T140000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, Aug. 06, 2024 ( GLOBE NEWSWIRE ) -- The Global Meal Replacement Market Size is projected to grow at a CAGR of 4.40% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/4889a22f-7bfd-4a7d-8546-5329ff3df3a5/meal-replacement-market-is-estimated-to-grow-at-a-cagr-of-4-40-reach-us-16-62-bn-by-the-end-of-2031-768x432.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.320962,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.03178",
          "ticker_sentiment_score": "0.109351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLF",
          "relevance_score": "0.03178",
          "ticker_sentiment_score": "0.109351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLAPF",
          "relevance_score": "0.03178",
          "ticker_sentiment_score": "0.109351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.03178",
          "ticker_sentiment_score": "0.109351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.03178",
          "ticker_sentiment_score": "0.170418",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adobe Q4 Earnings Beat Estimates, Shares Fall on Weak Outlook",
      "url": "https://www.zacks.com/stock/news/2382693/adobe-q4-earnings-beat-estimates-shares-fall-on-weak-outlook",
      "time_published": "20241212T141900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ADBE's fourth-quarter fiscal 2024 results reflect strong adoption of Digital Media and Digital Experience.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99992"
        }
      ],
      "overall_sentiment_score": 0.154824,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.093897",
          "ticker_sentiment_score": "0.010626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.168536",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "-0.016947",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "-0.015163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.082312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "-0.015163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.082312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.082312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.654648",
          "ticker_sentiment_score": "0.326761",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.082312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HUBS",
          "relevance_score": "0.031364",
          "ticker_sentiment_score": "0.168536",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.093897",
          "ticker_sentiment_score": "-0.018977",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Organ Transplant Diagnostics Market Size to Surpass USD 12.57 Billion by 2033 | Straits Research",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43301093/organ-transplant-diagnostics-market-size-to-surpass-usd-12-57-billion-by-2033-straits-research",
      "time_published": "20250129T132500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, United States, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- An organ transplant is a surgical procedure replacing a damaged organ with a healthy one. Diagnostics for organ transplants are clinical diagnostic methods that improve the efficacy of transplantation procedures.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.226134,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.143848",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVYTF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.143848",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.11675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.11675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.11675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.143848",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CDNA",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.11675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LH",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.11675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ERFSF",
          "relevance_score": "0.031159",
          "ticker_sentiment_score": "0.11675",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Chronic Total Occlusion Market Size to Surpass USD 42.21 Billion by 2031, Increasing Prevalence of Cardiovascular Diseases Fuels | The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45518525/chronic-total-occlusion-market-size-to-surpass-usd-42-21-billion-by-2031-increasing-prevalence-of-",
      "time_published": "20250520T134300",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 20, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the chronic total occlusion market is observing significant growth owing to the increasing prevalence of cardiovascular diseases and strategic initiatives by market players.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.164543,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AHICF",
          "relevance_score": "0.030563",
          "ticker_sentiment_score": "-0.008516",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.030563",
          "ticker_sentiment_score": "-0.008516",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITGR",
          "relevance_score": "0.030563",
          "ticker_sentiment_score": "-0.008516",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.061081",
          "ticker_sentiment_score": "0.113477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRUMF",
          "relevance_score": "0.061081",
          "ticker_sentiment_score": "0.113477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.030563",
          "ticker_sentiment_score": "-0.008516",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TFX",
          "relevance_score": "0.030563",
          "ticker_sentiment_score": "0.029521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.061081",
          "ticker_sentiment_score": "0.113477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASBRF",
          "relevance_score": "0.030563",
          "ticker_sentiment_score": "-0.008516",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Vascular Closure Device Market Size Projected to Grow to USD 3.03 Billion by 2030, Fuelled by Cardiovascular Disease Prevalence and Minimally Invasive Trends - The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44625022/vascular-closure-device-market-size-projected-to-grow-to-usd-3-03-billion-by-2030-fuelled-by-cardi",
      "time_published": "20250403T114122",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, April 03, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Apr, 01, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, \"Vascular Closure Device Market Size and Forecast ( 2020-2030 ) , Global and Regional Share, Trend, and Growth Opportunity Analysis ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.215498,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PINC",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.301704",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Breast Cancer Diagnostics Market Set for 6.9% CAGR Growth, projected to Hit USD 12.45 Billion by 2035",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44266198/breast-cancer-diagnostics-market-set-for-6-9-cagr-growth-projected-to-hit-usd-12-45-billion-by-203",
      "time_published": "20250311T233000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, March 11, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global breast cancer diagnostics market is estimated to reach a valuation of USD 6,389 million in 2025 and is expected to grow at a CAGR of 6.9% during the ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d5e3394a-4d06-441b-9b0e-ecf26085b653/breast-cancer-diagnostics-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.044553,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.060583",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.222978",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.060848",
          "ticker_sentiment_score": "-0.126853",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.060583",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.010788",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.060583",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYGN",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.010788",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.060583",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FUJIF",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.060583",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.060583",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSOI",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "-0.010788",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline - Achieve Life Sciences  ( NASDAQ:ACHV ) ",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41354690/achieve-life-sciences-promotes-jaime-xinos-to-chief-commercial-officer-to-advance-commercial-readi",
      "time_published": "20241016T120000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Achieve Life Sciences, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        }
      ],
      "overall_sentiment_score": 0.180707,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACHV",
          "relevance_score": "0.151349",
          "ticker_sentiment_score": "0.214115",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.052747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.030446",
          "ticker_sentiment_score": "0.052747",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's in Store for These 4 Medical Products Stocks in Q1 Earnings?",
      "url": "https://www.zacks.com/stock/news/2260506/whats-in-store-for-these-4-medical-products-stocks-in-q1-earnings",
      "time_published": "20240423T153600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/59/54380.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.231672,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICLR",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.031496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.029989",
          "ticker_sentiment_score": "-0.078017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.351416",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.1491",
          "ticker_sentiment_score": "0.126458",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBA",
          "relevance_score": "0.029989",
          "ticker_sentiment_score": "-0.078017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEOG",
          "relevance_score": "0.029989",
          "ticker_sentiment_score": "-0.078017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGN",
          "relevance_score": "0.178459",
          "ticker_sentiment_score": "0.19765",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PXXXF",
          "relevance_score": "0.029989",
          "ticker_sentiment_score": "0.338579",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Neurostimulation Devices Market Set to Reach US$ 11.83 Billion by 2030, Driven by Rising Neurological Disorders and Technological Advancements - The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44534541/neurostimulation-devices-market-set-to-reach-us-11-83-billion-by-2030-driven-by-rising-neurologica",
      "time_published": "20250328T122559",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, March 28, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Mar, 28, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners,\"Neurostimulation Devices Market Size and Forecasts ( 2020 - 2030 ) , Global and Regional Share, Trends, and Growth Opportunity Analysis ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/01970d6a-7de4-44f7-af01-a63ade309589/image1.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.175946,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ECOR",
          "relevance_score": "0.029078",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.029078",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.08708",
          "ticker_sentiment_score": "0.134075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.08708",
          "ticker_sentiment_score": "-0.011449",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIVN",
          "relevance_score": "0.029078",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXNX",
          "relevance_score": "0.08708",
          "ticker_sentiment_score": "0.203341",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "DNA Sequencing Market size is set to grow by USD 17.34 billion from 2024-2028, Growing adoption of ngs to boost the ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/dna-sequencing-market-size-is-set-to-grow-by-usd-17-34-billion-from-2024-2028--growing-adoption-of-ngs-to-boost-the-market-growth-technavio-302165939.html",
      "time_published": "20240607T180000",
      "authors": [],
      "summary": "DNA Sequencing Market size is set to grow by USD 17.34 billion from 2024-2028, Growing adoption of ngs to boost the ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.2875,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TXG",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PACB",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZTA",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OUSZF",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "-0.027248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ERFSF",
          "relevance_score": "0.028833",
          "ticker_sentiment_score": "0.02218",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardiac Marker Market Size Projected to Reach USD 28.27 billion by 2031 at a 13.2% CAGR | The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45644597/cardiac-marker-market-size-projected-to-reach-usd-28-27-billion-by-2031-at-a-13-2-cagr-the-insight",
      "time_published": "20250528T135032",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 28, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the cardiac marker market is witnessing significant growth owing to the rising prevalence of Cardiovascular diseases ( CVDs ) and growing technological advancements in diagnostic ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.273082,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.057559",
          "ticker_sentiment_score": "0.086997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRIB",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.069089",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.089071",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMAWF",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.069089",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.089071",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.057559",
          "ticker_sentiment_score": "0.086997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.057559",
          "ticker_sentiment_score": "0.086997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IDGXF",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.089071",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.089071",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer",
      "url": "https://www.globenewswire.com/news-release/2025/01/07/3005200/0/en/Bright-Minds-Biosciences-Appoints-Pharmaceutical-Leader-Stephen-Collins-M-D-Ph-D-as-Chief-Medical-Officer.html",
      "time_published": "20250107T115000",
      "authors": [
        "Bright Minds Biosciences"
      ],
      "summary": "-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences, Inc. ( \"Bright Minds,\" \"BMB\" or the \"Company\" ) ( NASDAQ: DRUG ) , a pioneering company focused on ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/e60bafec-185f-450a-95c9-34f79846184d",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.205156,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.171485",
          "ticker_sentiment_score": "0.1878",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.20775",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DSSMY",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.041692",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UCBJF",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.070027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.057559",
          "ticker_sentiment_score": "0.219001",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SUPN",
          "relevance_score": "0.028798",
          "ticker_sentiment_score": "0.109763",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight",
      "url": "https://www.prnewswire.com/news-releases/global-radioimmunoassay-market-to-grow-at-a-minimal-cagr-of-3-by-2030--delveinsight-302119197.html",
      "time_published": "20240418T213100",
      "authors": [
        "DelveInsight Business Research",
        "LLP"
      ],
      "summary": "The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.",
      "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.146788,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNTG",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EKTAY",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.082191",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.173153",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.173153",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "0.060148",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TCRT",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "0.02269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLDX",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "0.02269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BGNE",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "0.02269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "0.02269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "0.02269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARAY",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.082191",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYGN",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.028388",
          "ticker_sentiment_score": "-0.0967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.056741",
          "ticker_sentiment_score": "-0.035994",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunoassay Market Surges to USD 39.66 Billion by 2031, Propelled by 4.67% CAGR - Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/08/g40161821/immunoassay-market-surges-to-usd-39-66-billion-by-2031-propelled-by-4-67-cagr-verified-market-rese",
      "time_published": "20240805T141500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- The Global Immunoassay Market Size is projected to grow at a CAGR of 4.67% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/54097ce1-6e07-411d-8cc7-f86096bda0f1/immunoassay-market-size-and-forecast-1024x576.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.274905,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TRIB",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.168128",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.027795",
          "ticker_sentiment_score": "0.095953",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44194242/polycystic-ovarian-syndrome-treatment-market-set-for-usd-4-3-billion-by-2034-as-demand-for-persona",
      "time_published": "20250307T154925",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. -, March 07, 2025 ( GLOBE NEWSWIRE ) -- Rising awareness about women's reproductive health and increasing prevalence of hormonal disorders are driving the growth of the Polycystic Ovarian Syndrome Treatment Market.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/3510cf19-c124-4e24-8a2f-864116e23fe5/dielectric-fluid-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.263612,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.050894",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.108784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "-0.034866",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.081552",
          "ticker_sentiment_score": "0.057328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.030877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - Bright Minds Biosciences  ( NASDAQ:DRUG ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42839999/bright-minds-biosciences-appoints-pharmaceutical-leader-stephen-collins-m-d-ph-d-as-chief-medical-",
      "time_published": "20250107T115000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy --",
      "banner_image": "https://ml.globenewswire.com/media/e60bafec-185f-450a-95c9-34f79846184d/small/logo-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.204923,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.188612",
          "ticker_sentiment_score": "0.188212",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.027195",
          "ticker_sentiment_score": "0.206447",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DSSMY",
          "relevance_score": "0.027195",
          "ticker_sentiment_score": "0.038455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UCBJF",
          "relevance_score": "0.027195",
          "ticker_sentiment_score": "0.069417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.054359",
          "ticker_sentiment_score": "0.218891",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SUPN",
          "relevance_score": "0.027195",
          "ticker_sentiment_score": "0.108891",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardiac Marker Testing Market Surges to USD 8.69 Billion by 2031, Propelled by 8.8% CAGR - Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/06/g39481612/cardiac-marker-testing-market-surges-to-usd-8-69-billion-by-2031-propelled-by-8-8-cagr-verified-ma",
      "time_published": "20240625T141500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, June 25, 2024 ( GLOBE NEWSWIRE ) -- The Global Cardiac Marker Testing Market is projected to grow at a CAGR of 8.8% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.220659,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRIB",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EKDHF",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.167652",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEMHF",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SZIHF",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHG",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.023253",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sepsis Diagnostics Market Surges to USD 891.05 Million by 2031, Propelled by 7% CAGR - Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/05/g38873988/sepsis-diagnostics-market-surges-to-usd-891-05-million-by-2031-propelled-by-7-cagr-verified-market",
      "time_published": "20240516T140000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, May 16, 2024 ( GLOBE NEWSWIRE ) -- The Global Sepsis Diagnostics Market is projected to grow at a CAGR of 7% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.205421,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.02683",
          "ticker_sentiment_score": "0.111529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.02683",
          "ticker_sentiment_score": "0.111529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.02683",
          "ticker_sentiment_score": "0.111529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.02683",
          "ticker_sentiment_score": "0.167516",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.02683",
          "ticker_sentiment_score": "0.111529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TTOO",
          "relevance_score": "0.02683",
          "ticker_sentiment_score": "0.111529",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary",
      "url": "https://www.globenewswire.com/news-release/2025/02/24/3031047/0/en/Plus-Therapeutics-Announces-Leadership-Appointments-for-its-CNSide-Diagnostics-Subsidiary.html",
      "time_published": "20250224T123000",
      "authors": [
        "Plus Therapeutics Inc."
      ],
      "summary": "AUSTIN, Texas, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Plus Therapeutics, Inc. ( Nasdaq: PSTV ) ( the \"Company\" ) , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ( CNS ) cancers, today announced that is ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/92d7aa70-e37d-4870-bccf-d83b68ba5612",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.014499,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PSTV",
          "relevance_score": "0.302553",
          "ticker_sentiment_score": "0.04744",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.025845",
          "ticker_sentiment_score": "0.16832",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings  ( NASDAQ:FTRE ) , Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/07/g46287911/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-red-c",
      "time_published": "20250708T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, July 07, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc RBGLY, UroGen Pharma Ltd. URGN, Red Cat Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.126235,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FTRE",
          "relevance_score": "0.294093",
          "ticker_sentiment_score": "0.039162",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RCAT",
          "relevance_score": "0.449816",
          "ticker_sentiment_score": "-0.193864",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.025087",
          "ticker_sentiment_score": "-0.123893",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "URGN",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.02419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.025087",
          "ticker_sentiment_score": "0.024912",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sports Nutrition Market Size to Hit $46.41 Billion, Globally, by 2031 Growing at 8.6% CAGR | Exclusive Report by The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41272645/sports-nutrition-market-size-to-hit-46-41-billion-globally-by-2031-growing-at-8-6-cagr-exclusive-r",
      "time_published": "20241010T134833",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- According to The Insight \"Sports Nutrition Market Global Analysis - by Product Type, Distribution Channel, and Geography\" offers a comprehensive overview of the sports nutrition industry.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.281504,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEP",
          "relevance_score": "0.025008",
          "ticker_sentiment_score": "0.067232",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.025008",
          "ticker_sentiment_score": "0.067232",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLF",
          "relevance_score": "0.025008",
          "ticker_sentiment_score": "0.067232",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLAPF",
          "relevance_score": "0.025008",
          "ticker_sentiment_score": "0.067232",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings  ( NASDAQ:FTRE ) , Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g46065758/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-red-c",
      "time_published": "20250624T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc RBGLY, UroGen Pharma Ltd. URGN, Red Cat Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.114682,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FTRE",
          "relevance_score": "0.29032",
          "ticker_sentiment_score": "0.038761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RCAT",
          "relevance_score": "0.444442",
          "ticker_sentiment_score": "-0.192362",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.024749",
          "ticker_sentiment_score": "-0.123714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "URGN",
          "relevance_score": "0.074153",
          "ticker_sentiment_score": "0.024163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.024749",
          "ticker_sentiment_score": "0.024856",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings  ( NASDAQ:FTRE ) , Reckitt Benckiser Group  ( OTC:RBGLY ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45964659/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-red-c",
      "time_published": "20250617T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc RBGLY, UroGen Pharma Ltd. URGN, Red Cat Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.114682,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FTRE",
          "relevance_score": "0.29032",
          "ticker_sentiment_score": "0.038761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RCAT",
          "relevance_score": "0.444442",
          "ticker_sentiment_score": "-0.192362",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.024749",
          "ticker_sentiment_score": "-0.123714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "URGN",
          "relevance_score": "0.074153",
          "ticker_sentiment_score": "0.024163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBGPF",
          "relevance_score": "0.024749",
          "ticker_sentiment_score": "0.024856",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Global Immunoassay Market to Witness Growth at a CAGR of ~8% by 2030 | DelveInsight",
      "url": "https://www.prnewswire.com/news-releases/global-immunoassay-market-to-witness-growth-at-a-cagr-of-8-by-2030--delveinsight-302155907.html",
      "time_published": "20240527T140100",
      "authors": [
        "DelveInsight Business Research",
        "LLP"
      ],
      "summary": "The surge in the immunoassay market is mainly from the rising occurrence of persistent conditions like cancer and lifestyle-related ailments such as diabetes mellitus. Notably, the uptick in different types of cancer, including breast and prostate cancer, plays a pivotal role in driving market ...",
      "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.195097,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMXMF",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "A",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "0.068239",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHCCF",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.015846",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LAB",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "0.073213",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.076847",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "0.023626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSRLF",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "0.019682",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GRFS",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.023981",
          "ticker_sentiment_score": "0.022058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SZIHF",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "0.017711",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Daily: Samsung Overtakes Apple As iPhone Shipments Slump",
      "url": "https://www.forbes.com/sites/daniellechemtob/2024/04/16/forbes-daily-samsung-overtakes-apple-as-iphone-shipments-slump/",
      "time_published": "20240416T121004",
      "authors": [
        "Danielle Chemtob"
      ],
      "summary": "Forbes Daily: Samsung overtakes Apple in smartphone shipments Forbes ...",
      "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661e6a34d66b63cd31d40669/0x0.jpg?format=jpg&crop=2284,1284,x0,y44,safe&height=900&width=1600&fit=bounds",
      "source": "Forbes",
      "category_within_source": "n/a",
      "source_domain": "www.forbes.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.069949,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.094402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSNLF",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "-0.084059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.094402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.106542",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "-0.003907",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "-0.077911",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DJT",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.072974",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cell Counting Market is expected to generate a revenue of USD 16.5 Billion by 2031, Globally, at 6.20% CAGR: Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42166496/cell-counting-market-is-expected-to-generate-a-revenue-of-usd-16-5-billion-by-2031-globally-at-6-2",
      "time_published": "20241125T151500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- The Global Cell Counting Market Size is projected to grow at a CAGR of 6.20% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/4d4e92b6-a3bd-49ef-a14b-8c6a97bc1a35/global-cell-counting-market-size-and-forecast-1024x576.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.290559,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSMXF",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SUVPF",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.164405",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OCPNF",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.022368",
          "ticker_sentiment_score": "0.040417",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Molecular Biology Enzymes And Kits And Reagents Market Surges to USD 69.4 Billion by 2031, Propelled by 17.35% CAGR - Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/24/05/g38585243/molecular-biology-enzymes-and-kits-and-reagents-market-surges-to-usd-69-4-billion-by-2031-propelle",
      "time_published": "20240502T140000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, May 02, 2024 ( GLOBE NEWSWIRE ) -- The Global Molecular Biology Enzymes And Kits And Reagents Market is projected to grow at a CAGR of 17.35% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.296724,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "A",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.058747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRMNF",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.071137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.066499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.066499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.164373",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.058747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.058747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.066499",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth",
      "url": "https://www.globenewswire.com/news-release/2024/10/28/2969910/0/en/Fennec-Pharmaceuticals-Strengthens-Executive-Leadership-Team-with-Three-Key-Appointments-to-Accelerate-the-Company-s-Next-Stage-of-Growth.html",
      "time_published": "20241028T102300",
      "authors": [
        "Fennec Pharmaceuticals Inc."
      ],
      "summary": "~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/a7bddf94-9a70-4437-b5fa-d701f0b9426d",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.12886,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FENC",
          "relevance_score": "0.137222",
          "ticker_sentiment_score": "0.132138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KPTI",
          "relevance_score": "0.039386",
          "ticker_sentiment_score": "0.134458",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.019699",
          "ticker_sentiment_score": "0.143836",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth - Fennec Pharmaceuticals  ( NASDAQ:FENC ) ",
      "url": "https://www.benzinga.com/pressreleases/24/10/g41569189/fennec-pharmaceuticals-strengthens-executive-leadership-team-with-three-key-appointments-to-accele",
      "time_published": "20241028T102300",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Fennec Pharmaceuticals Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.128711,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FENC",
          "relevance_score": "0.148159",
          "ticker_sentiment_score": "0.134094",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KPTI",
          "relevance_score": "0.037242",
          "ticker_sentiment_score": "0.131719",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.018626",
          "ticker_sentiment_score": "0.14013",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition",
      "url": "https://www.globenewswire.com/news-release/2025/01/23/3014160/11974/en/Pluri-Secures-6-5-Million-Strategic-Investment-at-Premium-to-Market-Enters-Cacao-Market-Through-Acquisition.html",
      "time_published": "20250123T121500",
      "authors": [
        "Pluri Inc."
      ],
      "summary": "HAIFA, Israel, Jan. 23, 2025 ( GLOBE NEWSWIRE ) -- Pluri Inc. ( Nasdaq: PLUR ) ( TASE:PLUR ) ( \"Pluri\" or the \"Company\" ) , a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced a $6.5 million ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/538c9238-fc15-4a74-924b-b61db7f2953a",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.310592,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PLUR",
          "relevance_score": "0.515976",
          "ticker_sentiment_score": "0.409529",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AGTEF",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.192068",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.018611",
          "ticker_sentiment_score": "0.199707",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - Pluri  ( NASDAQ:PLUR ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43156280/pluri-secures-6-5-million-strategic-investment-at-premium-to-market-enters-cacao-market-through-ac",
      "time_published": "20250123T121500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri's Board of Directors Pluri to purchase approximately 71% of Kokomodo Ltd.'s shares, a leading AgTech company focused on the production of cacao, subject to shareholder approval",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Mergers",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.306253,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PLUR",
          "relevance_score": "0.520573",
          "ticker_sentiment_score": "0.395476",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AGTEF",
          "relevance_score": "0.07271",
          "ticker_sentiment_score": "0.190596",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.018201",
          "ticker_sentiment_score": "0.199296",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like",
      "url": "https://www.cnbc.com/2024/03/09/signos-review-i-learned-how-eating-and-exercise-impact-my-blood-sugar.html",
      "time_published": "20240309T150001",
      "authors": [
        "Ashley Capoot"
      ],
      "summary": "Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107384875-1709916022085-img_3015.jpg?v=1709916106&w=1920&h=1080",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.115986,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DXCM",
          "relevance_score": "0.077094",
          "ticker_sentiment_score": "-0.016192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.015442",
          "ticker_sentiment_score": "0.044344",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's a rapid-fire update on all 33 portfolio stocks including our tech giants reporting this week",
      "url": "https://www.cnbc.com/2024/04/24/jim-cramers-rapid-fire-update-on-all-33-investing-club-stocks.html",
      "time_published": "20240424T195309",
      "authors": [
        "Kevin Stankiewicz",
        "Morgan Chittum"
      ],
      "summary": "During the Investing Club's Monthly Meeting on Wednesday, Jim Cramer offered his updated thinking on the stocks in the portfolio.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107381791-1709565572170-gettyimages-2050810312-AFP_34KQ4DT.jpeg?v=1713980195&w=1920&h=1080",
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999974"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.147834,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DD",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VMW",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INFA",
          "relevance_score": "0.028473",
          "ticker_sentiment_score": "0.058975",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "F",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FL",
          "relevance_score": "0.042698",
          "ticker_sentiment_score": "0.061498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WYNN",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.05691",
          "ticker_sentiment_score": "0.062053",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.042698",
          "ticker_sentiment_score": "0.061498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.042698",
          "ticker_sentiment_score": "0.061498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BBY",
          "relevance_score": "0.042698",
          "ticker_sentiment_score": "0.061498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STZ",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PANW",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.042698",
          "ticker_sentiment_score": "0.061498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.028473",
          "ticker_sentiment_score": "0.058975",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.028473",
          "ticker_sentiment_score": "0.058975",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRWD",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TJX",
          "relevance_score": "0.028473",
          "ticker_sentiment_score": "0.058975",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GM",
          "relevance_score": "0.042698",
          "ticker_sentiment_score": "0.061498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HON",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.028473",
          "ticker_sentiment_score": "0.058975",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWK",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTRA",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.014239",
          "ticker_sentiment_score": "0.054481",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Best Dividend Stocks To Help Hedge Inflation",
      "url": "https://www.forbes.com/sites/investor-hub/article/best-dividend-stocks-to-hedge-inflation/",
      "time_published": "20240514T114547",
      "authors": [
        "CFP(R)",
        "Jason Kirsch"
      ],
      "summary": "As inflation seems to be sticking around with rates above 3%, investors seek refuge in assets that can offer stability and growth. Dividend stocks, known for their consistent payouts and potential for capital appreciation, emerge as a compelling option in turbulent economic times.",
      "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66427a30deb5a930366dabcb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
      "source": "Forbes",
      "category_within_source": "n/a",
      "source_domain": "www.forbes.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.998626"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.494702,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLK",
          "relevance_score": "0.131427",
          "ticker_sentiment_score": "0.282941",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PLD",
          "relevance_score": "0.144432",
          "ticker_sentiment_score": "0.251166",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DSGR",
          "relevance_score": "0.013202",
          "ticker_sentiment_score": "0.25193",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.013202",
          "ticker_sentiment_score": "0.064791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.092213",
          "ticker_sentiment_score": "0.276817",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Inside The Collapse Of A Former Billionaire's Foundation For Low-Income Students",
      "url": "https://www.forbes.com/sites/giacomotognini/2024/04/16/inside-the-collapse-of-a-former-billionaires-foundation-for-low-income-students/",
      "time_published": "20240416T103000",
      "authors": [
        "Giacomo Tognini"
      ],
      "summary": "Healthcare Investor Shuts Down Scholarship Program Forbes ...",
      "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661d8cbaf5f4c0c35485b8cb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
      "source": "Forbes",
      "category_within_source": "n/a",
      "source_domain": "www.forbes.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.090607,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BDSX",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "-0.001791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.011143",
          "ticker_sentiment_score": "0.078331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLNO",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.050415",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXDX",
          "relevance_score": "0.077881",
          "ticker_sentiment_score": "0.053955",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QDEL",
          "relevance_score": "0.055673",
          "ticker_sentiment_score": "-0.001001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses",
      "url": "https://www.cnbc.com/2025/04/23/trump-inauguration-donors-include-meta-amazon-target-delta-ford.html",
      "time_published": "20250423T161742",
      "authors": [],
      "summary": "Corporations like Target, McDonald's and Delta donated to Trump's inaugural committee after skipping the last two cycles. Now he has roiled their businesses.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.069256,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PPC",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.044287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.034488",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDNDF",
          "relevance_score": "0.044039",
          "ticker_sentiment_score": "-0.025811",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "F",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "0.07711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.010175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.147178",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.065325",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.033037",
          "ticker_sentiment_score": "0.048699",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.034488",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCVX",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "-0.00662",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EADSF",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "-0.064915",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.139909",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "0.008283",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KDP",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "-0.041557",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "-0.03107",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.033037",
          "ticker_sentiment_score": "-0.014293",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.079495",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "0.047462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "-0.041557",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GM",
          "relevance_score": "0.044039",
          "ticker_sentiment_score": "0.056981",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.089965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MOH",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.089965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "0.072655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DAL",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DEO",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.078118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HYMLF",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FAT",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "-0.057772",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNC",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.047694",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TM",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "-0.041557",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.165523",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BA",
          "relevance_score": "0.022028",
          "ticker_sentiment_score": "0.064647",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.044039",
          "ticker_sentiment_score": "0.025516",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adobe  ( ADBE )  Q4 2024 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2024/12/11/adobe-adbe-q4-2024-earnings-call-transcript/",
      "time_published": "20241212T023016",
      "authors": [
        "Motley Fool Transcribing"
      ],
      "summary": "ADBE earnings call for the period ending September 30, 2024.",
      "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.972756"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.308555,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PYPL",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.033786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSCDF",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.033786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.103242",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.009038",
          "ticker_sentiment_score": "0.03332",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.188754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.169675",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.188754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.009038",
          "ticker_sentiment_score": "0.140591",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSNLF",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.033786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.169675",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.009038",
          "ticker_sentiment_score": "0.028916",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.188754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.20117",
          "ticker_sentiment_score": "0.234009",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXP",
          "relevance_score": "0.009038",
          "ticker_sentiment_score": "0.118566",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNC",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.033786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HUBS",
          "relevance_score": "0.009038",
          "ticker_sentiment_score": "0.062295",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALIZF",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.033786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NSRGF",
          "relevance_score": "0.004519",
          "ticker_sentiment_score": "0.188754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    }
  ]
}